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O objetivo deste trabalho consistiu na investigação da síntese  de                                 
C-glucosil di-hidrochalconas como inibidoras das proteínas co-transportadoras de sódio 
e glucose 1 e 2 (SGLT). Estes novos compostos são análogos C-glucosilados da 
florizina, uma di-hidrochalcona O-glucosilada conhecida como inibidora não-seletiva das 
proteínas SGLT1 e SGLT2. Para tal, foi sintetizada uma pequena biblioteca de di-
hidrochalconas com grupos diferentes substituintes (halogenetos, grupos alcoxi, e 
hidroxilo) em ambos os anéis aromáticos de forma a entender a importância dos 
mesmos em relação à bioactividade destes compostos. A via sintética englobou uma 
reação de condensação aldólica em meio básico a partir de 2ʹ,4ʹ,6ʹ-tri-
hidroxiacetofenona, 2ʹ,4ʹ-di-hidroxiacetofenona e 4ʹ-fluoro-2ʹ-di-hidroxiacetofenona e 
diversos aldeídos aromáticos, utilizando quer aquecimento convencional, quer promovido 
por radiação de micro-ondas. A desproteção das chalconas foi investigada, utilizando 
FeCl3⋅6H2O, também pelo método convencional e assistido por micro-ondas. Com esta 
ultima metodologia, utilizando micro-ondas observou-se que os rendimentos não foram 
significativamente diferentes dos obtidos pelo método convencional, embora tenha sido 
possível diminuir os tempos de reação de 24 horas para 1 hora diminuindo de igual 
forma a formação de produtos secundários.  
Uma hidrogenação in situ com o sistema Et3SiH /Pd-C, aplicada pela primeira vez a 
chalconas, resultou na redução da ligação dupla das chalconas, originando as chamadas 
di-hidrochalconas em excelente rendimentos (90-99%). Curiosamente, partindo da 
chalcona com um grupo bromo na posição C-4ʹʹ (anel B) não foi obtida a correspondente 
dihidrochalcona. Neste caso, ocorreu uma substituição do grupo bromo por um protão.  
A C-glucosilação destas di-hidrochalconas foi posteriormente investigada e, após 
varias tentativas, foi possível obter os compostos  β-D-C-glucosilados, com rendimentos 
na gama dos 35-50%, usando 2,3,4,6-tetra-O-benzil-α-D-glucopiranose como dador de 
glicosilo na presença de TMSOTf em quantidade catalítica. Quando a di-hidrochalcona 
com um grupo furanoílo no anel B foi usada na C-glucosilação, diversos compostos 
foram formados não tendo sido possível isolar o composto C-glucosilado pretendido. A 
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di-hidrochalcona C-glucosilada preparada a partir de 2ʹ,4ʹ,6ʹ,4ʹʹ-tetra-hidroxi-di-
hidrochalona não originou o produto desejado e, como tal, foi necessário utilizar uma via 
alternativa envolvendo a C-glucosilacao de 2ʹ,4ʹ,6ʹ-tri-hidroxiacetofenona. O produto 
desta C-glucosilação, obtido com um rendimento de 57%, foi utilizado na reação de 
condensação aldólica de forma a obter a chalcona C-glucosilada em 63% de rendimento.  
Utilizando outros dadores de glucosilo, 1-O-acetil-2,3,4,6-tetra-O-benzil-D-
glucopiranose, 1,2,3,4,6-penta-O-acetil-D-glucopiranose, brometo de 2,3,4,6-tetra-O-
acetil-α-D-glucopiranosilo ou tricloroacetimidato de 2,3,4,6-tetra-O-acetil-α-D-
glucopiranosilo, não ocorreu qualquer reação de C-glucosilação, quer utilizando TMSOTf 
ou Sc(OTf)3 como ativadores.  
A remoção dos grupos protetores foi conseguida através de hidrogenação 
utilizando o sistema Et3SiH/Pd-C, previamente mencionado, originando os compostos 
pretendidos, com um rendimento global de 25-40%. 
Os sete compostos C-glucosilados foram, posteriormente, utilizados nos testes 
biológicos, bem como os correspondentes intermediários chalconas e di-hidrochalconas.  
Relativamente aos estudos biológicos, o objetivo consistiu na determinação das 
propriedades inibidoras dos compostos acima mencionados relativamente às proteínas 
SGLT1 e SGLT2, duas isoformas das proteínas SGLT presentes nos rins e intestinos. 
Foi necessário gerar duas linhas celulares estáveis que expressassem as proteínas 
SGLT1 e SGLT2, respetivamente. A linha de células escolhida para este estudo foi a 
HEK293 por terem uma capacidade de transfeção bastante elevada. O primeiro passo 
na geração dessas linhas celulares consistiu na otimização as condições de transfeção 
das células HEK293 tendo sido necessário preparar previamente os plasmídeos 
contendo os DNA’s pretendidos (SGLT1 e SGLT2) através da transformação de células 
competentes da estirpe de E. coli DH5α. Foi utilizado o antibiótico ampicilina de forma a 
permitir apenas o crescimento de bactérias contendo os plasmídeos pretendidos. A 
extração do DNA plasmídeo foi efetuada por maxi-prep utilizando um kit comercial. A 
concentração do DNA foi determinada através um equipamento NanoDrop, o qual 
também fornece a razão A260/A280 como uma medida da pureza do DNA (entre 1.8 e 1.9).  
A pureza dos plasmídeos foi também avaliada realizando uma reação de restrição 
na qual são usados enzimas de restrição que cortam o DNA em zonas específicas e 
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após uma eletroforese em gel de agarose foram observados os produtos expectáveis 
através da análise do gel com uma lâmpada UV.  
Relativamente à otimização do método de transfeção foi determinada a razão 
DNA/reagente necessária para obter uma máxima eficiência da mesma. Este processo 
foi efetuado com a proteína fluorescente EGFP (Enhanced Green Fluorescent Protein) 
recorrendo à microscopia confocal bem como à medição da fluorescência em cada 
condição utilizando um multiplate reader. Uma razão 2:1 DNA/reagente de transfeção 
originou a maior eficiência e, portanto foi a condição escolhida para os estudos 
seguintes. 
Para gerar as linhas celulares estáveis é necessário, após a transfeção com o 
plasmídeo desejado, proceder a um tratamento com um antibiótico adequado de forma a 
matar todas as células não-transfectadas num período de 7 dias. Neste caso, os 
plasmídeos tinham na sua estrutura um gene que confere uma resistência ao antibiótico 
geneticina e, como tal, foi necessário determinar a concentração mínima (600-700 
µg/mL) para matar todas as células não-transfectadas.  
As células HEK293 foram, então, transfectadas com os plasmídeos SGLT1 e 
SGLT2  e após a adição do antibiótico foram gerados diversos clones que foram 
posteriormente criopreservados e caracterizados por diferentes técnicas. Foram 
utilizadas duas concentrações 600 e 700 µg/mL para gerar as linhas celulares de forma 
a obter clones com maior taxas de expressão destas proteínas.  
Utilizando as técnicas Western Blot e RT-PCR foram identificados dois clones 
estáveis com elevada expressão das proteínas SGLT1 e SGLT2, 700B1 e 700A1, 
respetivamente. Estes dois clones estáveis foram então usados para os estudos de 
captação de glucose.  
Em paralelo, foi estudada a toxicidade dos compostos sintetizados nas células 
HEK293. Foi utilizado o kit Celltiter Blue no qual um agente não-fluorescente, a 
resazurina, a qual após redução por células viáveis é transformada no composto 
fluorescence resofurina. Assim, a fluorescência produzida pela resofurina é proporcional 
ao número de células viáveis. As células não-viáveis perdem a capacidade metabólica e 
portanto não geram qualquer fluorescência. Este ensaio revelou que a uma 
concentração de 100 µM nenhum dos compostos mostrou mais de 50% de toxicidade 
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embora alguns tenham mostrado cerca de 30-50%. Contudo, as C-glucosil di-
hidrochalconas bem como as chalconas e di-hidrochalconas revelaram mais de 90% de 
viabilidade celular. 
Em seguida, o método de captação de glucose por células HEK293 e pelos clones 
estáveis foi otimizado usando quer o método 2-NBDG (análogo fluorescente da D-
glucose) ou 2-DG (2-desoxiglucose) o qual envolve um ensaio enzimático. O método foi 
otimizado quer usando transfeção temporária quer usando linhas celulares estáveis.  
Após otimização, as células foram incubadas apenas no tampão KRPH (Krebs-
Ringer-Phosphate-HEPES). Após 24 h de incubação em DMEM (Dulbeco’s Modified 
Medium) foram adicionados os compostos inibidores e/ou o composto 2-NBDG (100 µM) 
ou 2DG (1 mM). 
No caso do ensaio com 2-NBDG, após 30 minutos de incubação as células foram 
lavadas e foi extraído todo o seu conteúdo através da adição de uma solução de lise. A 
fluorescência gerada por 2-NBDG que foi absorvido pelas células foi medida a 528 nm 
após excitação a 485 nm. Através de uma curva de calibração com diversas 
concentrações de 2-NBDG foi possível calcular a quantidade (ng/poço) absorvido pelas 
células durante o ensaio.  
Da mesma forma, no ensaio com 2-DG, após incubação com os compostos e/ou 2-
DG foi adicionada uma solução de lise básica. Após uma incubação a 80 ºC a solução foi 
neutralizada e tamponada; foi adicionada uma mistura cocktail contendo diaforase, 
G6PDH, NADP, resazurina e alguns sais e a mistura foi incubada a 37 ºC por algumas 
horas após as quais foi medida a fluorescência produzida pela redução da resazurina a 
590 nm após excitação a 560 nm. 
Apesar de ambos os métodos terem sido otimizados o método escolhido para o 
estudo das propriedade inibidores dos compostos sintetizados foi o segundo método 
(2DG), por gerar resultados mais fiáveis e reprodutíveis.  
Numa primeira triagem todos os compostos foram adicionados às duas linhas 
celulares estáveis (700B1-SGLT1 e 700A1-SGLT2) a uma concentração final de 100 µM 
e todos os compostos inibiram a captação de glucose quer pela proteína SGLT1 quer 
pela SGLT2.  
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Os valores de IC50 foram calculados nas mesmas condições mas usando diversas 
concentrações entre 0.1 nM e 200 µM. O composto florizina foi usado como controlo 
positivo para ambas as proteínas e o composto dapagliflozina foi utilizado como controlo 
positivo para SGLT2 e negativo para SGLT1. De acordo com os resultados obtidos, 
todas as C-glucosil di-hidrochalconas inibiram a proteína SGLT2 seletivamente, com 
valores de IC50 inferiores ao do composto florizina (< 67.3 nM) mas superiores ao do 
composto dapagliflozina (> 0.9 nM). Relativamente às agliconas chalconas e di-
hidrochalconas não-glucosiladas estas não são inibidoras seletivas da proteína SGLT2 
e, aparentemente poderão ser também inibidores das proteínas GLUT pois inibiram 
também a absorção de 2-DG na ausência de sódio (substituindo NaCl por cloreto de 
colina). As proteínas SGLT1 e SGLT2 são chamadas sódio-dependentes, ou seja, 
necessitam da presença de iões de sódio para fazer o transporte das moléculas de 
glucose para dentro das células. Contrariamente, as proteínas GLUT transportam 
glucose quer na presença quer na ausência de sódio e portanto são chamadas sódio-
independentes.  
Em conclusão, foi possível demonstrar que a C-glucosilação é de facto uma 
característica estrutural determinante para a bioactividade requerida, pois os derivados 
C-glucosilados sintetizados foram selectivos para SGLT2 e mais potentes que a florizina, 
uma di-hidrochalcona O-glicosilada e os compostos não glucosilados inibiram apenas 
parcialmente SGLT1 e SGLT2 e não foram selectivos para nenhuma destas proteínas. 
Relativamente à toxicidade exibida por estes compostos nas células HEK293, foi 
comprovado que as chalconas, di-hidrochalconas e aglíconas dos derivados C-
glucosilados que possuem três grupos hidroxilo no anel A não são tóxicas, enquanto que 
as chalconas e as di-hidrochalconas possuindo um ou dois grupos hidroxilo no anel A 
apresentaram uma toxicidade significativa. Os resultados obtidos nesta tese justificam a 
futura otimização estrutural dos derivados C-glucosilados, de forma a obter compostos 
líder e candidatos a fármacos antidiabéticos derivados desta família de compostos que 
provou não ser tóxica às concentrações testadas. 
 







A small library of C-glucosyl dihydrochalcones and their aglycones, chalcones and 
dihydrochalcones, were synthesized aiming at preparing new C-glucosyl analogues of 
phlorizin, a well-known non-selective sodium-glucose co-transporter inhibitor, bearing 
different substituents on the dihydrochalcone moiety. Chalcones were prepared by 
conventional aldol condensation methods and also by microwave-assisted synthesis. The 
yields using the latter were relatively similar to those obtained by conventional methods 
(70-95%) but it was possible to decrease the reaction time from 24 to 1 h. 
Dihydrochalcones were obtained in 90-99% by in situ hydrogenation using the system 
Et3SiH/Pd-C, a method that was used for the first time in this family of compounds, that 
revealed very promising and simple to run. 
C-Glucosylation of dihydrochalcones was investigated with the catalyst TMSOTf 
and using 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose as glycosyl donor, instead of a donor 
with a more effective leaving group at the anomeric position, e.g. trichloroacetimidate, to 
decrease the number of reaction steps. The C-glucosylation proceeded smoothly with 
yields ranging from 40-47% and the following debenzylation by in situ hydrogenation (80-
98% yield) afforded the C-glucosyl dihydrochalcones.  
Cytoxicity of chalcones, dihydrochalcones and C-glucosyl dihydrochalcones was 
evaluated in HEK293 cells and no significant toxicity was found for those compounds 
bearing three hydroxyl groups in ring A. Conversely, chalcones and dihydrochalcones 
bearing one or two hydroxyl groups on ring B showed significant cytoxicity in the same 
cell line.   
Two stable cell lines were generated, HEK293-SGLT1 and HEK293-SGLT2, and 
the two stable clones showing the highest expression by Western Blot and RT-PCR were 
used to evaluate the inhibitory properties of chalcones, dihydrochalcones, and C-glucosyl 
dihydrochalcones as well as to determine their IC50 values towards SGLT1 and SGLT2 
proteins. Results showed that chalcones and dihydrochalcones are able to partially inhibit 
SGLT1 and SGLT2 without showing significant selectivity towards with SGLT1 or SGLT2. 
On the other hand, C-glucosyl dihydrochalcones inhibit both SGLT1 and SGLT2 at 100 
µM but showed a > 500-fold SGLT2 selectivity. IC50 of these molecules were much better 
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than those of phlorizin, but slightly worse than the commercial drug dapagliflozin. 
Nevertheless, changing from the O-glucoside phlorizin to its C-glucosyl analog, it was 
possible to increase its inhibitory ability as well its selectivity. 
 



























Chapter 1. Diabetes, prevention and treatments 
 
1.1 Diabetes mellitus 
Diabetes mellitus (DM) is a group of metabolic diseases in which hyperglycemia 
results from deficiencies in secretion or action of insulin or both.1 Frequent urination, 
increased thirst and increased hunger are among the most common symptoms of 
diabetes. If not treated, it can cause many and severe complications such as diabetes 
ketoacidosisa and nonketotic hyperosmolar comab. Cardiovascular disease, strokes, 
kidneys failure, foot ulcers and damage in the eyes are the most serious long-term 
complications of the disease.2,3 
Around the world, ca. 387 million people have diabetes and the International 
Diabetes Federation (IDF) had estimate that this number will rise to 592 million by 2035, 
with 80% of cases occurring in low-income and middle-income countries such as the 
Middle East and North Africa. In 2014, 4.9 million people died due to diabetes and around 
179 million people had diabetes. More than 79 thousand children developed Type 1 
Diabetes (TDM1) in 2013 and more than 21 million pregnancies were affected by 
diabetes.4 
Diabetes can de divided into different types according to defect type5 (Table 1.1). 
Type 1 diabetes (TDM1) is characterized by the deficiency of insulin production by the 
pancreas and it is also known as “insulin-dependent diabetes”. This type of diabetes is 
more common in young children/teenagers but its cause it is still unknown and the 
treatment includes daily insulin injections. Type 2 diabetes occurs mostly due to insulin 
resistance, e.g., when the cells are unable to respond adequately to normal levels of 
insulin, especially in the muscles, liver and fat tissue. The pancreas generally produces 
more insulin in cases of insulin resistance, but after some time a degeneration of the beta 
cells occurs and insulin is no longer sufficient and effective. It is most common in adults, 
especially if there is a history of overweight/obesity and not enough exercise. Oral 
medications are normally used in this type of the disease. Another type of diabetes is 
                                            
a Results from a shortage of insulin. The body burns fatty acids and produces acidic ketones which cause most of the 
b High blood sugars cause severe dehydration, increases in osmolality and a high risk of complications, coma, and death  
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gestational diabetes, which occurs in pregnant women without a history of diabetes and 
generally resolves by itself after the birth.1  
There are two others types of DM, though not so common. Prediabetes is 
characterized by high glucose levels, higher than the normal but not high enough to be 
considered as TDM2 (many type 2 diabetic people spend many years in this state before 
developing TDM2) and latent autoimmune diabetes of adults (LADA), is a type 1 DM that 
is developed while adult. Most of patients are misdiagnosed as type 2 diabetic.4   
 
Table 1.1. Some major differences between TDM1 and TDM2 
 
The human body obtains glucose by intestinal absorption of this monosaccharide 
resulting from food digestion, breakdown of glycogenc and gluconeogenesisd. The 
hormone that regulates these three processes is insulin, which balances glucose levels.  
It is released by beta cells (β-cells), found in the islets of Langerhans in the pancreas, as 
a consequence of high glucose levels, especially after meals. If the glucose levels are 
low, a decrease in insulin occurs and glucagon acts by breaking down glycogen into 
glucose.6 Consequently, diabetic ketoacidosis (DKA) will occur and, in response, the 
body starts to burn fatty acids, producing acidic ketone bodies (Figure 1.1) causing 
nauseas, dehydration, gasping breathing, confusion and coma. Treatment typically 
requires intravenous fluids to restore dehydration and insulin to suppress the production 
of these ketones. DKA was first described in 1886 and, until insulin’s discovery in the 
1920s, it was almost fatal in every cases. Nowadays mortality related to DKA is less than 
1% if treated on time and adequately6 but can be a serious life-threatening complication 
TDM1 patients.  
                                            
c Storage form of glucose in the liver  
d Generation of glucose from non-carbohydrate substrates 
Feature Type 1 Diabetes Type 2 Diabetes 
Onset Sudden Gradual 
Age at onset Childhood Adulthood 
Body type Thin or normal Overweight 
Ketoacidosis Common Absent 
Endogenous insulin Low or absent Normal, decreased or increased 
Prevalence ~ 10% ~ 90% 
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Figure 1.1Examples of acidic ketone bodies. A. acetone; B. acetoacetic acid; C. beta-hydroxybutyric acid 
 
Similarly, kidneys also play an important role, which consists in the reabsorption of 
glucose to maintain the blood glucose levels.  Under normal conditions almost of the 
filtered glucose is reabsorbed and returned to the bloodstream in the proximal tubule. 
Sodium co-transporters (SGLTs) in concert with facilitative glucose transporters (GLUTs) 
are responsible for this process. However, if glucose concentration is too high the 
kidneys will reach a threshold of reabsorption and glucose is excreted in urine 
(glycosuria). This process will increase the osmotic pressure of the urine and promote the 
inhibition of water reabsorption by the kidneys leading to an increase of urine production 
(polyuria) and consequently dehydration and thirst (three of the most common symptoms 
in early stage of diabetes).6 
 
1.2 Prevention 
There are no known preventive measures for TDM1. This type of diabetes is partly 
inherited and can be triggered by one or more environmental factors such as a viral 
infection or diet.  On the other hand, TDM2 can be prevented in most cases by healthy 
habits and a normal body weight7. Nevertheless, recent studies have combined genetic 
data from a large number of people and scientists have identified many gene variants 
that increase susceptibility to TDM2. These genes appear to affect insulin production 
rather than insulin resistance. An example is the variant of TCF7L2 gene (transcription 
factor 7-like 2)e, which increases susceptibility to TDM2. For people who inherit two 
copies of the variant, the risk of TDM2 is about 80% higher that for those who do not 
carry this gene variant.8 
 
                                            
e TCF7L2 is a transcription factor influencing the transcription of several genes thereby exerting a large variety of functions 









1.3 Treatments  
Type 1 diabetic patients are typically administrated a combination of regular and 
NPHf insulin as well as synthetic analogues. Conversely, TDM2 is treated with oral 
medications. Currently, there are several drugs available in the market, divided into 4 
major classes: insulin sensitizers, insulin secretagogues, alpha glucosidase inhibitors and 
sodium-glucose co-transporters inhibitors. The first three classes will be discussed briefly 
and the latter will be discussed in more detail in Chapter 2.  
 
1.3.1 Insulin sensitizers 
1.3.1.1 Biguanides 
The most used drug in this family is metformin (Scheme 1.1, C), which acts mostly 
at the liver by reducing glucose output and by augmenting glucose uptake in the 
peripheral tissues, especially muscles. Its safety profile, benefic cardiovascular and 
metabolic effects, and capacity to be associated with other antidiabetic agent make it the 
first-line drug when it comes to choosing a lowering agent to treat TDM2.9  
The production of this drug is a very simple process. It was described for the first 
time in 1922 and involves the reaction of dimethylamine hydrochloride (A) and 2-
cyanoguanidine (B).10   
 
Scheme 1.1.Synthesis of metformin (C) 
 
1.3.1.2 Thiazolidinediones 
The thiazolidinediones (TZDs) or 'glitazones' (Figure 1.2) are a class of oral 
antidiabetic drugs that improve metabolic control in patients with type 2 diabetes through 
the improvement of insulin sensitivity. TZDs exert their antidiabetic effects through a 
mechanism that involves activation of the gamma isoform of the peroxisome proliferator-
activated receptor (PPARγ)g. TZD-induced activation of PPAR gamma alters the 
                                            
f Neutral Protamine Hagedorn insulin - long acting insulin given to help control the blood sugar level. 
















transcription of several genes involved in glucose and lipid metabolism and energy 
balance, including those that code for lipoprotein lipase, fatty acid transporter protein, 
adipocyte fatty acid binding protein, fatty acyl-CoA synthase, malic enzyme, glucokinase 
and the GLUT4 glucose transporter. TZDs reduce insulin resistance in adipose tissue, 
muscle and the liver.11 Generally, the insulin-sensitising effects occur in the skeletal 
muscle but TZDs seem to act in the free fatty acid supply from the adipocytes. Although 
there are still many unknowns about the mechanism of action of TZDs in type 2 diabetes, 
it is clear that these agents have the potential to benefit the full 'insulin resistance 
syndrome' associated with the disease.12 
The most prescribed drugs in this class are rosiglitazone, pioglitazone, englitazone 
and troglitazone (Figure 1.2A-D),13 specially when insulin resistance is present. There is 
evidence in animal models and in human studies that TZD treatment may preserve beta 
cell function, i.e. preserve the cells responsible for the production of insulin, which is the 
most beneficial effect of these drugs.14 However, the most common side effects are the 
weight gain, fluid retention and oedema.11 
 
Figure 1.2  Structure of A. rosiglitazone, B. pioglitazone, C. englitazone, and D. troglitazone 
 
1.3.2 Secretagoges  
1.3.2.1 Sulfonylureas 
This class of drugs binds to ATP-sensitive K+ (KATP) channel on the cell membrane 
of pancreatic  β-cells inhibiting a hyperpolarizing efflux of K+, which causes electric 





















leading to an increase in intracellular Ca2+ promoting the fusion of insulin granuleh with 
the cell membrane causing the secretion of proinsulin15, which is the precursor of the 
insulin and C-peptide. After its synthesis, proinsulin is packaged into secretory granules, 
where it is processed to C-peptide and insulin by prohormone convertases (PC1/3 and 
PC2) and carboxypeptidase E. Only 1 to 3% of proinsulin is secreted intact. 
In contrast to metformin, sulfonylureas (Figure 1.3) have several side effects 
especially hypoglycemia and weight gain. The first may occur if the dose is too high or if 
the patient is fasting and the second results from the increase in insulin levels.15 There 
are three generations of these drugs. The first includes tolbutamide; the second one 




Figure 1.3 Structure of A. tolbutamide, B. glipizide, C. glicazide, D. glibenclamide, and E. glimepiride 
 
1.3.2.2 Glinides 
This family of drugs (Figure 1.4) represents a group of insulin-secreting agents 
characterized by their rapid onset and short duration of action. Their action is based on 
the closure of the ATP-dependent K+ channel, in a manner similar to sulphonylureas. 
                                            















































According to several studies this class of drugs appears to be particularly useful in early 
stages of TDM2 and can be combined with metformin.16 The three major drugs in this 
class are repaglinide, nateglinide, and mitiglinide (Figure 1.4A-C). The side effects 
include weight gain and hypoglycemia. The potential for hypoglycemia is lower than for 
those on sulfonylureas, but it is still a serious potential side effect.16 
 
Figure 1.4 Structure of A. repaglinide, B. nateglinide, and C. mitiglinide 
 
1.3.2.3 Glucagon-like peptide-1 agonist 
Another important therapeutic approach was developed which targeted the incretini 
system.17,18 Some studies suggested that the incretin effect is severely reduced or lost in 
TDM2 patients. Augmentation of GLP-1 by the treatment with these drugs leads to an 
improvement of β-cell health in a glucose-dependent manner (post-prandial 
hyperglycemia) and suppression of glucagon (fasting hyperglycemia).  The approved 
drugs are exenatide, liraglutide, lixisenatide and albiglutide. One advantage of these 
drugs is that the incidence of hypoglycemia is relatively low (except when combined with 
sulfonylureas), because their mechanism of action is glucose-dependent.19 These drugs 
are normally prescribed for patients who have not been able to control their condition with 
tablet medication. However, its administration can result in side effects such as diarrhea, 
nausea, vomiting, increased sweating, and loss of appetite. 
 
1.3.2.4 Dipeptidyl peptidase-4 (DPP4) inhibitors 
The enzyme responsible for the degradation of incretin in the human body is the 
dipeptidyl peptidase-4. The inhibition of this enzyme originates an increase of incretin 
physiological activity, including the stimulation of insulin secretion and the inhibition of 
gastric emptying. The mechanism of action of these inhibitors is similar to the GLP-1 
agonists.20 Examples of drugs in this family are sitagliptin and vildagliptin (Figure 1.5A-B), 
                                            




















among others. Adverse effects include nasopharyngitis, headache, nauseas, heart 
failure, hypersensibility and skin reactions.20 
 
Figure 1.5 Structures of A. sitagliptin and B. vildagliptin 
 
1.3.3 Alpha-glucosidase inhibitors 
Alpha-glucosidase is an enzyme that hydrolyses terminal non-reducing 1-4 linked 
alpha-glucose residues, releasing single units of alpha-glucose. The inhibition of this 
enzyme is one of the most common methods used in diabetes therapy. Using alpha-
glucosidases inhibitors, it is possible to delay the absorption of carbohydrates from the 
small intestine leading to a lowering effect on postprandial blood glucose and insulin 
levels.21 These drugs have two major side effects: flatulence and diarrhea. These 
inhibitors prevent the degradation of complex oligosaccharides in glucose and, therefore 
the carbohydrates will remain in the intestines.  Subsequently, bacteria in the gut degrade 
these molecules generating gases (e.g. oxygen, nitrogen, carbon dioxide, hydrogen, and 
methane). Nevertheless, starting the treatment with a small dose and increasing it is one 
way of avoiding these side effects. The three commercially available drugs from this 
family are acarbose, miglitol, and voglibose (Figure 1.6A-C).21 Although the mechanism 
of action of acarbose and miglitol are similar, there are some differences between them.  



















Figure 1.6 Structures of A. acarbose, B. miglitol, and C. voglibose 
 
1.3.4 Sodium-glucose co-transporters inhibitors 
As previously mentioned SGLTs are partly responsible for the reabsorption of 
glucose in the kidneys and intestines. However, when diabetes is developed, the kidneys 
reach a threshold of reabsorption and glucose is excreted in urine. Researchers found 
that inhibiting these SGLTs would be possible to decrease glucose blood levels and 
some SGLT inhibitors were developed. In this work new potential SGLT inhibitors were 
synthesized and were evaluated in vitro. Therefore, the characteristics, structure, 
physiology, properties, and the development of SGLTs inhibitors will be further discussed 
in Chapter 2.  
 
 
In summary, diabetes is a metabolic disease characterized by high levels of glucose 
in the bloodstream. There are more than two types of diabetes but the most common are 
TDM1 and TDM2. Type 1 diabetic patients require daily injections of insulin, while type 2 
diabetic patients need the administration of oral hypoglycemic agents. Taken together, 
the main strategy for treating TDM2 is to lower the levels of glucose in the circulation, 





































its segregation, reducing the formation of glucose molecules by inhibiting the activity of 
the enzyme alpha glucosidase, or inhibiting the glucose reabsorption by the kidneys, 









Chapter 2. Sodium-glucose co-transporter Inhibitors  
 
2.1 Sodium-glucose co-transporters  
2.1.1 General Characteristics of SGLTs 
One of the characteristics of diabetes is the high levels of blood glucose; therefore, 
the control of plasma glucose level is of utmost importance in the treatment of this 
disease. The idea of inhibiting the glucose absorption in the intestine resulted in the 
development of inhibitors such as the alpha-glucosidase inhibitors (Chapter 1). However, 
more recently the inhibition of glucose reabsorption by the kidneys has gained more 
interest.24-27 
The kidney plays a crucial role in controlling the body’s energy. Glucose is filtered 
from the blood in the glomerulus and is reabsorbed by the kidneys. The average 
concentration of plasma glucose is ~5.5 mmol/L in normoglycemicj humans, the 
glomerular filtration rate (GFR) is 125 mL/min in adults. Approximately 180 g of glucose 
are filtered on a daily basis, with >99% being reabsorbed in the tubules, primarily in the 
proximal tubules28-30 by a protein family called sodium-glucose co-transporters (SGLTs).  
In diabetic patients, hyperglycemia can lead to hyperfiltration where the increased 
luminal glucose exceeds the maximal reabsorption rate, resulting in glucosuriak. This can 
lead to increased plasma glucose levels; therefore inhibition of renal reabsorption is a 
possible approach to resolving this problem.31  
Glucose transportation is mostly mediated by two types of transporters namely 
sodium-glucose co-transporters (SGLTs, discovered by Robert Crane in 1960,32,33 
(Figure 2.1) and facilitative glucose transporters (GLUTs).  
                                            
j Non-diabetic people 
k Excretion of glucose through urine. 
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Figure 2.1 The co-transport model drawn by Crane on August 24, 1960 in Prague33 
 
 
2.1.2 Human SLC5 Family 
SGLTs are members of the solute carrier familyl 5A (SLC5A) and there are six 
SGLT isoforms (Table 2.1)31,34 but the two most well known are SGLT1 and SGLT2, both 
of them mainly involved in diabetes. These proteins are symporters, i.e. they are integral 
membrane proteins that are involved in movement of two or more different molecules or 
ions across a phospholipid membrane such as the plasma membrane in the same 
direction. SLGT3, however, is not a transporter but a sensor.35,36 Other proteins from the 
SLC5 family were later discovered, the renal Na+/myo-inositol (SMIT1),37 the thyroid 
Na+/iodine (NIS)38 and the Na+/multivitamin (SMVT).32 
All members of the SLC5 family code for 60-80 kDa proteins, containing 596-681 
residues. The organization of all 6 SGLT genes is quite similar with 15 exons, although 








                                            
l Group of membrane transport proteins 
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Table 2.1. Sodium-glucose co-transporters’ isoforms 
Gene Protein Substrate Localization 
SLC5A1 SGLT1 Glucose and galactose 
Small intestine, heart, trachea and 
kidney 
SLC5A2 SGLT2 Glucose Kidney 
SLC5A3 SGLT3 Glucose sensor 
Small intestine, uterus, lungs, 
thyroid and testicles 
SLC5A4 SGLT4 
Mannose, glucose, fructose 
and 1,5-anhydroglucitol 
Small intestine, kidney, lung, liver 
SLC5A5 SGLT5 Fructose, mannose Kidney 
SLC5A6 SGLT6 
Myo-inositol, xylose and chiro-
inositol 





Figure 2.2 Organization of human SGLT1-6 genes. 
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Western blot has been used to map SGLT expression in human cells and tissues. 
Interestingly, membrane proteins run faster on SDS-PAGE gels than what would be 
based on their molecular weight. The bands are broad, presumably due to incomplete 
denaturing of membrane proteins by SDS. The molecular weight of these proteins can 
vary from 69 to 79 kDa depending on the different degree of glycosylation. SGLT1 was 
identified in mouse intestinal brush border membrane by Western blot using two different 
antibodies (Figure 2.3).33  
 
 
Figure 2.3 Western blot of mouse intestinal brush border membranes29. 
 
Relative to human SGLT1, there is 50-70-% identity and 67-84% similarity in the 
sequences for the remaining SGLTs (2-6). The main divergence in the sequence occurs 
at the extracellular NH2-terminal domain and the COOH-terminal third of the proteins.32 
Regarding the secondary structure of these proteins the amino acid sequence of 
hSGLT1 superimposed on a 14-transmembrane helix model as represented in          
Figure 2.4.33 The crystal structure of human SGLTs is unknown but one from the grape 





Figure 2.4 Secondary structure model of SGLT1 (Highlighted are the locations of the helical domains based on 




Figure 2.5 Struture of vSGLT. A: topology model; B: side view of the 3D structure viewed from the membrane 
plane. The sugar binding site is located on the black and red spheres; C: ligand biding sites in vSGLT. Overview of the 
galactose and sodium binding sites33 
 
2.1.3 Mechanism of SGLTs 
Glucose is a polar molecule; therefore, to cross lipid-rich cell membranes, it requires 
a membrane-associated carrier protein’s active transport (SGLTs). These proteins 
transport a glucose molecule against a concentration gradient into cells by coupling the 
“uphill” transport of sugar across the cell membrane with the “downhill” transport of 
sodium. SGLT1 is able to transport two molecules of glucose with one sodium ion, while 
SGLT2 transports only one glucose molecule with one sodium ion.39 The ability of these 
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proteins to accumulate sugar is highly dependent on the stoichiometry of the Na+ and 
sugar fluxes.  
The stoichiometry of SGLT1 was determined in 1998 by Wright et al 40 by 
measuring the currents and radioactive tracer fluxes into single oocytes expressing rabbit 
SGLT1. In Figure 2.6A is represented the measurement of the current in the absence of 
the sugar (α-D-methylglucopyranoside, αMDG) and radioactive tracer (2 min baseline) 
and after the addition of both for 10 minutes. The integrated sugar-induced currents 
(charge expressed in moles) are plotted against the 22Na uptakes is shown in Figure 
2.6B, with a slope of 1.0 ± 1.0 s-1. This means that the sugar-induced current is 
exclusively a Na+ current. The same experiment was performed measuring the currents 
upon the uptake of different concentrations of αMDG (Figure 2.6C) over 10 minutes. The 
slope for this was 1.6 ± 0.3 s-1; therefore the αMDG to Na+ ratio is 1:1.9. However, for 
SGLT2 the αMDG to Na+ ratio is 1:1, using the same methodology. 
 
Figure 2.6 Determination of the stoichiometry of SGLT1. A. Measurement of the current changes by 
the addition of sugar and radioactive tracer; B.  Measurement of the integrated sugar-induced currents 
against the 22Na uptake; C. Measurement of the integrated sugar-induced currents against the αMDG 
uptake40 
 
The mechanism of transport of glucose is based on the model described by Schultz 
in 1985, from the cell illustrated in Figure 2.7. The states 1-3 face outward and 4-6 faces 
inward. At first (state 1), the unloaded negatively charged carrier has low affinity for 
external sugar before sodium binds. After sodium and sugar binding, the carrier changes 
its conformational form to present sodium and sugar binding sites to the cytoplasm where 
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they are released. A further conformational change (state 6) is required to reexpose the 
binding sites to the external surface of the membrane.33 
 
Figure 2.7 Mechanical model for Na+-coupled sugar transport.33 
 
2.1.4 Role of SGLT1 and SGLT2 in the kidneys 
The two isoforms that transport glucose and are located in the kidney are SGLT1 
and SGLT2. The inhibition of these proteins leads to a decrease in glucose reabsorption. 
This fact has gained interest in the scientific community and efforts to develop SGLTs 
inhibitors have been made. 
SGLT2 and SGLT1 are expressed in the luminal membrane of the early and late 
proximal tubule (Figure 2.8a/b), respectively. SGLT2 is responsible for ~97% of the 
reabsorption of glucose while SGLT1 is only responsible for ~3% in normoglycemia. 
However, SGLT2 inhibition induces glucosuria only after the glucose reabsorption 
capacity of SGLT1 is fully saturated.30,41 Hyperglycemia increases the expression of 
SGLT2 possibly because the increase of angiotensin II (AngII), hepatocyte nuclear factor 
HNF-1α, and/or tubular growth. Increased SGLT2 expression enhances glucose and Na+ 
reabsorption in the proximal tubule, and glucose enters the blood stream through 
basolateral GLUT2 (Figure 2.8c).30 
Mutations on the gene encoding SGLT1 lead to malabsorption of glucose and 
galactose, whose intestinal absorption is mediated by this protein. On the other hand, 
mutations on the gene encoding SGLT2 results in persistent renal glycosuria but can also 
originate some adverse effects such as genitourinary, including frequent urination, 




Figure 2.8 Reabsorption of glucose in proximal tubules by SGLT1 and SGLT2. a/b. Expression of 
SGLT1/SGLT2. c. Increase of renal membrane expression of SGLT2 with hyperglycemia30 
 
 
2.2 Sodium-glucose co-transporters inhibitors  
2.2.1 Phlorizin and SGLTs 
Phlorizin, a dihydrochalcone glucoside  (Figure 2.9), was first isolated from the bark 
of the apple tree in 1835 by French chemists. The Merck index of 1887 lists phlorizin as a 
“Glycosid aus der Wurzelrinde des Apfelbaumes” (“glycoside from the bark of apple 
trees”). Later editions of the Merck Index noted that phlorizin in doses greater than 1.0 g 
produces glucosuria, encouraging scientists to investigate this compound and its 
properties. After some studies in animals, researchers confirmed that phlorizin was able 
to lower blood glucose levels by glucosuria.43   
In the 1950s, it was found that phlorizin at concentrations ranging from 0.1 mM to 1 
μM was able to block the transport of glucose in both kidney and intestine39. Later, it was 
discovered that phlorizin originates serious adverse effects in the gastrointestinal tract 
like diarrhea and dehydration (due to malabsorption of galactose) because it inhibits both 
hSGLT1 and hSGLT2 (Ki = 200-300 nM and Ki = 10-39 nM, respectively). SGLT1 also 
transports galactose; thus, inhibiting this protein causes an inhibition of both glucose and 
galactose absorption. For this reason, phlorizin was not suitable for clinical trials. 
Nevertheless, these studies were very useful in the development of new potential 





Figure 2.9 Phlorizin 
 
As showed in Figure 2.2 SGLT1 and SGLT2 are 59% identicalm (sharing the same 
15 exons, although SGLT2 is only 8 Kbp compared with 50 Kbp of SGLT1). How, then, is 
it possible to produce a selective SGLT2 inhibitor? 
 
 
2.2.2 Development of SGLT inhibitors   
As mentioned before, phlorizin is a nonselective SGLT inhibitor with poor oral 
bioavailability but with a high affinity towards SGLT2 (~ 400 nM). Over the years many 
pharmaceutical companies have exploited this problem by modifying the phlorizin 
structure to enhance selectivity. One example is T-1095A (Figure 2.10B), which is 
absorbed as a methyl carbonate (Figure 2.10A) and then is metabolized into its active 
form. This drug is absorbed without interacting significantly with the intestinal SGLT1 and 
the active form had a fourfold increase in SGLT2/SGLT1.33,44 However it did not proceed 
to clinical trials due to its poor bioavailability.  
 
 
A      B  
Figure 2.10 Structure of A.T-1095 and B. T-1095A 
 
This compound, however, encouraged the search for new molecular entities with 
higher potency, selectivity, and oral bioavailability by adding various substituents to the 
aglycone. The major change consisted on the replacement of O-glucosides by their        
                                            


























C-glucosyl analogs, which have higher resistance to endogenous enzymes, leading to an 
increased half-life and duration of action.  
In 2012 Powell et al45, from Lexicon Pharmaceuticals, reported a randomized, 
placebo-controlled trial using a compound, LX4211, with a dual SGLT1/SGLT2 inhibitory 
activity. SGLT1 is also expressed on L cells and K cellsn, particularly in the small 
intestine. These cells secrete the incretin glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP)o, respectively, in response to ingested glucose. 
The incretins act on pancreatic β cells to increase insulin release in a glucose-dependent 
manner.30,46 Some studies on SGLT1-/- mice with phlorizin suggested that SGLT1 in the 
proximal small intestine serves as the intestinal glucose sensor for the acute (within 5 
minutes) glucose-induced incretin secretion.30,45,47 Studies also provided evidence that 
the inhibition of SGLT1 (in mice and healthy humans) and consequent increase of 
glucose into the more distal gut and colon induced a sustained increase of circulating 
GLP-1 for up to 6 hours.45,47,48 The most remarkable fact on these studies using dual 
SGLT1/SGLT2 inhibitors was that there was no evidence of increased gastrointestinal 
side effects, which were expected to result from to SGLT1 inhibition.45 LX4211 is 
currently at Phase 2 of clinical trials and this achievement is a great breakthrough since 
so far researchers have looked only for SGLT2-selective inhibitors.  
For the last couple of years several glycosides with different aglycones were 
developed as SGLT inhibitors. Some of them are illustrated in Figure 2.11.  
 
                                            
n L cells and K cells are enteroendocrine cells, specialized endocrine of the gastrointestinal tract and pancreas, that produce 
gastrointestinal or peptides 
o Also called gastrointestinal inhibitory peptide or gastric inhibitory peptide and was found to decrease the secretion of 
stomach to protect the small from acid damage, reduce the rate at which food is transferred through the stomach, and inhibit the GI 




Figure 2.11 Some new SGLT inhibitors of synthetic origin 
 
Table 2.2 - Sodium glucose co-transporters in advanced development or already approved49 







40 countries including EU, USA, China, Russia 
40 countries including EU, USA, Japan, 
Phase 3  
Japan 










































































After some years of research, FDA approved a few drugs and some of them are 
already in the market while other compounds are in phase 3 of clinical trials (Table 2.2 
Figure 2.12).  
Canagliflozin and dapagliflozin were the first SGLT inhibitors to be approved. Their 
safety and efficacy has received the attention in the past year. According to these studies 
these two drugs are considered safe although long-term safety remains unknown. Both 
drugs present communal adverse effects such as urinary tract infections, renal-related 
adverse events, and adverse events related to volume depletion, documented 
hypoglycaemia episodes, female genital mycotic infections, and nasopharyngitis.50,51 
New drugs with fewer adverse effects are still needed.  
There are no records that the C-glucosyl derivative of phlorizin acts either as SGLT1 
or SGLT2 or as dual inhibitor. Hence, the purpose of this work was to develop a variety of 
new C-glucosyl dihydrochalcones and evaluate their inhibitory properties. The synthesis 
of these types of compounds will be discussed in Chapter 3.  
 
2.2.3 Protective effects of SGLT inhibitors on the kidneys and cardiovascular 
system  
The primary consequence of diabetes is the chronic kidney disease (CKD), and the 
combination of CKD and hyperglycemia increases the risk of cardiovascular diseases. 
Diabetic kidney growth and its contribution to senescence have been linked to diabetic 
nephropathy. Knockdown of SGLT2 in STZ/diabetic mice lowered blood glucose levels 
but did not limit the rise in kidney weight or markers of kidney growth, inflammation, and 
injury after 4.5 months, indicating that SGLT2-mediated glucose reabsorption itself is not 
critical for these changes.52 The SGLT2 inhibitor empagliflozin however induced a 
stronger blood glucose-lowering effect in mice. It did not prevent kidney growth but it 
strongly attenuated it and reduced molecular markers of renal growth and inflammation 
when compared to hyperglycemia.47 Another inhibitor, luseogliflozin, was able to reduce 
the degree of glomerular injury, renal fibrosis, and tubular necrosis.53 These results 
suggested that SGLT2 inhibition induces a reduction of all these factors, despite a high 




2.2.4 Screening Methods 
The activity of SGLTs has been evaluated using different methodologies; including 
transport assays with radioactively labeled sugars in brush border membrane vesicles 
and transiently or stably transfected cells.54-58 Voltage-clamp techniques have yielded 
interesting and important details regarding the mechanisms underlying the binding and 
translocation reactions of the transporter59 as described in section 2.1.3.  
Methods using radioactive labeled substances are expensive due to the amount of 
the radioactive compound and also require a certain expertise handling these materials. 
Therefore, methods using fluorescent probes (section 2.2.4.1) or using an enzymatic 
reaction (section 2.2.4.2) were developed to avoid the problems with waste disposal and 
safety from radioactive methods.  
 
2.2.4.1 Fluorescent probes for direct glucose uptake measurement 
Prior to the development of fluorescent-tagged glucose bioprobes, radioisotopically 
tagged sugars were used for the measurement of glucose uptake by cells. The most 
common radiolabeled tracers include [14C] 2-deoxy-D-glucose, [18F] fluoro-2-deoxy-D-
glucose (FDG), and [14C] or [3H] 3-methyl-D-glucose. FDG is still used as non-invasive 
tool for monitoring glucose uptake and FDG-PET is routinely used for brain mapping or 
cancer diagnosis.60  
6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-D-deoxyglucose (6-NBDG) (Figure 
2.13A) was developed in 1985 and was the first fluorescent glucose derivative developed 
to probe the behavior of glucose transport systems.61,62 During the development of this 
fluorescent probe, fluorophore 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) was selected 
because of its relative strong fluorescence and the C-6 position of 2-deoxyglucose was 
preferred because it can not be phosphorylated.62  A study in red blood cells showed that 
6-NBDG can enter the cells, but its uptake is inhibited by D-glucose. This indicated that 6-
NBDG entered the cell through glucose transporters (GLUTs).62 This was further 
validated by showing that the entrance was also inhibited by cytochalasin B, a mycotoxin 
and high affinity GLUT inhibitor that disrupts actin polymerization.63 However, 6-NBDG 
enters the cell with a much lower rate (Vmax) than glucose.60 After compound 
34  
commercialization by two companies, research involving this probe was quite scarce 
(only four reports were published over nine years).  
In 1996, a group from Tokyo (Japan) was interested in monitoring bacteria viability 
and metabolic events. The probe 6-NBDG could not be use due to the substituent NBD in 
position 6 that would inhibit the phosphorylation pathway.  Therefore, the NBD group in 
position C-2 would be a much better choice for their studies and would allow 
phosphorylation by hexokinase and subsequent degradation to non-fluorescent 
metabolites. 2-NBDG (Figure 2.13B) was found to accumulate in live cells but not in dead 
cells and, similarly to 6-NBDG, its uptake was inhibited by D-glucose but not by L-
glucose.60  
A follow-up study regarding the intracellular fate of 2-NBDG revealed that this 
compound is phosphorylated after uptake, producing a fluorescent derivative, 2-NBDG-6-
phosphate, by hexokinase, which is converted back into 2-NBDG by glucose 6-
phosphatase and finally degraded into non-fluorescent products by the glycolytic 
pathway.64,65 In the same year 2-NBDG was validated as an indicator of cell viability.66  
In the last few years a large number of publications report the use of 2-NBDG to 
validate novel anti-diabetic compounds with similar effects as the hormone insulin, i.e., 
the promotion of glucose uptake in insulin-sensitive cells, such as adipocytes and skeletal 
muscle cells.67-72 In cancer research, 2-NBDG has been playing a significant role on 
targeting cell metabolism to develop cancer drugs and monitoring glucose uptake in 
cancer cells (the Warburg effectp).73-75 Potential clinical applications for 2-NBDG have 
also been developed as a tracer for cisplatin treatment in ovarian cancer.76 
In 2010, another research group successfully synthesized and tested 1-NBDG as a 
glucose probe. When used well-known inhibitors were used they obtained similar results 
to those so far published.77 Nevertheless, some issues concerning the use of NBDG 
glucose probes still remain. One example is the kinetic behavior of these tracers, e.g. 
NBDG permeates the cell 50-100 times slower than glucose, which means that the 
NBDG uptake can be easily inhibited by glucose.78 Hence, to quantify the cellular glucose 
                                            
p The Warburg effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis 
followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of 
pyruvate in mitochondria as in most normal cells 
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uptake in specific cases other methodologies, such the indirect method using the 
enzymatic assay, must be used.   
 
 
Figure 2.13 Structures of A. 6-NBDG, B. 2-NBDG, C. 1-NBDG 
 
2.2.4.2 Enzymatic assay for glucose uptake measurement 
2-Deoxyglucose (2DG) and glucose are similarly transported into the cells and are 
phosphorylated by hexokinases. However, 2-deoxyglucose 6-phosphate (2DG6P) cannot 
be either converted to an analogue like fructose 6-phosphate, or rapidly metabolized like 
glucose. Therefore, after 2DG passes through the cell membrane it is completely 
phosphorylated and accumulated inside the cell providing a measurement of glucose 
consumption.79   
In 1987 Lowry et al79 reported sensitive enzymatic methods for the measurement of 
2DG and 2DG6P as well as glucose and glucose 6-phosphate (G6P) in the same tissue 
sample.  These methods are based on the fact that both G6P and 2DG6P can be 
oxidized by G6P dehydrogenase (G6PDH). The NADH or NADPH produced indicated the 
relative amount of sugar. Higher levels of G6P and 2DG6P can be measured using of 
NADPH, which absorbance can be read at 390 nm or fluorescence at 470 nm. However, 
the weak fluorescence of NADPH and the interference from other autofluorescent 
biological molecules does not allow the direct measurement of lower levels of NADPH 
(detection limit ~ 3 µM).79-81 
Methods to increase the sensitivity of the enzyme immunoassays have been 
developed (e.g. amplification detection systems) and are based on the addition of an 
enzyme that produces a catalytic activator for a secondary system, which amplifies the 
detectable change. An example is the diaphorase-rezasurin system (Scheme 2.1).82-85 






























and 2DG6P. In these assays NADPH reduces the weakly fluorescent dye resazurin to the 
highly fluorescent resofurin in the presence of diaphorase. As the emission peak of 
resofurin is around 570 nm the autofluorescence from biological samples is negligible.81  
The reaction mixture includes ATP, NADP+, hexokinase, G6PDH, diaphorase and 
rezasurin. However, to measure 2DG6P alone, ATP and hexokinase can be left out and 
the amount of resofurin should be equal to the amount of 2DG6P, which is also 
proportional to the amount of 2DG that was phosphorylated upon entry on the cell.85 
Other recycling systems can be used in this assay such as the glutathione-DTNBq 
system,86 with the same principle.  
 
 
Scheme 2.1. Principle of the assay for measuring 2DG and/or 2DG6P. 
 
In summary, glucose is transported by SGLT1 and SGLT2 in the kidneys and 
intestines. SGLT1 inhibition can lead to severe side effects in the gastrointestinal tract; 
but the inhibition of SGLT2 can provide benefits for diabetic patients, lowering their 
plasma glucose levels by glucose excretion through the urine. Phlorizin was the first 
SGLT inhibitor and it helped, throughout the years, the development of new selective 
SGLT2 inhibitors. The assessment of new SGLT2 inhibitors can be accomplished by a 
                                            



























variety of methods including radioactive analogs, fluorescent probes, and using an 
enzymatic assay to quantify indirectly the amount of glucose taken up by the cells.  
Despite the fact that some compounds have already been approved by FDA and 
are already being commercialized some studies regarding they long-term safety are 
required to fully understand the outcomes in patients with normal or impaired kidney 



























Chapter 3. Synthesis of C-glucosyl dihydrochalcones 
 
3.1 Synthesis of chalcones and dihydrochalcones 
Chalcones and dihydrochalcones are a class of polyphenols constituted by two 
aromatic rings as illustrated in Figure 3.1, linked by the a C3 chain containing an               
α,β-unsaturated carbonyl functionality (chalcones), as shown in structure-type A, while 
dihydrochalcones (structure-type B) the three carbon atom chain linking both aromatic 
rings does not embody a double bond.  
In the literature, synthesis and biological activities of chalcones are very well 
documented. Some examples of chalcones biological properties are antimalarial,87,88 
anticancer,89-92 antibacterial,93 anti-obesity,94 antidiabetic,95 and antioxidant.94 They have 
also been reported as PET probes for in vivo imaging of β-amyloid plaques in Alzheimer’s 
disease.96 
The most common method to synthesize chalcones is based on aldol condensation 
under basic conditions which mechanism is shown In Scheme 3.1. Other renowned 
techniques for chalcone preparation include the Suzuki reaction,97 the Heck reaction,98 
the Wittig reaction,99 or organometallic-catalyzed reactions.100 These techniques employ 
several catalysts and reagents, some expensive, toxic or explosive, such as SOCl2,101 
lithium nitrate,102 zeolites,103 zinc oxide,104 or silica-supported materials.105 The main 
disadvantage of these methodologies is the fact that they require the preparation of 
starting compounds prior to the aldol condensation itself. Two examples are the pre-
preparation of the corresponding boronic acid for the Suzuki reaction or the ylide for the 
Wittig reaction. Most boronic acids are unstable in air atmosphere and need to be used 
right after their preparation or to be prepared in situ. 
 
 









Scheme 3.1 Mechanism of a basic aldol condensation for the synthesis of chalcones 
 
In nature, di-hydrochalcones are often glycosylated. The most well-known di-
hydrochalcone glycosides are narigenin dihydrochalcone (Figure 3.2A), neohesperidin 
dihydrochalcones (Figure 3.2B), and phlorizin (Figure 3.2C). However, a natural non-
glycosylated dihydrochalcone, found in apple trees and other tree barks39 is phloretin 
(Figure 3.2D). A natural C-glucosyl dihydrochalcone, found in rooibos, is nothofagin  
(Figure 3.2E).106  
 
Figure 3.2 Structures of A. Narigenin dihydrochalcones, B. Neohesperidin dihydrochalcones, C. Phlorizin, D. 
Phloretin and E. Nothofagin 
 
In 1968, Riter et al107 reported the synthesis of glycosylated dihydrochalcones 
starting from a glycosylated acetophenone and an aldehyde, forming the glycosylated 




































































The synthesis of non-glycosylated dihydrochalcones can be achieved by reduction 
of the double bond of chalcones using the common catalytic hydrogenation methods (H2, 
Pd-C) or directly via palladium-catalyzed coupling of aryl halides and 1-arylprop-2-en-1- 
ols.108 In 2008, selective reduction of the double bond using zinc systems was 
published.109,110 However the latter method cannot be use if susceptible groups (e.g. 
esters, some ethers, amides, etc.) are present.  
To avoid handling of explosive H2 it was developed a system based on Pd-C and 
triethylsilane (Et3SiH) that produces H2 in situ, achieving efficient reduction of multiple 
bonds, azides, imines, and nitro groups, as well as deprotecting benzyl and allyl groups 
under mild, neutral conditions.111 
 
3.2 Synthesis of C-glucosyl compounds 
C-Glucosyl compounds possess a furanosyl or pyranosyl group linked to an 
aglycone (aliphatic or aromatic) through a C-C bond, as illustrated in Figure 3.3.              
The  synthesis of these molecules is particularly challenging, especially when 
glycosylation takes place in aromatic rings. 
 
Figure 3.3 Model structures of A. aliphatic C-glycosyl compounds and B. aromatic C-glycosyl compounds 
 
For several years researchers searched for an easy way to synthesize C-glycosyl 
compounds. Although Wittig-like reactions112 (Scheme 3.2A), Mitsunobu 
transformations113,114 (Scheme 3.2B), reactions catalyzed by palladium115,116 (Scheme 
3.2C)  or promoted by samarium114,117 (Scheme 3.2D), and free radical reactions118 
(Scheme 3.2E), have been applied for C-glycosylation, the  most common methods 
involve a glycosyl donor as starting material which activation yields the electrophile 









Scheme 3.2 C-glycosylation by A. Wittig-like reaction, B. Mitsunobu reaction, C. palladium-catalyzed reaction,               
D. samarium-catalyzed reaction, E. radical reaction. 
 
The glycosyl donors commonly used are divided into four groups: good leaving 
groups (after appropriate activation) (Scheme 3.3A) (e.g fluoride, trichloroacetimidate, 
phosphate), glycals (Scheme 3.3B), 2,3-anhydrosugars (Scheme 3.3C), and sugar 
lactones (Scheme 3.3D). These glycosyl donors can react with organocuprates (Scheme 
3.4A), Grignard species (Scheme 3.4B), or other activated compounds (e.g phenols, 
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OAc 1. PhI(OAc)2, NaN3, PhSeSePh, 82%2.Et2B, n-Bu3SnH, PhMe, 











Scheme 3.3 C-glycosylation using A. good leaving groups (after activation); B. glycals; C. anhydrosugars; D. lactones. 
 
 
Scheme 3.4 C-glycosylation using different glycosyl donors and A. organocuprate reagent, B. Grignard reagent, and 
C. phenols 
 
The stereoselectivity of C-glycosylations is mostly determined by the 
stereochemistry of the substituent in position C-2 of the glycosyl donor and usually          
1,2-trans products are obtained. For example, with a glucosyl donor formation of the          






















































































α-anomeric configuration. However, when the glycosyl acceptor is an aromatic 
compound, the electron density of the aromatic ring, the protecting groups of the glycosyl 
donor, and the reaction conditions strongly determine reaction selectivity for either O- or 
C-glycosylation.114 Oyama et al119 demonstrated, by treating glycosyl fluoride either with 
boron trifluoride etherate (BF3⋅Et2O) (Scheme 3.5A) or the combination of BF3⋅Et2O  and 
2,6-di-tert-butyl-4-methyl pyridine (DTBMP) (Scheme 3.5B), that the former catalyst 
promoted C-glycosylation, whilst the latter promoted the O-glycosylation.  
 
Scheme 3.5 O- vs C-glucosylation using A. BF3⋅Et2O, and B. the combination of BF3⋅Et2O and DTBMP 
 
The mostly described methodology to afford C-glycosylation of aromatic compounds 
is based on the Fries-type reaction (Scheme 3.6). This one-pot reaction involves a 
glycosyl donor, an activator and a glycosyl acceptor. It proceeds through an initial 
glycoside that is rapidly formed at low temperature. Upon warming, an in situ O→C 
rearrangement occurs to give regioselectively an ortho-hydroxy C-glycosyl aromatic 
compound. 120 
 
Scheme 3.6 Fries-type rearrangement for the synthesis of C-glycosyl compounds 
 
The activators reported in literature for this type of reaction include: boron trifluoride 
etherate (BF3⋅Et2O)120-122 (Scheme 3.7A), tin chloride (SnCl4)120,123,124 (Scheme 3.7B), 
biscyclopentadienyl hafnium dichloride/silver perchlorate (Cp2HfCl2-AgClO4)124,125 
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(Scheme 3.7D), scandium(III) trifluoromethanesulfonate (Sc(OTf)3)129  (Scheme 3.7E), 
protic acid in ionic liquids130 (Scheme 3.7F), and montmorillonite K-10131 (Scheme 3.7G). 




Scheme 3.7C-glucosylation using A. BF3⋅Et2O, B. SnCl4, C. Cp2HfCl2-AgClO4, D. TMSOTf, E. Sc(OTf)3,                             























































































































More recently, the coupling between unprotected sugars and unprotected narigenin 
(a flavananone) was reported using rare-earth metal triflates (e.g Sc(OTf)3, Y(OTf)3, 
Pr(OTf)3, etc) 132 (Scheme 3.8), however, there are no reports of direct C-glucosylation of 
unprotected dihydrochalcones.  
 
Scheme 3.8 C-glucosylation of narigenin using different rare-earth metal triflates 
 
Hence, this project’ goals comprise the development of an easy to carry out and 
good yielding pathway for the synthesis of C-glucosyl dihydrochalcones and evaluate the 
prepared compounds in vitro as SGLT inhibitors (Scheme 3.9).  
 
 
Scheme 3.9 General Strategy for the synthesis of C-glucosyl di-hydrochalcones 
 
3.3 Chemo-enzymatic synthesis of glucosyl compounds 
 
The main problem for the pharmacological application of most of the biologically 
active compounds is their solubility in water; but the introduction of a higher number of 
sugar units with or without substituents such as phosphate or sulfates can, very often, 
solve the problem. However, in general, the synthesis of complex carbohydrate and 
related structures can be a difficult task, especially from a practical point of view. Chemo-
















































because it employs both chemical and enzymatic synthesis to obtain the desired 
molecules.  
In literature it is possible to find several reports regarding the chemo-enzymatic 
synthesis of glycans,133 glycoproteins,134 heparin derivatives,135 and other natural 
products.136 Many oligosaccharides can be synthesized on multi-gram or kilogram scales 
using glycosyltransferases (GTFs),137 which are enzymes that catalyse the transfer of a 
saccharide from a sugar nucleotide (sugar-UDPr) to a glycposyl acceptor (e.g ROH) 
(Scheme 3.10). The biosynthesis of oligosaccharides, catalyzed by GTFs resembles the 
corresponding chemical procedure, whereas a glycosyl donor is activated in the first step, 
followed by the transfer of the activated sugar to an appropriate acceptor sugar. Leloir 
GTFss primarily utilize one of eight different nucleotide mono- or diphosphates (UDP-Glc, 
UDP-GlcNAct, UDP-Galu, UDP-GalNAcv, GDP-Manw, GDPFucx, UDP-GlcAy, and CMP-
NeuAcz) as monosaccharide donors to build the new glycosidic bond. 
 
 
Scheme 3.10 Glycosylation using a glycosyltransferase 
 
Glycosyltransferases are specific for the type of linkage (α or β), and the linkage 
position of the glycoside bond formed [e.g. α(1à3) or β(1à4)]. They were initially 
considered to be specific for a single glycosyl donor and acceptor, however subsequent 
observations have refuted the theory of absolute enzymatic specificity by describing the 
transfer of analogues of some nucleoside mono- or diphosphate sugar donors. This class 
of enzymes can tolerate modifications to the acceptor sugar, if the acceptor meets 
                                            
r Uridine diphosphate 
s Glycosyltransferases that use UDP sugars as glycosyl donors. Non-Leloir glycosyltransferases use non-nucleotide donors 
such as sugar phosphates 
t Uridine diphosphate N-acetylglucosamine 
u Uridine diphosphate galactose 
v Uridine diphosphate N-acetylgalactosamine 
w Guanosine diphosphate mannose 
x Guanosine diphosphate fucose 
y Uridine diphosphate glucosuronic acid 














specific structural requirements (e.g. appropriate stereochemistry and availability of the 
reactive hydroxyl group involved in the glycosidic bond).138,139  
According to the Carbohydrate-Active enZymes Datable (CAZY) there are ca. 97 
families of GTFs. Among them only few C-GTF are known, and the most well 
characterized C-GT is the C-GT UrdGT2 (from streptomyces fradiae) with its crystal 
structure already determined. This enzyme catalyse the C-glucosylation between TDP-D-
olivose and different polyhydroxylated anthraquinones. Other C-GTs, which crystal 
structure is still unknown, are IroB (from E. coli) that catalyse C-glycosylation between 
UDP-D-glucose and the tricatecholic sidophore enterobactin, and Os_C-GT (from rice, 
Oryza sativa) that catalyse the glycosyl transfer from UDP-D-glucose to 2,5,7-tri-hydroxy-
substituted flavanones and dihydrochalcones acceptors (e.g. phloretin, Figure 2.9). One 
common fact between all these enzymes is the fact that the C-glucosylation occurs at 
positions ortho or para to phenolic hydroxyls, suggesting that the mechanism underneath 
this reaction is a Fries-type rearrangement (Scheme 3.6).  
The enzymatic synthesis of di- and trisaccharides was investigated, and the 
chemical O- and C-glycosylation of dihydrochalcones using these oligosaccharides would 















Chapter 4. Results and Discussion: Chemical & Enzymatic 
Synthesis 
 
One of the goals of this Ph.D. project was to synthesize C-glucosyl 
dihydrochalcones. In Scheme 4.1 are shown the two main envisioned approaches that 
were investigated in this Ph. D. project, as well as the synthesis of required glucosyl 
donors and acceptors.  
 
 
Scheme 4.1 Approaches investigated in this work for the synthesis of C-glucosyl dihydrochalcones 
 
4.1 Synthesis of glucosyl donors  
As mentioned in chapter 3 (section 3.2) sugars bearing a good leaving in the 
anomeric position can be used as glycosyl donors in electrophilic C-glycosylations. 
Therefore, the synthesis of a variety of glycosyl donors with different leaving groups was 
investigated.  
 
4.1.1 Synthesis of 1-O-acetyl-2,3,4,6-tetra-O-benzyl-α-D-glucopyranose and 
2,3,4,6-tetra-O-benzyl-α-D-glucopyranose 
The synthesis of 1-O-acetyl-2,3,4,6-tetra-O-benzyl-α-D-glucopyranose (4) 
(Scheme 4.2) was successfully accomplished in 63% overall yield over a three step 
procedure, comprising benzylation of α-methyl-D-glucopyranoside (1), followed by acid 
catalysed anomeric demethylation of 2 to afford compound 3, in which an acetyl group 









































Another approach for the synthesis of glycosyl donor 4 was investigated starting 
from D-glucose, as illustrated in Scheme 4.3. 
The first step consisted on the protection of the anomeric position with an 
isopropyl group. Without further purification of the residue obtained, it was used directly 
for the benzylation reaction to obtain compound 6. Hydrolysis of isopropyl group and 
acetylation afforded compound 4 in 60% overall yield, which is slightly lower than that 
achieved by the other pathway. However, the synthesis of compound 4 is accomplished 
in less time and with less purification steps.  
Both compounds 3 and 4 were tried as glucosyl donors in the C-glucosylation 
reaction as it will be discussed in section 4.4. 
 
 
Scheme 4.2  Synthesis of glycosyl donor 1-O-acetyl-2,3,4,6-tetra-O-benzyl-α-D-glucopyranose. 
Reaction conditions: a. BnBr (4.4 equiv.), NaH (4.4 equiv.), DMF, 0 ºC then rt, 24h, 82%; b. 2N H2SO4, AcOH, 
reflux, 24h, 81%; c. Ac2O (1.2 equiv.), pyridine, DMAP (cat.), rt, 30 min, 96%. 
 
 
Scheme 4.3 Alternative synthesis of glycosyl donor 1-O-acetyl-2,3,4,6-tetra-O-benzyl-α-D-glucopyranose 
Reaction conditions: a. 1. iPrOH, Dowex H+ exchange resin, reflux, 5 h, 2. BnBr, NaH, DMF, rt, 15 h, 79%; b. 
1. 2N H2SO4, AcOH, reflux, 24 h, 2. Ac2O, pyridine, DMAP, rt, 30 min, 76%. 
 
 
4.1.2 Synthesis of 2,3,4,6-tetra-O-trimethylsilyl-D-gluconolactone 
C-glycosyl compounds can also be synthesized using lactones as glycosyl donors; 
therefore, gluconolactone (7) required protection of hydroxy groups prior to the                   
C-glucosylation step. Benzyl groups are one of the most stable protecting groups 
because they are easily introduced and endure numerous reaction conditions. However, 














































halogenides and acid conditions with benzyl trichloroacetimidate) are unsuited when a 
lactone is the starting material and, therefore trimethylsilyl (TMS) groups were used as an 
alternative (Scheme 4.4). TMS groups were introduced in weakly basic conditions using 
pyridine as solvent and catalyst; and 2,3,4,6-tetra-O-trimethylsilyl-D-gluconolactone (8) 
was obtained in 96% yield.  
 
Scheme 4.4Synthesis of lactone 2,3,4,6-tetra-O-trimethylsilyl-D-gluconolactone (8) 
Reaction conditions: a. TMSCl, pyridine, DCM, -15 ºC then rt, 1 h, 96% 
 
4.1.3 Synthesis of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide and 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate 
The synthesis of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate 
(11) and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (12) followed a 
straightforward pathway in which D-glucose (5) was peracetylated affording compound 9; 
which was either used directly to form the glycosyl bromide (13) or, after selective 
anomeric deacetylation to give 10, used to obtain the glycosyl tricholoroacetimidate 
(Scheme 4.5). Due to its reactivity, compound 12 was not purified prior to the C-
glycosylation reaction. 
 
Scheme 4.5 ynthesis of glycosyl trichloroacetimidate and glycosyl bromide 
Reaction conditions: a. Ac2O, pyridine, DMAP, rt, 30 min, > 99%; b. BnNH2, THF, 24 h, rt, 98%; c. ClCCl3CN, 
DCM, K2CO3, rt, 24 h, 80%; d. AcBr, MeOH, AcOH (without purification)aa 
 
                                            





















































4.3 Synthesis of glucosyl acceptors  
4.3.1 Synthesis of 2ʹ ,4ʹ-di-O-benzyl-6ʹ-hydroxyacetophenone 
According to Scheme 4.1, strategy A, a protected acetophenone is required to be used as 
glycosyl acceptor in the first step. Therefore, 2ʹ,4ʹ-di-O-benzyl-6ʹ-hydroxyacetophenone 
(14) was synthesized starting from 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13), which was 
dibenzylated with benzyl bromide under basic conditions (Scheme 4.6). However, in the 
purification step a second product was detected with a similar polarity to compound 14, 
making the isolation of the desired product very challenging. Nevertheless, after careful 
separation and purification, it was possible to confirm by NMR the structure of this 
second product as that of compound 15. A singlet at δ 3.96 ppm, integrating two protons 
and five extra protons on the aromatic region (at δ 7.53-7.11 ppm) indicated the presence 
of a benzyl group (Figure 4.1). A benzyloxy group was ruled out on the basis of the 
methylene chemical shift (at δ 3.96 ppm). The benzylic protons would be expected to 
appear at δ 5.27 ppm. In 2D spectra (HMBC) it was possible to observe a correlation 
between the signal at δ 3.96 ppm and C4ʹ and C6ʹ carbons (Figure 4.2) suggesting that 
the benzyl substituent was located at position C5ʹ. The signals of carbons C4ʹ (at δ 163.7 
ppm) and C6ʹ (at δ 162.7 ppm) were identified by their correlation with the signal of OH-2ʹ 
(at δ 14.24 ppm) in the HMBC spectrum. This type of alkylation of acetophenones has 
aalready been reported by Jain et al140 using a potassium carbonate in the presence of 
benzyl chloride.  
Compounds 14 and 15 were isolated in 40% and 30% yield, respectively.  
 
Scheme 4.6 Synthesis of 2ʹ ,4ʹ-di-O-benzyl-6ʹ-hydroxyacetophenone. 



















Figure 4.1 1H-NMR of compound 15 in CDCl3 
 
Figure 4.2 HMBC spectrum of compound 15 in CDCl3 
 
4.3.1 Synthesis of chalcones  
To investigate the feasibility of strategy B described earlier on Scheme 4.1 a partly 
benzylated dihydrochalcone was prepared (Scheme 4.7). The first step on its synthesis 
consisted on the aldol condensation of compound 14 with the benzaldehyde derivative 16 
under basic conditions, and the corresponding chalcone 17 was isolated in 73% yield. 
Catalytic hydrogenation (step b) and selective dibenzylation (step c) of 18 lead to the 
54  
formation of the desired benzylated dihydrochalcone (19) in 46% overall yield. 
Nevertheless, C-glucosylation of compound 18 was also investigated. 
 
 
Scheme 4.7. Synthesis of benzylated dihydrochalcone. 
Reaction conditions: a. 50% (w/v) NaOH, 1,4-Dioxane, rt, 24 h, 73%; c. Pd/C, Et3SiH, EtOAc, MeOH, 5 h, rt, 
90%; d. BnBr, K2CO3, DMF, 0 ºC then rt, 2 h, 70%. 
 
With the optimized procedure in hand, a library of chalcones and dihydrochalcones 
was synthesized. Chalcones, as mentioned in Chapter 3, are also important biological 
molecules and in this study were investigated as potential SGLT inhibitors. To obtain the 
unprotected chalcones derivatives benzyl groups cannot be used as protecting groups. 
Hence, ethoxymethyl (CH3CH2OCH2) (EOM) groups were used instead because like 
benzyl groups they are easily introduced under mild conditions but unlike benzyl groups 
they can be cleaved in mild acidic conditions without reducing the double bond. After 
protection of 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13), chalcones (21a-21i, Scheme 4.8) were 
obtained in very good yields (85-95%) by aldol condensation of compound 13 with a 
variety of aromatic aldehydes (16a-16i). Aldehydes 16e-16g were prepared in the 
laboratory prior their used in the aldol condensation reaction; their preparation included 
the reaction of 4ʹ-hydroxybenzaldehyde with the corresponding alkyl halide under basic 
conditions (e.g. KOH or K2CO3) (Scheme 4.9). 
Deprotection of these chalcones was investigated. In literature there are no reports 
regarding the removal of EOM group, but the analogue methoxymethyl group is generally 
removed with HCl141 or other strong acids142. However, when the hydrolysis of EOM 
groups was performed in the presence of HCl the corresponding isoflavanone was 






























removal of EOM groups was achieved with no further problems and unprotected 
chalcones (22a-22i) were obtained in moderate to very good yields (67-96%).  
Microwave-assisted synthesis has been extensively exploited over the last couple of 
years. Conventional heating usually involves a furnace or an oil bath, which heats the 
walls of the container by convection or conduction and the samples take a longer time to 
achieve the desired temperature. On the other hand, with microwave heating it is 
possible to heat the target compounds without heating the entire container, which saves 
energy and time. Another advantage of this technology is the fact that it is possible to run 
reactions at a temperature higher than the boiling point of the solvent in use. This 
generally leads to cleaner/faster reactions with less secondary products. 
To evaluate the reliability of this technology synthesis of chalcones and chalcone 
deprotection were carried out in a microwave oven and in a conventional heating plate 
(Table 4.1). 
 
Scheme 4.8 Synthesis of 2ʹ ,4ʹ ,6ʹ-trihydroxychalcones. 
NOTE: EOM= CH3CH2OCH2; Reaction conditions: a. ClCH2OCH2CH3, DCM, DIPEA, 0 ºC then rt, 2 h, 74%; b. 
50% aq. NaOH (w/v), 1,4-Dioxane, rt, 24 h; c. 50% aq. NaOH (w/v), 1,4-Dioxane, 120 ºC, 250W, 1 h; d. FeCl3⋅6H2O, 





























Scheme 4.9 Synthesis of aromatic aldehydes 
Conditions used: a. MeI, Acetone, K2CO3, reflux, 6h, 98.5% ; b. EtBr, EtOH, KOH, reflux, 6 h, 98.6%; c. AllylBr, 
EtOH, KOH, reflux, 7 h, 98.6% 
 
In order to study the importance of substituents on both chalcone rings two other 
chalcone families were prepared, starting from different acetophenones. On both the 
hydroxy group on position C-6ʹ was removed; and the hydroxy group on position C-4ʹ was 
either maintained or replaced by a fluorine atom. Then, aldol condensation of both 2ʹ,4ʹ-
dihydroxyacetophenone (23, Scheme 4.10) or 4ʹ-fluoro-2ʹ-hydroxyacetophenone (27, 
Scheme 4.11) with different aromatic aldehydes afforded the chalcone scaffolds in good 
yields (67-98%). In the case of acetophenone 27 it did not require any protection prior the 
reaction while acetophenone 23 was protected with an EOM group as previously 
described. Removal of EOM group was accomplished as before, in the presence of 
FeCl3⋅6H2O and the desired 2ʹ,4ʹ-dihydroxychalcones were obtained in good yields. 
Interestingly, when aldol condensation was carried out with acetophenones 23 or 27 
in 1,4-dioxane, a precipitate was formed, that dissolved when ethanol was added to the 
reaction mixture. Consequently, reactions with these two acetophenones were carried out 
in ethanol to guarantee full homogeneity of the reaction mixture. This precipitate resulted 
probably from the extra hydroxy group in the acetophenone, that ionized in the presence 
of the base. 
In Table 4.1 is summarized the results obtained for the synthesis of these three 




















Scheme 4.10 Synthesis of 2ʹ,4ʹ-dihydroxychalcones 
Reaction conditions: a. ClCH2OCH2CH3, DCM, DIPEA, 0 ºC then rt, 1 h, 93.8%; b. 50% aq. NaOH (w/v), EtOH, 
rt, 24 h; c. 50% aq. NaOH (w/v), EtOH, 120 ºC, 250 W, 1 h; d. FeCl3⋅6H2O, MeOH, reflux, 2-3 h; e. FeCl3⋅6H2O, MeOH, 
80 ºC, 250 W, 7-10 min 
 
 
Scheme 4.11 Synthesis of 4ʹ-fluoro-2ʹ-hydroxychalcones 
Reaction conditions: a. 50% aq. NaOH (w/v), EtOH, rt, 24 h; b. 50% aq. NaOH (w/v), EtOH, 120 ºC, 250 W, 1 h  
 
Table 4.1. Synthesis of 2ʹ ,4ʹ ,6ʹ-trihydroxychalcones, 2ʹ ,4ʹ-dihydroxychalcones and 4ʹ-fluoro-2ʹ-hydroxychalcones 
using conventional and microwave methodologies 
Aldehyde Compound 
Ar group Yield (%) 
 R Conventional Microwave 
16a 21a 
 
F 91.6 97.8 
16b 21b Br 91.0 96.6 
16c 21c H 95.2 96.0 
16d 21d Me 91.6 96.0 
16e 21e OMe 87.0 90.8 









b or c EOMO
OH O
Ar



















Table 4.1 Synthesis of 2ʹ ,4ʹ ,6ʹ-trihydroxychalcones, 2ʹ ,4ʹ-dihydroxychalcones and 4ʹ-fluoro-2ʹ-hydroxychalcones using 
conventional and microwave methodologies (cont.) 
Aldehyde Compound 
Ar group  Yield (%) 
 R Conventional Microwave 
16g 21g 
 
OAllyl 98.7 98.9 
16h 21h OBn 87.7 92.3 
16i 21i 
 
Me 67.1 98.8 
16a 22a 
 
F 87.7 97.1 
16b 22b Br 96.0 94.6 
16c 22c H 79.9 82.0 
16d 22d Me 80.7 73.0 
16e 22e OMe 79.6 83.4 
16f 22f OEt 88.5 89.8 
16g 22g OAllyl 82.4 88.8 
16h 22h OBn 86.8 85.9 
16i 22i 
 
Me 67.1 92.8 
16a 25a 
 
F 91.2 86.3 
16b 25b Br 85.0 86.0 
16d 25d Me 89.2 92.8 
16h 25h OBn 92.3 93.8 
16i 25i 
 
Me 68.9 74.6 
16a 26a 
 
F 84.6 94.5 
16b 26b Br 93.7 98.2 
16d 26d Me 96.8 97.2 
16h 26h OBn 96.7 97.8 
16i 26i 
 
Me 90.9 97.6 
16a 28a 
 
F 72.6 87.5 
16b 28b Br 87.3 93.4 
16d 28d Me 83.0 95.1 
16h 28h OBn 89.9 90.5 
16i 28i 
 













According to these results, when the synthesis was performed in the microwave 
oven the yields did not change substantially but the reaction time was drastically 
decreased; from 24 hours to 1 hour in the aldol condensation step; and from 2-3 hours to 
7-10 minutes in the case of the deprotection of chalcones. The only disadvantage of this 
new technology was the limit on the amount of reactants/volume that the vessel could 
tolerate (max. 10 mL). In this case, the maximum of starting acetophenone/chalcone that 
was possible to use was 1 g. In traditional reaction vessel it was possible to scale up 
using 5 g of starting material, without significant losses of materials/products. However, 
microwave assisted synthesis has proven to be extremely efficient for the preparation of 
these chalcone families. 
 
4.3.2 Synthesis of dihydrochalcones  
In situ generation of molecular hydrogen by addition of triethylsilane to palladium-
charcoal catalyst was then applied for the first time to chalcones, resulting in a rapid and 
efficient reduction of chalcone olefinic bond to afford the corresponding dihydrochalcones 
(Scheme 4.12). The reaction was carried out at room temperature for 10 min and the 
yields were very good (93.0-98.8%, Table 4.2). Reaction completion could be detected by 
discoloration of the yellow-reddish colour of the chalcone solution. 
All the reactions afforded the desired compound in high yield, except compounds 
22b, 26b, 28b, 28i and 26i were used as starting material. In the case of compounds 
22b, 26b and 28b, reduction of the bromoaryl moiety occurred and 18c, 29c and 30c, 
respectively, were formed (Table 4.3). Some authors have already reported this 
exchange by other hydrosilane derivatives143. NMR confirmed the assigned structure 
resulted from the hydrogenation of compound 22b (Figure 4.3), in particular by the signal 
at δ ~ 7.20 ppm integrating 5 protons corresponding to the phenyl group. HRMS also 
confirmed this exchange and the mass of resulted product was the same as of compound 
18c (Figure 4.4); the calculated mass for C15H14NaO4 of compound 18c s 281.07843 m/z 
and the mass found was 281.07847 m/z.  
60  
 




Figure 4.4 HRMS spectrum of 18c resulted from 22b hydrogenation 
  
Hydrogenation of compound 28i gave two products, 30i and 30j, whose structures 
(see Table 4.2) were confirmed by NMR spectroscopy. While NMR spectrum of 
compound 30i presented the signals characteristic of the desired dihydrochalcone, the 
NMR signals of compound 30j confirm that it is a dihydrochalcone bearing a 
tetrahydrofuranyl group, resulting from reduction of both double bonds of the furanyl 
group.  
 
Scheme 4.12 Synthesis of 2ʹ,4ʹ,6ʹ-trihydroxydihydrochalcones, 2ʹ,4ʹ-dihydroxydihdrochalcones and 4ʹ-fluoro-                 
2ʹ-hydroxydihydrochalcones 


























18c H 94.4 
18d Me 98.8 
18e OMe 96.9 
18f OEt 96.1 
18g OPr 93.8 







29c H 98.7 
29d Me 99.1 







30c H 99.0 
30d Me 99.0 









4.4 Synthesis of C-glucosyl dihydrochalcones  
As shown in Scheme 4.1 different approaches were investigated to synthesize C-
glucosyl dihydrochalcones by a methodology easy to carry out, high yielding and 
comprising only a few reaction steps. Two strategies were envisioned, namely pathway A 









anomeric position, using as glycosyl donor a lactone (strategy 2) or by investigation of 
O→C rearrangement (strategy 3). 
 
Strategy 1: 
The first strategy (pathway A on Scheme 4.1) consisted on the C-glucosylation of 
2ʹ,4ʹ-di-O-benzyl-6ʹ-hydroxyacetophenone (13) using 1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-
glucopyranose (4) as glycosyl donor in the presence of a catalytic amount of Sc(OTf)3 
(Scheme 4.13). The chalcone derivative (32) prepared by an aldol condensation, from 
compound 31 with aldehyde 16a under basic conditions, was deprotected with Et3SiH/Pd-
C, affording the desired C-glucosyl dihydrochalcone (33) in 28% overall yield.  
 
 
Scheme 4.13 C-glycosylation of 2ʹ ,4ʹ-di-O-benzyl-6ʹ-hydroxyacetophenone 
Reaction conditions: a. Sc(OTf3) (0.5 equiv.), DCE, Drierite, -30 ºC then rt, 5 h, 49%; b. 16a, 50% (w/v) NaOH, 
1,4-Dioxane, reflux, 24 h, 60%; c. Pd-C, Et3SiH, EtOAc, MeOH, 5 h, rt, 96%. 
 
The strategy showed in Scheme 4.13 was developed in our group, in a different 
project, to prepared the intermediate for the synthesis of C-glucosyl isoflavones.144 In the 
current project the goal was to develop an original pathway for the synthesis of this type 
of compounds; therefore other methodologies were investigated.  
 
Strategy 2: 
As mentioned in Chapter 3, C-glucosyl compounds can also be synthesized using 
lactones as glycosyl donors. Hence, using 5ʹ-bromo-2ʹ-hydroxyacetophenone (34) as 










































intermediate hemiacetal, which after reduction by Et3SiH and BF3⋅Et2O would afford the 




Scheme 4.14 C-glucosylation using lactone as glycosyl donor. 




Alternatively, and based on the fact that the mechanism of C-glucosylation by a 
Fries-type rearrangement involves the formation of a glycoside prior to the OàC 
rearrangement, C-glucosylation starting from a glucoside was considered. Glucosides 
can be synthesized by a variety of methods, two of them using either glycosyl 
trichloroacetimidates (11) or glycosyl bromides (12) as glycosyl donors.  
Small glycosyl acceptors (13, 14 or 34) were used to prepare the glucosides 
(Scheme 4.15); however, despite the efforts, no products were detected from the reaction 
between glycosyl donors 11 or 12 with these glycosyl acceptors, using three different 
reaction conditions. The only compound detected, using both glycosyl donors, was 
compound 10 resulted from the hydrolysis of the glycosyl trichloroacetimidate or the 

























Scheme 4.15 Glycosylation using glycosyl donors 11 or 12 with glycosyl acceptors 13, 14 and 34, activated by 
BF3⋅Et2O, Sc(OTf)3 or AgOTf, depending on the glycosyl donor used 
Reaction conditions: a. 11, 13 or 14 or 34, BF3⋅Et2O, DCM, 24 h, rt then 50 ºC, 90%; b. 11, 13 or 15 or 34, 
Sc(OTf)3, DCE, 24 h, -30 ºC then rt, 10.92%; c. 12, 13 or 14, AgOTf, DCM, TMU, -20 ºC then rt, 10. 85%. 
 
Strategy 4: 
According to strategy 1, C-glucosylation should occur without significant problems 
when using compound 4 as glycosyl donor and a benzylated dihydrochalcone as glycosyl 
acceptor in the presence of catalytic amount of Sc(OTf)3. To confirm that dihydrochalcone 
19 was used as glycosyl acceptor (Scheme 4.16); but no products were detected from 
this reaction. Replacing Sc(OTf)3 by TMSOTf, and glycosyl donor 4 by 3, no product were 
obtained up to 48 h. 
 
 
Scheme 4.16 C-glycosylation of a benzylated dihydrochalcone. 
Reaction conditions: a. Sc(OTf)3 or TMSOTf, DCE, drierite, -30 ºC then rt, 48h. 











































































Alternatively, dihydrochalcone 19 was replaced by dihydrochalcone 18a and the 
reaction was carried out in the conditions above described, with both activators (Sc(OTf)3 
and TMSOTf) and both glycosyl donors (3 and 4). Only when compound 3 was used as 
glycosyl donor and TMSOTf (0.25 equiv.) as activator the expected product was 
obtained, and in 12% yield (Scheme 4.16). Increasing the amount of catalyst up to 0.5 
equiv. the yield increased to 43%, whereas the increase up to 0.75 equiv. led to the 
formation of secondary products. After deprotection by catalytic hydrogenation, the 
corresponding C-glucosyl dihydrochalcone was obtained in 36% overall yield. The overall 
yield resulted from this innovative pathway was significantly higher that with the one 
described in strategy 1, which was 28%. The C-glucosylation of dihydrochalcones          
18a-18g was then carried out using the conditions described above (Scheme 4.17) and             
C-glucosyl dihydrochalcones were successfully prepared in moderate to good                 
yields (39-52%).  
 
 
Scheme 4.17 Synthesis of C-glucosyldihydrochalcones. 
Reaction conditions: a. TMSOTf, DCM, ACN, drierite, 0 ºC then rt, 2-5 h; b. Et3SiH, MeOH, EtOAc, rt, 5 h 
 
When dihydrochalcone 18i was used in the C-glucosylation step several products 
















































The C-glucosylation of dihydrochalcone 18h did not afford any product, possibly due 
to the presence of the hydroxyl group in position 4ʹʹ on the aglycone. Hence C-glucosyl 
dihydrochalcone 33h was synthesized using the methodology described in strategy 1 
with a slightly modification, in which 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13) was                    
C-glucosylated without protection, generating compound 38 in 56.4% yield (Scheme 
4.18). The aldol condensation step did not occur with 4ʹ-hydroxybenzaldehyde (16i) 
neither with 4ʹ-benzyloxybenzaldehyde (16h) due to the acidity of the hydroxyl groups 
from the acetophenone moiety. In alternative, compound 38 was selectively dibenzylated 
affording compound 32 in 73.8% yield, which was used in the aldol condensation. 
Protected C-glucosyl chalcone, obtained in 62.5% yield, was deprotected yielding the 
desired compound 33h. The overall yield of this pathway was 36%, slightly higher than 
the one described in strategy 1 for the synthesis of an analogue, with the same number 
of steps. This methodology revealed to be more suitable than strategy 1 because it 
avoids the formation of the secondary product (compound 15) that occurred when 
dibenzylation of 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13) was carried out prior to C-
glycosylation (Scheme 4.6). 
 
 
Scheme 4.18 Synthesis of compound 33h 
Reaction conditions: a. TMSOTf, DCM, ACN, drierite, 0 ºC then rt, 2-5 h, 56.4%; b. 50% aq NaOH (w/v), 1,4-
Dioxane, reflux, 24h; c. BnBr, K2CO3, DMF, rt, 1-2 h, 73.8%; d. 50% aq NaOH (w/v), 1,4-Dioxane, reflux, 24h, 62.5%; 



































































Reaction with dihydrochalcones 29a-29i and 30a-30j (Scheme 4.19) applying the 
same conditions described above for the C-glycosylation reaction, no products were 




Scheme 4.19 C-glucosylation of 2ʹ,4ʹ-dihydroxydihydrochalcones and 4ʹ-fluoro-2ʹ-hydroxydihydrochalcones 
Reaction conditions: TMSOTf, ACN, DCM, drierite, 0 ºC then rt, 24h 
 
 
4.5 Enzymatic Synthesis of trisaccharides 
As mentioned in Chapter 4 oligosaccharides can induce solubility in compounds 
with low solubility in water. Therefore, the synthesis of two trisaccharides was 
investigated.  
The synthesis of one of the trisaccharides started from the monomer p-nitrophenol 
glucuronic acid (GlcApnp, 44), which was converted into the disaccharide α-D-GlcNAc-
(1→4)-β-D-GlcApnp (45) via N-acetyl-D-glucosaminyl transferase (KfiA) using UDP-GlcNAc 
(46, Figure 4.5) as glucosyl donor, in 70.7% yield (Scheme 4.20). Next, using UDP-GlcA (47, 
Figure 4.5) in the presence of Pasteurella multocida heparosan synthase (pmHS2), 
compound 45 was converted into the trisaccharide β-D-GlcA-(1→4)-α-D-GlCNAc-(1→4)-β-D-
GlcApnp (46) in 89.9% yield. The overall yield for the synthesis of 46 was 63.0%, over two 
steps. Alternatively, synthesis accomplished solely by chemical methods would require 
several steps including protection/deprotection steps. The avoidance of these extra steps is a 




























Scheme 4.20 Enzymatic synthesis of trisaccharide β-D-GlcA-(1→4)-α-D-GlCNAc-(1→4)-β-D-GlcApnp 





Figure 4.5 Struture of compounds 48. UDP-GlcNAc, 49. UDP-GlcA, and 50.UDP-GlcNTFA 
 
The second trisaccharide contained GlcNTFA units instead of GlcNAc. The 
conditions were the same as in the previous case and disaccharide 50 was obtained in 
89.7% yield using UDP-GlcNTFA as glycosyl donor in the presence of KfiA, followed by 
the synthesis of the trisaccharide 51 in 88.2% yield using UDP-GlcA as glycosyl donor in 
the presence pmHS2. The overall yield of this synthesis was 79.1% over two steps.  
The enzyme KfiA could be applied in this pathway because it recognizes both GlcNAc 
and GlcNTFA units; but pmHS2 only recognizes glucoronic acid units. 
All compounds were purified by HPLC and the structures were confirmed either by NMR 
or ESI-MS. Unfortunately, it was not possible to test the C-glycosylation reaction of 
dihydrochalcones with disaccharides or trisaccharides as glycosyl donors, not available 







































































































Scheme 4.21 Enzymatic synthesis of trisaccharide β-D-GlcA-(1→4)-α-D-GlcNTFA-(1→4)-β-D-GlcApnp 
Reaction conditions: a. UDP-GlcNTFA, KfiA, Tris (pH 7.2), MgCl2, 88.2%; b. UDP-GlcA, pmHS2, Tris (pH 7.2), MgCl2, 
89.7% 
 
In parallel, pmHS2 enzyme was expressed in bacterial cells and purified.  BL21 
cells were grown overnight in Luria Broth (LB) containing 50 µg/mL of ampicillin and then, 
one portion was expanded to a bigger volume, in same growth media, which was 
incubated for a couple of hours until an optimal densitybb at 600 nm was reached (4-6 
hours). 
The temperature was decreased and isopropyl β-D-1-thiogalactopyranoside, which 
is effective inducer of protein expression, was added to the medium. The incubation 
proceeded until an optimum induction yield was reached (ca. 18 hours). The expressed 
enzyme was harvested and purified using an NTA-agarose column yielding 0.17 µg/µL of 
pure enzyme. 
To test the activity of this enzyme a 100 µL reaction to synthesize disaccharide 45 
was carried out. An aliquot of the reaction mixture was used for HPLC to ensure that          
> 95% of UPD-GlcNAc was consumed. To confirm the purity of the enzyme a SDS-PAGE 
electrophoresis was conducted and analysing the gel it was possible to conclude that the 
enzyme was considerably pure (Figure 4.6).  
                                            














































Figure 4.6 SDS-PAGE Electrophoresis Gel of pmHS2 
 
In summary, in chapter 4 the successful generation of a small library of chalcones 
and dihydrochalcones bearing different substituents on both aromatic rings is described. 
Microwave assisted synthesis proved to be an excellent methodology for the synthesis of 
chalcones, with the ability of decreasing substantially reaction time providing the same 
high yields. The combination of Et3SiH and Pd-C is an alternative to the use of H2, and is 
an innovative method for the synthesis of dihydrochalcones. However, it cannot be 
applied if substituents or functionalities, that will be also reduced, should be kept in the 
target chalcone, such as bromides or double bonds.  
Moreover, an original and innovative methodology for the synthesis of C-glucosyl 
dihydrochalcones was developed based on a direct C-glycosylation of dihydrochalcones 
in moderate overall yields, few steps and less secondary products. 
An enzymatic approach was successful for the synthesis of two disaccharides and 
two trisaccharides, that can be later transformed into glycosyl donors for glycosylation 
reactions to induce solubility in compounds with low solubility in water. An enzyme was 
expressed in bacterial cells and purified; SDS-PAGE was used to confirm its purity.  
With all the C-glucosyl dihydrochalcones in hand, biological studies were 











Chapter 5. Results and Discussion: In vitro studies 
 
5.1 Generation of stable cell lines 
Evaluation of SGLT inhibition using chemical compounds is, in general, 
accomplished by a glucose uptake assay in live cells. There are two different methods 
currently described in the literature. One uses either the fluorescent analogue of glucose 
2-NBDG whereas the other uses 2-DG. Both are described in more detail in Chapter 2. 
The advantage of using these two sugars as probes of glucose uptake when compared 
with glucose is the fact that they accumulate inside the cells, whereas glucose is further 
metabolized. Ideally, the biological studies should be carried out using a stable cell line, 
i.e., a cell line that has been transfected with foreign DNA that has been “stably” 
incorporated into the cell’s genome.  
Briefly, the generation of a stable cell line requires two main steps: a transientcc 
transfection with the gene of interest; and the addition of a specific antibiotic, after a 
certain period of time, to kill all the non-transfected cells (all the growing cells will have 
the gene integrated). Some preparation/optimization steps are require to obtain a stable 
clone with high expression of the gene of interest, such as the preparation of the 
plasmid(s), the optimization of the transfection process, the determination of the effective 
concentration of antibiotic to be added to the cells, among others. These will be 
discussed within this chapter.  
 
5.1.1 Preparation of the plasmids hSGLT1 and hSGLT2 
DH5α cells were transformed with pCMV6-Neo vectors containing human SGLT1 
and SGLT2 complementary DNAs (cDNAs) and plated on LB agar plates containing 
ampicillin (Figure 5.1). The pCMV6-Neo vectors contain a gene conferring ampicillin 
resistance to bacterial cells; therefore, it was possible to grow only cells containing these 
plasmids. A negative control was used, in which no vector was added and no cell growth 
was observed.  
 




A                     B       C 
Figure 5.1 Agar plates of transformed DH5α cells after 24 h of incubation: A. Control; B. SGLT1; C. SGLT2 
 
After an overnight incubation two colonies were picked and grown overnight in 
media that contained the same antibiotic at the same concentration. The media was 
removed by centrifugation and the bacteria were recovered in a pellet form that was later 
purified using a Maxiprep kit® from Sigma.  
The purity and concentration of each plasmid was confirmed using a NanoDrop 
spectrometer. The purity of DNA using a spectrometer is given by the ratio of the 
absorbance at 260 and 280 nm, which should fall in the range of 1.8–1.9. In this case 
plasmids had a ratio A260/A280 of 1.87 and 1.89, respectively. SGLT1 and SGLT2 
concentrations were 5.8 µg/µL and 5.0 µg/µL, respectively.  
A digest restriction was performed to verify the integrity of the two plasmids. Herein, 
the restriction enzymes used were BamHI, KpnI, SacI and SacII. The products were 
separated in an agarose gel electrophoresis and the resulted bands were visualized 
using a fluorescent UV light (Figure 5.2). A standard DNA ladder was used to be able to 
identify the molecular weight of each fragment. The two lanes on the left side of the gel 
are the wild type plasmids without digestion, in their circular form; on the right side are 
the bands of the fragments after digestion. If one enzyme cuts only in one site of the 
sequence the resulted band has the same molecular weight as the wild type plasmid, but 
if the enzyme cuts in two or more sites two or more fragments are obtained. To predict 
the number of sites where each enzyme is able to cut restriction maps were generated 
using the Vector NTI® software (Figure 5.3). Therefore, e.g. enzyme SacI cuts SGLT2 
DNA only in one place and the predicted molecular weight is the same as the wild type 
(~8Kbp); but SacII cuts SGLT2 DNA in two places originating two fragments, one with a 
very low molecular weight (~900bp, which is not detected in the gel) and other with a 
slightly lower molecular weight than the wild type (~7Kbp). The same analogy can be 
applied for the other enzymes. Both plasmids seemed to be intact because the fragments 
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resulted from the digest restriction are in concordance with the expected from the 
restriction map.  
 
Figure 5.2 Gel Electrophoresis of the products from the digest restriction of SGLT1 and SGLT2 plasmids 
 
 
   
Figure 5.3 Restriction maps for SGLT1 and SGLT2 plasmids 
NOTE: In parenthesis is the exact location of the cut size of each enzyme. 
 
To further confirm the integrity and correct sequence of the plasmids prior the stable 
cell line generation, they were sequenced (Bioneer). Using the Clustal W2 software, 
theoretical and experimental sequences were superimposed (Figure 5.4) and it was 
found that they were completely aligned, for both plasmids, meaning that the amplified 
plasmids have the right sequence. A partial alignment sequence for SGLT1 and SGLT2 is 
shown in Figure 5.4. (For the full sequences see Supplemental Section) NOTE: The 
symbol star (*) under each nucleotide unit means that the nucleotide was found.  
Based on the results obtained from Bioneer along with the results from the digest 
restriction it was possible to confirm that the plasmids had the right sequence and they 












        A                B 
Figure 5.4 Partial alignment sequence of A. SGLT1 and B. SGLT2 plasmids 
 
5.1.2 Transfection Optimization 
To generate a stable cell line is necessary to introduce the gene of interest (GOI) 
into the cells through a process called transfection. One of the most common methods to 
transfect cells is by ‘Cationic Lipid Transfection’ whereas a cationic lipid-based reagent 
spontaneously form condensed nucleic acid-cationic lipid complexes via electrostatic 
interactions between the negatively charged nucleic acid and the positively charged head 
group of the synthesis lipid. Despite the fact that the exact mechanism remains unknown 
it is believed that the cells take up these complexes through endocytosis and then 
released into the cytoplasm followed by the translocation to the nucleus where it will be 
expressed. The advantage of this method relies on the fact that a broad range of cell 
lines can be transfected with high efficiency, it can be applied to high-throughput screens 
and it can deliver all sizes of DNA as well as RNA and proteins. However, the efficiency 
of cationic lipid-mediated transfection depends on the cell type and culture conditions, 
requiring the optimization of transfection conditions for each cell type and transfection 
reagent.  
HEK293 cells were chosen for this project due to their quick and easy reproduction 
and maintenance, a high amenability to transfection using a wide variety of 
methods/reagents, and a high efficiency of transfection and protein production. 
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The optimization of HEK293 cell line transfection was required and Lipofectamine 
LTX® to transfect this cell line with EGFP, which is a fluorescent protein that belongs to 
the GFP (Green Fluorescent Protein) family. Among other purposes, this protein is 
greatly used for the optimization of transfection conditions since transfected cells can be 
seen by fluorescence microscopy or the fluorescence can be measured using a 
microplate reader. 
The first step in this optimization process consisted in the determination of the 
optimal cell number to use in a 96-well plate. HEK293 cells were plated with different 
1.0×104, 2.0×104, 3.0×104 and 1.0×104 cells/well, in duplicate. After 24 hours of 
incubation cells were observed under the microscope and the cell number was that 
provided 80-90% confluence. For example, 50% confluence means that roughly half of 
the surface is covered and there is still space for cells to grow; 100% confluence means 
the surface is completely covered by the cells, and no more space is left for the cells to 
grow as a monolayer. Thus, 2.0×104 cells/well was the cell number chosen for the 
transfection. HEK293 cells were plated and transfected using eight different conditions 
(Table 5.1). These conditions were chosen based the specifications from the 
manufacturer; whereas the amount of DNA must be lower than 2.5 µg and the volume of 
Lipofectamine should be between 1 and 2.5 µL. Nevertheless, DNA and Lipofectamine 
amounts should never be higher enough to cause toxicity to the cells neither should be 
lower enough to cause a low transfection yield.  
As it is possible to observe on Graph 5.1 the condition 7 (ratio 1:2, 
DNA/Lipofectamine) was the one that afforded the highest fluorescence intensity. 
Conditions 1, 7 and 8 were chosen for analysis by fluorescence confocal microscopy 
(Figure 5.5) and it was confirmed that condition 8 is indeed the best condition to use in 
transfection of HEK293 cells due to the higher number of fluorescent cells, which means 







Table 5.1 Conditions for Transfection Optimization 
Condition Characteristics 
1 2.5 µL lipo + 1.25 µg DNA 
2 2.0 µL lipo + 1.25 µg DNA 
3 1.5 µL lipo + 1.25 µg DNA 
4 1.0 µL lipo + 1.25 µg DNA 
5 1.0 µL lipo + 0.5 µg DNA 
6 0.8 µL lipo + 0.4 µg DNA 
7 0.6 µL lipo + 0.3 µg DNA 
8 0.4 µL lipo + 0.2 µg DNA 
 
 
Graph 5.1 Fluorescence results using different conditions in transfection 
 
 
Condition 1       Condition 7             Condition 8 

























5.1.3 Generation of SGLT1 and SGLT2 stable cell lines 
To generate a stable cell line it is necessary to transfect the cells with the GOI and 
treat them with a specific antibiotic for a period of time, necessary to kill all of the non-
transfected cells and guarantee that the growing cells will have incorporated the gene.  
In this case, SGLT1/SGLT2 plasmids are hosted in a pCMV6-Neo vector, which 
means that they have a Neo (neomycin) resistance gene, i.e. if the cells are treated with 
neomycin or similar antibiotic all of the non-transfected cells dye after a certain period of 
time, normally 7 days. Neomycin or kanamycin can be used to select prokaryotes but 
geneticin (G418) is generally needed for selection in eukaryotes. 
The antibiotic concentration requires optimization, using a killing curve to guarantee 
that all of the non-transfected were killed after 7 days of treatment. According to the 
literature145 the optimal concentration of G418 as a selection antibiotic should fall in the 
range of 400-800 µg/mL; therefore, HEK293 cells were plated in a 96-well plate and after 
24 h of incubation, G418 was added to each well so that the final concentration ranged 
from 0-1000 µg/mL, in 100 µg/mL increments. The media was replaced every two days 
adding fresh antibiotic for up to 7 days of treatment. Results can be classified as low, 
optimal or high dose. Low dose is the concentration where there is a minimal visual 
toxicity apparent even after 7 days of selection. Optimal dose is the lowest concentration 
at which all cells are dead after 7 days of selection. High dose is the concentration where 
a visual toxicity (cells start to become rounded and start to detached from the well) is 
evident and all cells are dead after 2-3 days. The low dose was 100-500 µg/mL, optimal 
dose was 600 µg/mL, and the high dose was > 800 µg/mL. Therefore, 600-700 µg/mL 
was the concentration of G418 chosen to select the SGLT1/SGLT2-HEK293 transfected 
cells.  
After selecting the optimal concentration of G418, HEK293 cells were transfected to 
generate the stable cell lines in two different conditions.  
First, HEK293 were plated on two 24-well plates and incubated for 24 h, after which 
cells were transfected with SGLT1 and SGLT2, respectively, with TrueFect with a ratio of 
DNA/TrueFect 1:2. NOTE: TrueFect was used instead of Lipofectamine because it was 
the reagent available at the moment of the generation of the stable cell lines. 
Nevertheless, the conditions optimized for Lipofectamine were tested with TrueFect and 
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the same results were obtained. On the next day media was changed and the cells were 
incubated for another 24 h after which G418 was added to each well. The media was 
replaced every two days and fresh G418 was added for up to 7 days. After this period the 
concentration of G418 was reduced to 300 µg/mL and cells were allowed to grow until 
confluent enough for cryopreservation. Cells treated with TrueFect alone were used as 
control and after the 7 days of treatment all cells were dead. Clones resulted from this 
condition were named 600-Row-Column-Plasmid, e.g., 600B1SGLT1. 
Second, HEK293 cells were plated on three 60 mm dishes and 24 h later cells were 
transfected with both plasmids, respectively, and Truefect alone was used for the control 
as previously described. On the next day cells were trypsinized and plated onto a 24-well 
plate and incubated for another 24 h after which G418 was added to a concentration of 
700 µg/mL. The same procedure was followed until the cells were confluent for 
cryopreservation. Clones resulted from this condition were named 700-Row-Column-
Plasmid, e.g., 700B1SGLT1. 
Several clones of HEK293-SGLT1 and HEK293-SGLT2 were cryopreserved and 
some clones were characterized by Western Blot and RT-PCR. The stable clones used in 
the glucose uptake assay, to determine the inhibitory properties of the target compounds, 
were also evaluated by 2-NBDG assay using fluorescence confocal microscopy.    
 
5.2 Western Blot 
The Western Blot is a widely used analytical technique to detect specific proteins in 
a sample using antibodies. The native proteins are separated by SDS-PAGE and then 
are transferred to a membrane, generally nitrocellulose or PVDF (Polyvinylidene fluoride) 
membrane. This membrane is later incubated with a primary antibody, which bind to the 
immobilized target protein. A second solution is then added, containing a secondary 
antibody that binds specifically to the first one (Figure 5.6). This secondary antibody can 
possess a fluorescent dye or a radioactive label that enables the visualization of protein-
antibody complexes. This technique is sensitive to the amount of the target protein 
present in the sample, and therefore it can be used to monitor how well a stable cell line 





Figure 5.6 Illustration of detection of a protein by Western Blot 
 
Stable clones were plated on 60 mm dishes and after 24h of incubation cells were 
lysed and protein content was quantified by the Bradford protein assay. For each clone, 
an aliquot of 50 µg of protein was used in the SDS-PAGE. Proteins were then transferred 
to a nitrocellulose membrane, which was blocked with a solution of TBST (tris-buffered 
saline) containing non-fat milk and Tween-20 (a detergent) to avoid non-specific binding. 
NOTE: Before the incubation with antibodies it is necessary to block the remaining 
binding surface otherwise the antibodies or other detection reagents will bind to any 
remaining sites that initially served to immobilize the proteins of interest.  
The primary antibody (1:200 for SGLT1-AB and 1:500 for SGLT2-AB) in TBS-T and 
5% of BSA was added to the membrane and then incubated for 75 min at room 
temperature. After that period the membrane was washed three times with TBS-T and 
then incubated with the secondary antibody (1:2000 for SGLT1 and 1:4000 for SGLT2) 
for 45 minutes. ECL reagent (Enhanced ChemiLuminescence) was added to each 
membrane and incubated for a short period (3-5 minutes). The membranes were imaged 
on a film and protein blots were visualized (Graph 5.2) and the blots were quantified 
using Fiji software (Graph 5.9). According to the results all the clones overexpress 
SGLT1protein, but clone 700B1 seemed to be the one with the higher expression, as 
showed in Graph 5.2. Regarding the SGLT2 expression, clone 700A1 revealed the 
highest expression although clones 700A3 and 700A4 are also overexpressing the 
protein.   
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Since the process of growing the stable clones is a time-consuming process some 
clones were evaluated using this technique while others were directly used in the glucose 
uptake assay, which will be discussed later in detail.  
 
 
Figure 5.7 Western Blot for some SGLT1 and SGLT2 stable clones 
 
 
Graph 5.2 Quantification of SGLT1 and SGLT2 expression by Western Blot 
 
Analyzing the results it was established that clones 700B1SGLT1 and 700A1SGLT2 
were those overexpressing the proteins in higher proportion and, therefore used for the 
glucose uptake assay (discussed later). During the generation of these clones some 
conclusions were taken: cells must be trypsinized and diluted after 24 h post-transfection 
to avoid overgrowth (high confluence), the addition of the selection antibiotic must be 
added only 48 h post-transfection to guarantee a maximum of transient expression of the 
GOI and increase the number of transfected cells, and the addition of the antibiotic must 
be continued after the days of treatment otherwise the plasmid might be expelled from 
























































Reverse transcription polymerase chain reaction (RT-PCR) is a technique 
commonly used in molecular biology to detect gene expression through the synthesis of 
complementary DNA (cDNA) transcripts from RNA, which is subsequently amplified using 
traditional PCR (Figure 5.8). After the addition of a fluorescent dye to the reaction 
mixture, an agarose gel electrophorese is carried out and the products are visualized 
using fluorescence UV light.  
 
Figure 5.8 Schematic illustration of cDNA synthesis and RT-PCR 
 
The presence of hSGLT1 and hSGLT2 genes in the two clones (700B1SGLT1 and 
700A1SGLT2) was confirmed by RT-PCR, which revealed strong PCR products (bright 
bands) in both cell lines, as it is possible to visualize in Figure 5.9 and Graph 5.3. 
Moreover, the two products observed on the gel were in agreement with the expected 
size 328 bp and 321 bp for SGLT1 and SGLT2, respectively. No expression of either 
protein was observed on wild type HEK293 cells. Transiently transfected cells served as 
positive controls, and it was possible to observe the expected increase in expression of 
both proteins in stable cell lines.  
 
 









Graph 5.3 Quantification of the mRNA 
 
5.5 Cytotoxicity assays 
Cytotoxicity assays are widely used in in vitro toxicology studies and used by 
researchers to screen for cytotoxicity in compound libraries. Compounds that have 
cytotoxic effects often compromise cell membrane integrity. There are several methods to 
evaluate the cytoxicity in live cells. Some dyes, such as trypan blue or propidium iodide, 
freely cross the membrane of dead cells or non-healthy cells, when the membranes have 
been compromised, and stain intracellular components. This method is commonly used 
in cell culture.  
Membrane integrity can also be assessed by monitoring the passage of substances 
that are normally retained inside the cells, such as lactate dehydrogenase. One of the 
most common methods to evaluate cytoxicity is the MTT assay (Scheme 5.1A), in which 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) is added to the 
cells, and the viable ones reduce the reagent generating the corresponding formazan 
product, which is colored. Its absorbance can be read and it is proportional to the number 
of live cells. A similar method has also been developed using the non-fluorescent dye 
resazurin, which after reduction by live cells generates the fluorescent resofurina 
(Scheme 5.1B). Similarly, fluorescence output is proportional to the number of live cells. 
Nonviable cells rapidly lose metabolic capacity and thus do not generate a fluorescent 
signal. In this study the method used was the CellTiter-Blue® Cell Viability Assay, which 






















Scheme 5.1 A. Reaction of MTT assay, B. Reaction of CellTiter-Blue® assay 
 
 
All the compounds synthesized were tested toward their toxicity in the cell line used 
in this study prior the glucose uptake assay. Compounds at a concentration of 100 µM 
were added to the cells, in triplicate, and incubated for 20-24 h. After this period CellTiter-
Blue® was added to each well and incubated for 4 h. Fluorescence was measured at       
λem = 590 nm after excitation at λexc = 530 nm. DMSO treated cells were used as the 
positive control and the cell viability (%) was calculated by comparison with the       
untreated cells.  
Compounds 18a-18h, 22a-22h and 33a-33h revealed no significant cytoxicity towards 
HEK293 cells (Graph 5.4). On the other hand, compounds 26a-26h, 28a-28h, 29a-29h 
and 30a-30a showed significant cytoxicity, although none of them showed more then 





























Graph 5.4 Cell viability assay 
 
5.6 Glucose uptake assay 
The ability of a compound to inhibit SGLTs has been measured using several 
methods, including transport assays with radiolabelled sugars, voltage-clamps 
experiments, and more recently using fluorescent sugars and enzymatic methods, which 
are less expensive and easier to perform.  
 
5.6.1 2-NBDG uptake assay 
The 2-NBDG method (Chapter 2.2.4.1) seemed to be the easiest method to use for 
this study and its feasibility was investigated in transiently transfected cells, while the 
stable cell lines was being established. HEK293 and HEK293 SGLT1-transiently 
transfected cells were plated in a 96-well plate and incubated overnight in DMEM without 
FBS (Fetal Bovine Serum). NOTE: The serum-starvation is to ensure that all the cells are 
in the same stage of growth and to avoid the action of insulin present on FBS. On the 
next day the media was removed, cells were carefully washed with Krebs-Ringer-
Phosphate-HEPES buffer and incubated for 40 min. After this period, 2-NBDG at 100 and 
200 µM was added to the wells followed by incubation for 60 min after which the media 
was removed, cells were washed three times with KRPH buffer and lysed. Fluorescence 
of lysate was measured at λem = 528 nm and λexc=485 nm. The same experiment was 



































































































2-NBDG (Graph 5.5). In both assays the 96-well plates were pre-coated with poly-D-
lysine to avoid the detachment of the cells. Moreover, two different lysis buffers were 
tested, specifically 0.1 N NaOH, 0.1 N HCl and 0.5% SDS, and 40 mM, 20 mM Tris (pH 
7.4) and 1% sodium deoxycholate. The former abolished fluorescence whereas the latter 
did not.  
 
Graph 5.5 2-NBDG uptake on HEK293 and COS-7 wild type cells vs SGLT1-transfected HEK293 and COS-7 
cells. 
 
In Graph 5.5 it is possible to observe that there was a slight increase on the uptake 
of 2-NBDG in SGLT1-transfected cells on both cell lines, when it was given 100 µM of 2-
NBDG. However, when the concentration was increased to 200 µM their fluorescence 
increased almost 2-fold, when compared to the 100 µM values. Nevertheless, HEK293 
cells, transfected and non-transfected, seemed to uptake 2-NBDG to a higher degree 
than COS-7 cells. Later, the same assay was run with non-transfected HEK293 cells in 
the presence of phlorizin (Figure 2.9) and almost no inhibition was observed. Another 
feature observed always in this assay was that there was no consistency among the 
three wells and no reproducibility between assays. For this reason, the other assay           
(2-deoxyglucose uptake) was investigated to obtain more consistent results. 
 
5.6.2 2DG uptake assay 
In this assay, HEK293 were cultured on a 96-well plate and incubated overnight. On 


























for 40 minutes prior the addition of 2-DG at a concentration of 1 mM. Cells were 
incubated for 1 h 30, then washed three times and lysed with a 0.1 N NaOH solution. 
Lysates were incubated at 80-85 ºC for 40 minutes, and then neutralized with 0.1 N HCl 
solution and buffered with TEA buffer (triethanolamine, pH 8.2). To an aliquot of each 
lysate was added a solution containing 50 mM TEA pH 8.2, 50 mM KCl, 0.5 mM MgCl2, 
0.02% BSA, 670 µM ATP, 0.12 µM NADP, 5.5. U/mL hexokinase, 16 U/mL G6PDH, 1 
U/mL diaphorase and 25 µM resazurin, later incubated at 37 ºC for 1 h 30. Fluorescence 
was measured in a microplate reader at λem = 590 nm and λexc = 560 nm (Graph 5.6). 
However, after some repetitions using exactly the same conditions it was found that the 
results were not reproducible. The 2-DG that enters the cell is phosphorylated by 
endogenous hexokinase but, if the cells are not properly washed and all the extracellular 
2-DG removed, the hexokinase present in the cocktail mixture will be able to 




Graph 5.6 2DG uptake in HEK293 wild type cells 
 
Hexokinase can be left out and fluorescence values represent the amount of 
2DG6P, which is the amount of 2DG that entered into the cell and phosphorylated by 
endogenous hexokinase. Therefore, not using hexokinase in the enzymatic cocktail 
completely removes the error from the extracellular 2-DG since the cells do not require 
the washing step, leading to more reproducible results. To verify and confirm this 
hypothesis a standard curve of serial dilutions of 2DG6P was performed using a cocktail 

























G6PDH, 0.1 U/mL diaphorase, 10 µM resazurin. Similarly, an aliquot of 2DG6P solutions 
at different concentration were placed into a 96-well plate and this cocktail mixture was 
added. Fluorescence was measured after overnight incubation to guarantee that the 
reading corresponded to the end-point of the enzymatic reaction (Graph 5.7). It was 
observed that more than 4 h of incubation gives the most accurate results. NOTE: the 
cocktail mixture was prepared on the day of the assay from stock solutions of the several 
components. This experiment was repeated more than once and showed that the assay 
is reliable and can be used to evaluate the 2DG uptake into the cells.  
 
Graph 5.7 2DG6P standard curve 
 
To use transiently transfected cells for the evaluation of the compounds, HEK293 
and HEK293T cells were transfected with SGLT1 and SGLT2 plasmids using two 
different transfection reagents, TrueFect and X-TremeGene. The enzymatic assay was 
carried out and it was observed that HEK293T after transfection can uptake more 2-DG 
than HEK293 cells (Graph 5.8). Moreover, X-TremeGene reagent seemed to have a 
better transfection efficiency and it seemed to be less toxic to the cells than TrueFect as 
a high percentage of cell death was observed before running the assay when the later 



























Graph 5.8 2DG uptake on HEK293 vs HEK293T cells and TrueFect vs X-TremeGene 
 
Western Blotting on HEK293 and HEK293T using these two transfection reagents 
also confirmed the fact that HEK293T is a better cell line to work with if the assay is ran 
with transiently transfected cells (Figure 5.10, Graph 5.9). Unfortunately, HEK293T 
cannot be used to generate a stable cell line since they possess a neomycin resistance 
gene; therefore, in the presence of G418 the cells will not die.  
 
 
Figure 5.10 Western Blot of HEK293 and HEK293T cells using different transfection reagents 
 





























































































HEK293T cells were chosen to proceed on the optimization of the enzymatic 
method to evaluate the inhibition properties of the target compounds. Therefore, 
HEK293T cells were plated on 35 mm dishes and incubated overnight. Two dishes were 
transfected with SGLT1 and SGLT2, respectively and the third was used as a control and 
only transfection reagent was added (no DNA). The media was replaced by DMEM 
without FBS prior the addition of DNA mixtures and the dishes were incubated overnight. 
On the next day, media was replaced by KRPH buffer after a brief washing step, and the 
cells were incubated for 1 h. After this period phlorizin was added to the wells at a final 
concentration of 100 µM along with 2-DG (0.5 mM or 1 mM) in different conditions as 
showed in Table 5.2.  
 
Table 5.2 Different conditions used during optimization of 2DG uptake assay 
Condition Method Remarks 
1 1 µL Phlo (100 µM) + 10 µL 2-DG (10 mM) Added together, same time 
2 1 µL Phlo (100 µM) + 5 µL 2-DG (10 mM) Added together, same time 
3 1 µL Phlo (100 µM) then 10 µL 2-DG (10 mM) 10 min apart 
4 1 µL Phlo (100 µM) then 5 µL 2-DG (10 mM) 10 min apart 
5 10 µL Phlo (1mM) + 10 µL 2-DG (10 mM) Added together, same time 
6 10 µL Phlo (1mM) + 5 µL 2-DG (10 mM) Added together, same time 
7 10 µL Phlo (1mM) then 10 µL (10 mM) 10 min apart 
8 10 µL Phlo (1mM) then 5 µL (10 mM) 10 min apart 
 
After the addition of 2-DG the plates were incubated for 1 h and the enzymatic 
assay was performed as described previously. Fluorescence (Graph 5.10) was measured 
and it was observed that, when phlorizin is added from the stock solution of 10 mM (1 µL) 
there is very low inhibition (40-60%), whereas when phlorizin is added from a buffer 
diluted solution (from 1 mM, 10 µL) the inhibition percentage is much higher, which 
means that some insolubility might be the responsible for such low values of inhibition. 
Therefore, phlorizin and all the others compounds were pre-diluted before their addition 
to the cells to avoid solubility issues.  
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Graph 5.10 2DG uptake assay using different conditions 
 
Once the conditions for the assay were optimized, some stable clones were 
confluent enough for cryopreservation, some were used for Western Blot (as showed 
before), and some were also used in this assay to evaluate their ability to uptake 2DG 
more efficiently than the wild type cell line. The stable clones were plated on 96-well plate 
and, using condition 7 (Table 5.2), assayed as described previously (Graph 5.11). The 
assay confirmed the data from the Western Blot, RT-PCR and microscopy that the clones 
700B1SGLT1 and 700A1SGLT2 were the ones with higher expression of the proteins 
and consequently higher uptake of 2DG.  
 









































































































With the two stable cell lines in hand all the compounds were screened at a 
concentration of 100 µM (Graph 5.12) and at this concentration all the compounds 
completely inhibited the 2-DG uptake in both cell lines.  
 
Graph 5.12 2DG uptake inhibition at 100µM 
 
IC50 values were determined using the enzymatic assay. Both cell lines were plated 
in 96-well plates and incubated in low-glucose DMEM without FBS. On the next day cells 
were treated as described previously and compounds 18a-18h, 22a-22h, 33a-33h, 
phlorizin (Phlo, Figure 5.11A) and dagliflozin (DAPA, Figure 5.11B) were added at 
different concentrations, ranging from 0.1 nM up to 200 µM. Phlorizin (a non-selective 
SGLT1/SGLT2 inhibitor) and dapagliflozin (a FDA approved selective SGLT2 inhibitor) 
were used as controls. 
Adequate diluted stock solutions in KRPH buffer were prepared on the day of the 
assay, to guarantee maximum solubility.  
The inhibition curves (Figure 5.12 and Table 5.3) were obtained using Prism6 
software and are given by the mean of three independent assays.  
From the results obtained, it was possible to observe that all the aglycones 18a-18h 
and 22a-22h have similar IC50 values and do not have significant selectivity towards 
either SGLT1 or SGLT2. On the other hand all the C-glycosyl dihydrochalcones (33a-

















phlorizin. However, none of these compounds as potent and SGLT2 selective than the 
commercial drug Dapagliflozin (DAPA) neither a similar IC50. 
Among all the compounds, 33h was to be the best lead. The IC50 of this compound 
toward SGLT1 (19.0 µM) is 10-fold higher than the IC50 of DAPA (1.8 µM) and 20-fold 
higher than the than the IC50 of phlorizin (~ 0.5 µM), which means that its SGLT1 
inhibition is significantly lower than both DAPA and phlorizin.  
Regarding the inhibition of SGLT2 protein, the IC50 of DAPA and phlorizin is 0.8 and 
67.3 nM, respectively, whereas the IC50 of compound 33h is 11.9 nM; therefore, 
compound 33h is 10 times less active than DAPA but 7 times more active than phlorizin.  
Comparing the selectivity toward SGLT2 protein, compound 33h is highly selective, 
although selectivity of DAPA is 1.4 times higher.  Nevertheless, changing from an             
O-glucoside (phlorizin) to the corresponding C-glucosyl derivative (33h) it was possible to 
increase its selectivity and decrease the SGLT1 inhibition. 
 
 












































































































































































































































































































Figure 5.12 Inhibition curves of compounds Phlo, DAPA, 18a-18h, 22a-22h, and 33a-33h for SGLT1 protein 
 
  
   
  





































































































































































    
  
    
  
Figure 5.13 Inhibition curves of compounds Phlo, DAPA, 18a-18h, 22a-22h, and 33a-33h for SGLT2 protein 
 











































































































































































































Graph 5.13 IC50 values for SGLT1 and SGLT2 
 
 
Table 5.3 In vitro screening data for SGLT inhibitory activity and selectivity 
Compound SGLT1 IC50 (µM)a SGLT2 IC50 (µM)a Selectivity 
Phlorizin 0.499 ± 0.12 0.0673 ± 5.1 7.4 
Dapagliflozin 1.8 ± 0.33 0.008 ± 0.29 2250 
18a 9.6 ± 0.87 15.8 ± 1.1 - 
18c 7.9 ± 1.0 14.7 ± 0.63 - 
18d 9.9 ± 0.78 18.0 ± 0.95 - 
18e 13.3 ± 0.65 18.7 ± 1.4 - 
18f 15.1 ± 0.61 16.7 ± 1.7 - 
18g 11.6 ± 0.60 16.4 ± 1.0 - 
18h 12.4 ± 1.4 18.3 ± 0.59 - 
22a 25.6 ± 1.73 51.7 ± 1.9 - 
22b 34.6 ± 0.98 23.5 ± 1.2 - 
22c 25.4 ± 1.98  33.3 ± 0.99 - 
22d 10.4 ± 0.70 34.1 ± 1.7 - 
22e 50.9 ± 1.37 18.2 ± 0.24 - 
22f 33.9 ± 1.0 26.0 ± 1.4 - 
22g 31.0 ± 1.30 26.2 ± 2.4 - 

















































































































Table 5.3 In vitro screening data for SGLT inhibitory activity and selectivity (cont.) 
Compound SGLT1 IC50 (µM)a SGLT2 IC50 (µM)a Selectivity 
33a 9.7 ± 0.89 0.0091 ± 0.00057 1065 
33c 9.9 ± 0.43 0.0198 ± 0.0024 500 
33d 10.6 ± 0.89 0.0182 ± 0.0020 582 
33e 13.8 ± 0.57 0.0213 ± 0.0031 648 
33f 14.6 ± 0.10 0.0217 ± 0.0044 673 
33g 15.6 ± 0.92 0.0227 ± 0.0039 661 
33h 19.0 ± 1.3 0.0119 ± 0.0026 1596 
a IC50 is ± standard deviation 
 
Interestingly, when the 2-DG uptake assay was performed in choline buffer (NaCl 
substituted by choline chloride) (Graph 5.14) the C-glucosyl dihydrochalcones did not 
inhibit the uptake, but on the other hand all the aglycones (chalcones and 
dihydrochalcones) inhibited both SGLT1 and SGLT2. Cytochalasin B was used as a 
GLUT positive control. This could mean that these compounds can inhibit both SGLT 
proteins and GLUT proteins, because GLUTs are sodium-independent proteins, i.e., they 
do not require the presence of sodium ions to transport glucose; but SGLTs are sodium-
dependent proteins, i.e., they do required sodium to do the co-transport. Therefore, if the 
compounds are able to inhibit in presence or absence of sodium they might act as 
inhibitors of both family of proteins. Nevertheless, further studies would be required to 
fully understand their action.  
 




















The clones selected for the glucose uptake assay were also elected for 
Fluorescence Confocal Microscopy (Figure 5.14) using the fluorescent analog of                   
D-glucose, 2-NBDG, to evaluate if the two stable clones were able to uptake more              
2-NBDG than the wild type HEK293 cells.  
Cells were cultured in a glass bottom 4-well dish, previously coated with poly-D-
lysine (PDL) and incubated overnight. Media was then removed and cells were washed 
and incubated with KRPH for 1 h after which 2-NBDG (600 µM) was added to the wells 
containing the two stable clones and HEK293 wild type cells. The other well containing 
HEK293 cells were treated with DMSO alone and served as the negative control. After 30 
minutes of incubation at 37 ºC the media was removed and cells were washed carefully 
three times with KRPH buffer to ensure that all the extracellular 2-NBDG was removed. 
Cells were maintained in KRPH buffer for fluorescence confocal microscopy. As expected 
the two clones were able take up much more 2-NBDG than the wild type HEK293 cells. 
 
Figure 5.14 Fluorescence Confocal Microscopy on stable clones using 2-NBDG uptake assay 
 
 
In summary, all the C-glucosyl dihydrochalcones showed a significant selectivity for 
SGLT2, but more interesting the change from a glucoside the corresponding C-glucosyl 





optimization of these C-glucosyl dihydrochalcones is required to increase their 















Chapter 6. Conclusions 
 
In this work, an innovative and original pathway for the synthesis of C-glucosyl 
dihydrochalcones was developed. The synthesis included the preparation of the glucosyl 
acceptors dihydrochalcones, which were prepared by the formation of the intermediate 
chalcone, through an aldol condensation, followed by a catalytic hydrogenation. Three 
different families of chalcones were prepared, but only one proved to be suitable for the 
C-glucosylation reaction.   
The toxicity of C-glucosyl dihydrochalcones as well as their aglycones, chalcones 
and dihydrochalcones, was evaluated in HEK293 cells. None of the C-glucosyl 
dihydrochalcones showed cytotoxicity, but some of the aglycones showed cytotoxicity 
between 30-50%.  
Two HEK293 stable cell lines were generated, overexpressing SGLT1 and SGLT2 
proteins, respectively. After the characterization and evaluation of the expression levels 
of each protein, the best clone from each cell line was used in the glucose uptake 
assays.  
The glucose uptake assay was assessed directly using a fluorescent analogue of D-
glucose, 2-NDBG; but also using an indirect method based on an enzymatic reaction in 
which a non-fluorescent compound is transformed into a fluorescent derivative. The latter 
proved to be the most reliable assay and provided the more consistent results.  
Using the enzymatic assay, all the compounds were screened in both stable cell 
lines at the same concentration, and the IC50 of each compound towards either SGLT1 or 
SGLT2 were determined. All the C-glucosyl dihydrochalcones proved to be selective 
SGLT2 inhibitors whereas, all the aglycones showed no selectivity.  The best compound, 
the C-glucosyl derivative of phlorizin, has a significantly higher selectivity for SGLT2 than 
phlorizin, and showed a drastic increase in the inhibition of SGLT2 and a tremendous 
decrease in the inhibition of SGLT1.    
In summary, the goals of this project were successfully accomplished, but further 
studies and structural optimization are required to improve the selectivity and potency of         





Chapter 7. Experimental  
 
Materials and Methods – CHEMISTRY 
Solvents and reagents were bought from Fluka, Merck, Sigma, Alfa Aeser or Acros 
Organics. Solutions were concentrated below 50 ºC in vacuum on Büchi rotary 
evaporators. Qualitative TLC was performed on pre-coated silica gel G-50 UV254 plates 
(Macherey-Nagel); compounds were detected by UV light (254 nm) and spraying with a 
10% methanolic solution of sulfuric acid or with a 5% ethanolic solution of iron chloride 
hexahydrate (FeCl3•6H2O) followed by heating. Column chromatography was carried out 
on silica gel (40-60 µm) from Acros Organics. Microwave-assisted synthesis was carried 
out with a CEM Discover system. NMR spectra were recorded on Bruker spectrometer 
Advance 400 (400.13 MHz for 1H-NMR and 100.62 MHz for 13C-NMR). Chemical shifts 
are given in ppm relative to tetramethylsilane. Assignments were made, when needed, 
with the help of COSY, HMQC, and HMBC experiments. HRMS spectra were acquired in 
an Apex Ultra FTICR Mass Spectrometer equipped with an Apollo II Dual ESI/MALDI ion 
source, from Bruker Daltonics, and a 7T actively shielded magnet from Magnex 
Scientific.  The samples were introduced by direct infusion into the ESI source with a flow 
rate of 720 µL/h. Mass spectra were acquired in the positive ion mode with an acquisition 
size of 512k in the mass range of 195 to 1200 and 20 scans were accumulated for each 
sample. The nebulizer gas flow rate was set to 2.0 L/min, the dry gas flow rate was set to 
4.0 L/min at a temperature of 200 ºC. The capillary voltage was set to 4100 V and the 
spray shield voltage was set to 3700 V. The ions were accumulated in the collision cell 
during 0.5 s with a time of flight of 1.8 ms prior to their transfer to the ICR cell. Samples (1 
mg) were diluted in 1 mL of methanol or dichloromethane and further diluted in 1 mL of 
methanol. FTICR was externally calibrated with Luteinizing Hormone-Releasing 
Hormones fragments (1 µL in 600 µL of methanol and 400 µL of water miliq). All the data 
were processed by Compass Data Analysis version 4.1. Melting points were determined 
with a Stuart SMP 30 apparatus. 
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7.1 Synthesis of starting materials  
 
7.1.1 Glycosyl donors 
Methyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside (2) 
To a 1M solution of NaH in DMF at 0 ºC (4.4 equiv.) was added dropwise a 1.3 M 
solution in DMF of α-methyl D-glucopyranoside (1, 5.14 mmol). The reaction mixture was 
stirred for 30 minutes at 0 ºC and then temperature was allowed to increase to room 
temperature. BnBr (4.4 equiv.) was added dropwise and the stirring continued for more 
24 h. MeOH was added until no effervescence and DMF removed under vacuum. The 
residue was dissolved in DCM, washed with water and brine. The organic layer was dried 
over MgSO4 and concentrated. The resulting syrup was purified on a silica gel column 
(15:1 P. Ether/EtOAc) to give compound 2 (87%) as colourless oil. Rf 0.68 (3:1 P. 
Ether/ETOAc); 1H NMR (CDCl3), δ  (ppm) 1 7.54-7.31 (m, 20H, ArH); 5.17, 5.00 (each d, 
2H, J=11.53 Hz, -OCH2Ph); 5.02, 4.67 (each d, 2H, J=11.10 Hz, -OCH2Ph); 4.91, 4.80 
(each d, 2H, J=11.87 Hz, -OCH2Ph); 4.83 (d, 1H, J1,2 =3.85 Hz, H-1); 4.73, 4.60 (each d, 
2H, J=12.54 Hz, -OCH2Ph); 4.21 (t, 1H, J3,4=9.25 Hz, H-3); 3.94 (ddd, 1H, J5,6a =1.73 Hz, 
J5,6b =3.23 Hz, H-5); 3.90-3.78 (m, 3H, H-4, H-6a, H-6b); 3.75 (dd, 1H, J2,3 =9.67 Hz, H-
2); 3.52 (s, 3H, -OCH3-1); 13C NMR (CDCl3) δ  (ppm) 1139.9, 138.4, 138.4, 138.1 (Cq-
Ph), 128.7, 128.6, 128.6, 128.3, 128.2, 128.1, 128.1, 127.8, 127.9 (CH, ArH), 98.4 (C-1), 
82.3 (C-3), 80.0 (C-2), 77.8 (C-4), 75.9, 75.2, 73.7, 73.8 (-OCH2Ph), 70.2 (C-5), 68.6 (C-
6), 55.4 (-OCH3-1) 
 
2,3,4,6-tetra-O-benzyl-1-isopropyl-α-D-glucopyranose (6)  
D-glucose (5) (5.55 mmol) was dissolved in isopropyl alcohol (62.5 mL) and kept at 
reflux temperature. Then, Dowex H+ exchange resin (2g) was added to the reaction 
vessel (previously washed with methanol). After 5 h the resin was filtered off and the 
solvent removed under vacuum. This residue was then dissolved in DMF (62.5 mL) and 
NaH (12.0 equiv.) added at 0 ºC. BnBr (10 equiv.) was added at 0 ºC and then the 
temperature was allowed to reach 25 ºC and the reaction continued for 15 h. Methanol 
was added until no effervescence was observed and the solvents removed by vacuum. 
The residue was purified by column chromatography yielding the desired product in oil 
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form in 79.0%. Rf = 0.71 (Hexane/EtOAc 6:1); 1H NMR (CDCl3) δ  (ppm) 7.44-7.20 (m, 
20H, ArH); 5.05-4.49 (m, 10H, -OCH2Ph, H-1, H-2); 4.16 (q, 1H, J=6.61 Hz, J=14.43 Hz, 
-OCH(CH3)2); 3.83-3.43 (m, 5H, H-3, H-4, H-5, H-6a, H-6b); 1.30 (t, 6H, -OCH(CH3)2); 13C 
NMR (CDCl3) δ  (ppm) 138.6, 138.4, 138.2, 138.1 (Cq-Ph); 128.5, 128.4, 128.3, 128.2, 
127.9, 127.8, 127.7, 127.5 (-CH, Ar); 102.6 (C-1); 84.8 (C-3); 82.3 (C-2); 77.9 (C-4); 75.8 
(C-5); 74.9, 73.5, 73.4 (-OCH2Ph); 68.9 (C-6); 60.4 (-OCH(CH3)2); 21.1 (-OCH(CH3)2) 
 
2,3,4,6-tetra-O-benzyl-D-glucopyranose (3)  
To a solution of 2 or 6 (9.0 mmol) in AcOH (79.5 mL) was added a solution of 2N 
H2SO4 (39.5 mL) and the reaction mixture stirred at 90-95 ºC for 24 h. Cold water (300 
mL) was added and the stirring continuing for 30 minutes. A white powder was 
recrystallized from hot hexane, filtered off and washed with iced cold hexane and dried in 
vacuum affording compound 3 in 81% yield.  mp. 135.8 – 137.4 oC; Rf = 0.54 (Et.P/EtOAc 
3:1); 1H NMR (CDCl3) δ  (ppm) 7.37-7.15 (m, 60H, ArH); 5.25 (t, 2H, J1α,2=3.52 Hz, H-1α); 
4.99-4.50 (m, 25H, H-1β, -OCH2Phα, -OCH2Phβ); 4.07 (ddd, 2H, J5α,6aα =1.87 Hz, J5α,6bα 
=3.35 Hz, J4α,5α=10.01 Hz, H-5α), 4.02 (t, 2H, J2 ,3β = 9.31 Hz, H-3β); 4.01 (0.58H, J2 ,3α = 
9.31 Hz, H-3α), 3.75-3.41 (m, 10H, H-2α, H-4β, H-4α, H-5β, H-6a, H-6b); 13C NMR 
(CDCl3) δ  (ppm) 138.7; 138.2; 137.9; 137.8 (Cq-Phα); 137.8; 137.9; 138.5; 138.4 (Cq-
Phβ); 128.5; 128.4; 128.4; 128.2; 128.1; 128.0; 127.9; 127.9; 127.8; 127.7; 127.7 (-CH, Ar 
α and β); 97.5 (C-1β); 91.3 (C-1α); 84.6 (C-3α); 83.1 (C-2β); 81.8 (C-3α); 79.97 (C-2α); 
77.8 (C-4α); 74.7 (C-4β); 75.8; 75.1; 75.0; 73.5; 73.3 (-OCH2Phα); 75.7; 75.1, 74.8; 74.5 
(-OCH2Phβ); 70.25 (C-5α, C-5β); 68.9 (C-6β); 68.6 (C-6α). 
 
1-O-acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranose (4)  
To a solution of 3 (1.0 g, 1.72 mmol) in pyridine (10 mL) acetic anhydride (1.5 
equiv.) and DMAP (5% mol) were added. The reaction proceeded for 30 minutes and 
after completion confirmed by TLC pyridine was co-evaporated with toluene and 
compound 4 was purified by column chromatography (7:1 Hexane/ EtOAc) in the form of 
oil in 96 % yield. Rf = 0.50 (Et.P/EtOAc 4:1); 1H NMR (CDCl3) δ  (ppm) 7.40-7.19 (m, 
80H, ArHα, ArHβ); 6.44 (d, 3H, J1α,2α =4.27 Hz, H-1α); 5.69 (d, 1H, J1β,2β = 7.83 Hz, H-
1β); 5.05-4.53 (m, 32H, -OCH2Phα, -OCH2Phβ); 4.03 (t, 3H, J2α,3α =8.81 Hz, H-3α); 3.97-
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3.63 (m, 3H, H-5α); 3.85-3.63 (m, 18H, H-2α, H-4α, H-6aα, H-6bα, H-2β, H-3β, H-4β, H-
5β, H-6aβ, H-6bβ); 2.20 (s, 9H, -COOCH3α); 2.12 (s, 3H, -COOCH3β); 13C NMR (CDCl3) 
δ  (ppm) 169.5 (-COOCH3α); 169.4 (-COOCH3β); 138.7, 138.1, 137.8, 137.6 (Cq-Phα); 
138.4, 138.1, 138.0, 137.9 (Cq-Phβ); 128.6, 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 
127.7 (-CH2Phα, -CH2Phβ); 94.1 (C-1β); 90.1 (C-1α); 84.9 (C-3β); 81.7 (C-3α); 81.1 (C-
2β); 78.9 (C-2α); 77.2 (C-4β); 76.9 (C-4α); 75.8 (-OCH2Phβ); 75.7 (-OCH2Phα); 75.5 (-
OCH2Phβ); 75.4 (-OCH2Phα); 75.1, 75.0 (-OCH2Phβ); 73.6 (-OCH2Phα); 73.5 (C-5β); 
73.3 (-OCH2Phα); 72.9 (C-5α); 68.1 (C-6α); 68.0 (C-6β); 21.2 (-COOCH3α); 21.1 (-
COOCH3β) 
 
1,2,3,4,6-tetra-O-acetyl-D-glucopyranose (9)  
To a DMF (50 mL) solution of D-glucose (5) (5.0 g, 28.7 mmol) was added Ac2O 
(26.5 mL) and DMAP (100 mg). Upon completion after 75 min the solvent was removed 
under vacuum. Compound 9 was purified by column chromatography (EtOAc 
/cyclohexane 1:2) and obtained in quantitative yield. Colorless oil, Rf = 0.50 
(EtOAc/Cyclohexane 1:2); 1H NMR (CDCl3) δ  (ppm) 6.34 (d, 1H, J1α,2α =3.65 Hz, H-1α); 
5.72 (d, 1H, J1β,2β =8.32 Hz, H-1β); 5.48 (t, 1H, J3α,4α =9.88 Hz, H-3α); 5.26 (t, 1H, J3β,4β 
=9.41 Hz, H-3β); 5.17-5.12 (m, 4H, H-2α, H-2β, H-4α, H-4β); 4.29, 4.26 (each d, 2H, H-
6aα, H-6bα); 4.14-4.08 (m, 3H, H-5α, H-6aβ, H-6bβ); 3.84 (ddd, 1H, J =2.17 Hz, J =12.34 
Hz, H-5β); 2.19, 2.10, 2.05, 2.03, 2.02 (s, 15H, -COOCH3); 13C NMR (CDCl3) δ  (ppm) 
170.7, 170.1, 169.4, 168.6 (-COOCH3); 91.4 (C-1β); 88.8 (C-1α); 72.9 (C-5β); 72.8 (C-
3β); 69.7 (C-5α); 69.6 (C-3α); 69.0 (C-2α, C-2β); 68.0 (C-4α, C-4β); 61.2 (C-6α, C-6β); 
20.5 (-COOCH3) 
 
 2,3,4,6-tetra-O-acetyl-D-glucopyranose (10)  
Compound 9 (2.0 g, 5.1 mmol) was dissolved in THF (15 mL) and BnNH2 was 
added (2.0 equiv.). The reaction was carried out at room temperature for 24 h. After the 
completion of the reaction THF was evaporated and compound 10 was purified by 
column chromatography (EtOAc /cyclohexane 1:2) and obtained in 98% yield. Colorless 
oil, Rf = 0.40 (EtOAc/Cyclohexane 1:2); 1H NMR (CDCl3) δ  (ppm) 5.5 (t, 1H, J3β,4β =9.74 
Hz, H-3β); 5.26 (t, 1H, J3α,4α =9.56 Hz, H-3α); 5.47 (d, 1H, J1α,2α =3.20 Hz, H-1α); 5.09 (t, 
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2H, H-4α, H-4β); 4.93-4.88 (m, 2H, H-2α, H-2β); 4.75 (d, 1H, J1β,2β =7.99 Hz, H-1β); 4.23-
4.20 (m, 3H, H-5α, H-6aα, H-6bα); 4.17-4.11 (m, 2H, H-6aβ, H-6bβ); 3.76 (ddd, 1H, J 
=2.17 Hz, J =12.34 Hz, H-5β); 2.10, 2.09, 2.04, 2.02 (s, 12H, -COOCH3); 13C NMR 
(CDCl3) δ  (ppm) 95.4 (C-1β); 90.0 (C-1α); 71.7 (C-5β); 70.9 (C-3β); 71.0 (C-2α, C-2β); 
69.8 (C-3α); 68.3 (C-4α, C-4β); 67.2 (C-5α);  61.6 (C-6α, C-6β) 
 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranyl trichloroacetimidate (11)  
To a solution of compound 10 (3.5 g, 7.9 mmol) in DCM (10.6 mL) was added 
CNCCl3 (2.0 equiv.) and K2CO3 (2.0 equiv.). After 24 h at room temperature the reaction 
mixture was filtered off through celite and the organic filtrate was concentrated. 
Compound 11 was purified by column chromatography (EtOAc/CycloHexane 1:2) and 
obtained in 80%. Colorless oil, Rf = 0.590 (EtOAc/CycloHexane 1:2); 1H NMR (CDCl3) δ  
(ppm) 8.71 (s, 1H, -OCNHCCl3); 6.58 (d, 1H, J1,2 =3.70 Hz, H-1); 5.58 (t, 1H, J2,3 = J3,4 
=9.59 Hz, H-3); 5.20 (t, 1H, H-4); 5.15 (dd, 1H, H-2); 4.31, 4.28 (each d, 1H, H-6a); 4.23 
(ddd, 1H, J = 1.70 Hz, J = 4.04 Hz, J =10.04 Hz, H-5); 4.16, 4.13 (each d, 1H, H-6b); 
2.10, 2.07, 2.05, 2.04 (-COOCH3); 13C NMR (CDCl3) δ  (ppm) 69.8 (C-1); 67.9 (C-4); 69.0 
(C-2); 69.8 (C-5); 61.7 (C-6); 20.5 (-COOCH3) 
 
7.1.2 Protected acetophenones 
Synthesis of 2ʹ ,4ʹ-bis(benzyloxy)-6ʹ-hydroxyacetophenone (14) 
2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13, 5.95 mmol) was dissolved in DMF (10 mL) and 
K2CO3 (2.2 equiv.) was added at 0 ºC. After 15 minutes BnBr (2.2 equiv.) was added to 
the reaction and kept at 0 ºC for an extra 20 minutes. The ice bath was removed and the 
reaction proceeded at room temperature for 1 h. The reaction was neutralized after 
completion and extracted with DCM. The organic layers were combined, washed with 
brine and dried over MgSO4. The desired product (15) was purified by column 
chromatography (30:1 Hexane/ EtOAc) and obtained in 52% yield. The secondary 
product (9) was isolated in 41% yield.  
 
2ʹ,4ʹ-bis(benzyloxy)-6ʹ-hydroxyacetophenone, 14: Rf = 0.35 (8:1 P. Ether/EtOAc); 
m.p. 103.5-104.0 ºC; 1H NMR (CDCl3) δ  (ppm) 14.17 (s, 1H, OH-2ʹ); 7.47-7.40 (m, 20H, 
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ArH); 6.22 (d, 1H, J5,7 =2.32 Hz, H-5ʹ); 6.15 (d, 1H,H-3ʹ); 5.09 (s, -OCH2Ph); 5.08 (s, -
OCH2Ph); 2.61 (s, 3H, -COOCH3); 13C NMR (CDCl3) δ  (ppm) 203.2 (-COOCH3); 167.6 
(C-4ʹ, C-6ʹ); 162.1 (C-2ʹ); 135.9, 135.7 (Cq-Ph); 128.8, 128.7, 128.5, 128.4, 128.1, 127.7 
(CH, Ph); 106.3 (C-1ʹ); 94.8 (C-5ʹ); 92.4 (C-3ʹ); 71.2 (-OCH2Ph); 70.3 (-OCH2Ph); 33.4 (-
COOCH3). 
2ʹ,4ʹ-bis(benzyloxy)-3ʹ-benzyl-6ʹ-hydroxyacetophenone, 15: Rf = 0.33 (8:1 P. 
Ether/EtOAc); m.p. 103.3-104.6 ºC; 1H NMR (acetone-d6) δ  (ppm) 14.24 (s, 1H, OH-2ʹ); 
7.57-7.11 (m, 15H, ArH); 6.52 (s, 1H, H-3ʹ); 5.27 (s, 4H, -OCH2Ph); 3.96 (s, 2H, -CH2Ph-
5ʹ); 2.55 (s, 3H, -COCH3); 13C NMR (acetone-d6) δ  (ppm) 203.4 (-COCH3); 163.7 (C-4ʹ); 
162.7 (C-6ʹ); 161.4 (C-2ʹ); 141.6 (Cq, -CH2Ph); 136.7, 136.3 (Cq, -OCH2Ph); 128.6, 128.5, 
128.4, 128.3, 127.9 127.8, 127.5 (CH, -CH2Ph, -OCH2Ph); 109.4 (C-5ʹ); 105.8 (C-1ʹ); 
89.3 (C-3ʹ); 71.0, 70.0 (-OCH2Ph); 32.8 (-COCH3); 27.7 (-CH2Ph). 
 
1-(2,4-bis(ethoxymethoxy)-6-hydroxyphenyl)ethan-1-one (20) 
To a solution of 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13) (29.7 mmol) in DCM (50.3 mL) 
was added N,N-diisopropylethylamine (2.2 equiv.) at 0 ºC and stirred for 15 minutes. 
Ethoxymethyl ether chloride (2.2 equiv.) was added and the reaction continued for 15 
minutes at 0 ºC and then allowed to reach room temperature. The reaction was controlled 
by TLC and after 2h the mixture was poured into water and extracted with 
dichloromethane. The organic layers were combined, washed with brine, dried over 
MgSO4 and concentrated in vacuum. The product, as oil at room temperature, was 
purified by column chromatography (30:1 hexane/ EtOAc) and obtained in 75.8% yield. Rf 
(6:1 Hexane/EtOAcEtOAc)=0.51; 1H NMR (CDCl3), δ  (ppm) 13.73 (s, 1H, OH-4); 6.25 (d, 
1H, J5,7=2.21 Hz, H-7); 6.22 (d, 1H, H-5); 5.27 (s, 2H, H-1ʹʹ); 5.19 (s, 2H, H-1ʹ); 3.74 (d, 
2H, J2ʹʹ,3aʹʹ= 7.13 Hz, J2ʹʹ,3bʹʹ= 14.20 Hz, H-2ʹʹ); 3.71 (q, 2H, J2ʹ,3aʹ= 7.19 Hz, J2ʹ,3bʹ=14.19 Hz, 
H-2’); 2.64 (s, 3H, H-1); 1.22 (t, 3H, H-3ʹʹ); 1.19 (t, 3H, H-3ʹ); 13C NMR (CDCl3), δ  (ppm) 
203.2 (C-2); 166.7 (C-4); 163.6 (C-6); 160.5 (C-8); 106.7 (C-3); 96.9 (C-5); 94.0 (C-7); 
93.2 (C-1ʹʹ); 92.7 (C-1ʹ); 65.0 (C-2ʹʹ); 64.7 (C-2ʹ); 33.0 (C-1); 15.0 (C-3ʹ, C-3ʹʹ); HRMS 
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1-(2-(ethoxymethoxy)-6-hydroxyphenyl)ethan-1-one (24) 
To a solution of 2ʹ,4ʹ-dihydroxyacetophenone (23) (65.7 mmol) in DCM (55.0 mL) 
was added N,N-diisopropylethylamine (2.2 equiv.) at 0 ºC and stirred for 15 minutes. 
Ethoxymethyl ether chloride (2.2 equiv.) was added and the reaction continued for 15 
minutes at 0 ºC and then at room temperature. The reaction was controlled by TLC, and 
after 2 h the mixture was poured into water and extracted with dichloromethane. The 
organic layers were combined, washed with brine, dried over MgSO4 and concentrated in 
vacuum. The product, as oil at room temperature, was purified by column 
chromatography (60:1 hexane/ EtOAc) and obtained in 93.8% yield. Rf (6:1 Hexane/ 
EtOAc)=0.60; 1H NMR (CDCl3),  δ  (ppm) 12.63 (s, 1H, OH-4); 7.62 (d, 1H, J7,8=8.87 Hz, 
H-8);  6.59 (d, 1H, J3,5=1.66 Hz, H-5); 6.55 (dd, 1H, H-7); 5.25 (s, 2H, H-1’); 3.72 (q, 2H, 
J2ʹ,3aʹ=7.11 Hz, J2ʹ,3bʹ=14.19 Hz, H-2ʹ); 2.56 (s, 3H, H-1); 1.22 (t, 3H, H-3ʹ); 13C NMR 
(CDCl3), δ  (ppm) 202.7 (C-2); 164.8 (C-4); 163.8 (C-6); 132.4 (C-8); 114.6 (C-3); 108.2 
(C-7); 103,7 (C-5); 92.7 (C-1ʹ); 64.8 (C-2ʹ); 26.3 (C-1); 15.1 (C-3ʹ); HRMS calcd for 
C11H15O4 211.09649 (MH+) found 211.09656 
 
7.1.3 Aromatic Aldehydes 
4-methoxybenzaldehyde (16e) 
4-hydroxybenzaldehyde (5g, 40.9 mmol) was dissolved in acetone (94.4 mL) and 
K2CO3 (1.1 equiv.) was added. The mixture stirred for 30 minutes at reflux and then MeI 
(1.3 equiv.) was added and the mixture was kept stirring overnight at reflux. After 
completion of the reaction (confirmed by TLC) the salt was filtered off, acetone was 
removed, the flask was washed with DCM and starting material was filtered off. Solvent 
was evaporated and 4-methoxybenzaldehyde was obtained as a liquid without further 
purification in 98.5% yield. Rf (6:1 Hexane/ EtOAc)=0.39; 1H NMR (CDCl3), δ  (ppm) 9.89 
(s, 1H, H-1); 7.84 (d, 2H, J3,4 =J6,7 =8.79 Hz, H-3, H-7); 7.01 (d, 2H, H-4, H-6); 3.89 (s, 
3H, -OCH3); 13C NMR (CDCl3), δ  (ppm) 190.8 (C-1); 164.6 (C-5) 131.9 (C-3, C-7); 129.9 






4-hydroxybenzaldehyde (5g, 40.9 mmol) was dissolved in acetone (94.4 mL) and 
K2CO3 (1.1 equiv.) was added. The mixture stirred for 30 minutes at reflux and then ethyl 
bromide (1.3 equiv.) was added and the mixture was kept stirring overnight at reflux. After 
completion of the reaction (confirmed by TLC) the salt was filtered off, acetone was 
removed, the flask was washed with DCM and starting material was filtered off. Solvent 
was evaporated and 4-ethoxybenzaldehyde was obtained as a liquid without further 
purification in 98.6% yield. Rf (6:1 Hexane/ EtOAc)=0.34; 1H NMR (CDCl3), δ  (ppm) 9.90 
(s, 1H, H-1); 7.86 (d, 2H, J3,4 =J6,7 =8.90 Hz, H-3, H-7); 7.06 (d, 2H, H-4, H-6); 4.13 (q, 
2H, J=6.28 Hz, J=14.12 Hz, -OCH2CH3); 1.40 (t, 3H, -OCH2CH3); 13C NMR (CDCl3), δ  
(ppm) 190.8 (C-1); 164.0 (C-5); 131.9 (C-3, C-7); 129.7 (C-2); 114.7 (C-4, C-6); 63.9 (-
OCH2CH3); 14.6 (-OCH2CH3) 
 
4-allyloxybenzaldehyde (16g) 
4-hydroxybenzaldehyde (5g, 40.9 mmol) was dissolved in ethanol (94.4 mL) and 
KOH (1.5 equiv.) was added. The mixture was kept at reflux for 30 minutes and then allyl 
bromide (1.5 equiv.) was added. The reaction stirred for 7 h until reaction completion and 
the salt was filtered off, ethanol removed, the flask washed with DCM and starting 
material filtered off. Solvent was evaporated and pure 4-allyloxybenzaldehyde was 
obtained as a liquid without further purification in 98.6% yield. Rf (6:1 Hexane/ 
EtOAc)=0.60; 1H NMR (CDCl3), δ  (ppm) 9.87 (s, 1H, H-1); 7.83 (d, 2H, J3,4 =J6,7 =7.52 
Hz, H-3, H-7); 7.02 (d, 2H, H-4, H-6); 6.09-6.02 (m, 1H, -OCH2CHCH2); 5.45, 5.32 (each 
d, 2H, J=17.47 Hz, J=9.78 Hz, -OCH2CHCH2);  4.62 (dd, 2H, J=1.67 Hz, J=5.03 Hz, -
OCH2CHCH2); 13C NMR (CDCl3), δ  (ppm) 190.9 (C-1); 163.6 (C-5); 132.3 (-





     109 
7.2 Synthesis of Chalcones 
7.2.1 General conventional procedure for the synthesis of 2ʹ ,4ʹ-
bis(ethoxymethoxy)-6ʹ-hydroxychalcones 
To solution of 1-(2,4-bis(ethoxymethoxy)-6-hydroxyphenyl)ethan-1-one (20) (200 
mg, 0.703 mmol) and an aryl aldehyde (16a-16i, 2.0 equiv.) in 1,4-dioxane (4.1 mL) was 
added at room temperature sodium hydroxide aqueous solution 50% (w/v) (4.1 mL). The 
reaction stirred for 24 h at room temperature. The solution was neutralized using 10% 
HCl aqueous solution and extracted with DCM. The organic layers were combined, 
washed with brine, dried over MgSO4 and concentrated in vacuum. The chalcones 
derivatives were purified by column chromatography (30:1 hexane/ EtOAc).  
 
7.2.2 General microwave assisted procedure for the synthesis of 2ʹ ,4ʹ-bis(ethoxy-
methoxy)-6ʹ-hydroxychalcones  
To solution of 1-(2,4-bis(ethoxymethoxy)-6-hydroxyphenyl)ethan-1-one (24) (200 
mg, 0.703 mmol) and the aryl aldehyde (16a-16i, 2.0 equiv.) in 1,4-dioxane (2.1 mL) was 
added at room temperature sodium hydroxide aqueous solution 50% (w/v) (2.1 mL). The 
reaction proceeded in a microwave oven at 150 W and 40 ºC for 2-3 h. The solution was 
neutralized using 10% HCl aqueous solution and extracted with DCM. The organic layers 
were combined, washed with brine, dried over MgSO4 and concentrated in vacuum. The 
chalcones derivatives were purified by column chromatography (30:1 hexane/ EtOAc).  
 
(E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(4-fluorophenyl)prop-2-en-1-
one (21a): Yield 94.7%; orange solid; m.p.=58.5-59.0 ºC; Rf (6:1 Hexane/EtOAc)=0.54; 1H 
NMR (CDCl3), δ  (ppm) 13.86 (s, 1H, OH-2ʹ); 7.87 (d, 1H, J2,3 =16.01 Hz, H-2); 7.73 (d, 1H, 
H-3); 7.58 (dd, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6’’ =8.46 Hz, J2’’,F =J3’’,F = J6ʹʹ,F =J5ʹʹ,F =5.80 Hz, H-2ʹʹ, H-6ʹʹ); 7.10 
(t, 2H, H-3ʹʹ, H-5ʹʹ); 6.32 (d, 1H, J3ʹ,5ʹ =2,17 Hz, H-3ʹ); 6.25 (d, 1H, H-5ʹ); 5.33 (s, 2H, H-1ʹʹʹʹ); 
5.24 (s, 2H, H-1ʹʹʹ); 3.79-3.70 (m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 1.24 (t, 6H, J3ʹʹʹ,2ʹʹʹ=J3ʹʹʹʹ,2ʹʹʹʹ=7.02 Hz, H-
3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.7 (C-1); 167.4 (C-2ʹ); 163.8 (C-4ʹ,); 163.7 (d, J = 
251.3 Hz, C-4ʹʹ); 159.9 (C-6ʹ); 141.1 (C-3); 131.7 (d, J = 3.3 Hz, C-1ʹʹ); 130.1 (d, J = 8.5 Hz 
C-2ʹʹ, C-6ʹʹ); 127.2 (C-2); 116.1 (d, J = 21.2 Hz, C-3ʹʹ, C-5ʹʹ); 107.3 (C-1ʹ); 97.4 (C-3ʹ); 94.8 
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(C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 65.3 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 15.0 (C-3ʹʹʹ, C-3ʹʹʹʹ); HRMS 
calcd for C21H23FNaO6 413.13709 (MNa+) found 413.13773 
 
(E)-3-(4-bromophenyl)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]prop-2-en-
1-one (21b): Yield 91.0%; orange solid; m.p.=80.9-81.6 ºC; Rf (6:1 
Hexane/EtAOc)=0.58;1H NMR (CDCl3), δ  (ppm) 13.83 (s, 1H, OH-2ʹ); 7.94 (d, 1H, 
J2,3=16.29 Hz, H-2); 7.71 (d, 1H, H-3); 7.56 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.15 Hz, H-3ʹʹ, H-5ʹʹ); 
7.48 (d, 2H, H-2ʹʹ, H-6ʹʹ); 6.34 (d, 1H, J3ʹ,5ʹ =2.32 Hz, H-3ʹ); 6.26 (d, 1H, H-5ʹ); 5.35 (s, 2H, 
H-1ʹʹʹʹ); 5.25 (s, 2H, H-1ʹʹʹ); 3.78 (q, 2H, J2ʹʹʹʹ,3aʹʹʹʹ=7.08 Hz, J2ʹʹʹʹ,3bʹʹʹʹ =14.18 Hz, H-2ʹʹʹʹ); 3.75 
(q, 2H, J2ʹʹʹ,3aʹʹʹ =7.08 Hz,  J2ʹʹʹ,3bʹʹʹ =14.08 Hz, H-2ʹʹʹ); 1.26 (t, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR 
(CDCl3), δ  (ppm) 192.6 (C-1); 167.4 (C-2ʹ); 163.9 (C-4ʹ); 159.9 (C-6ʹ); 140.9 (C-3); 134.4 
(C-1ʹʹ); 132.2 (C-3ʹʹ, C-5ʹʹ); 129.7 (C-2ʹʹ, C-6ʹʹ); 128.1 (C-2); 124.3 (C-4ʹʹ); 107.3 (C-1ʹ); 
97.4 (C-3ʹ); 94.8 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 65.4 (C-2ʹʹʹʹ); 64.9 (C-2ʹʹʹ); 15.1 (C-ʹʹʹ, -
3ʹʹʹʹ); HRMS calcd for C21H23BrNaO6 473.05702 (MNa+) found 473.05807 
 
 (E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(phenyl)prop-2-en-1-one 
(21c): Yield 95.2%; orange solid; m.p.=52.7-53.1 ºC; Rf (10:1 Heptane/EtOAc)=0.24; 1H 
NMR (CDCl3), δ  (ppm) 13.91 (s, 1H, OH-2ʹ); 7.96 (d, 1H, J2,3=15.23 Hz, H-2); 7.81 (d, 1H, 
H-3); 7.63 (dd, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ= J3ʹʹ,4ʹʹ= J4ʹʹ,5ʹʹ=7.45 Hz, J2ʹʹ,4ʹʹ= J4ʹʹ,6ʹʹ=2.02 Hz, Hz, H-3ʹʹ, H-
5ʹʹ); 7.43-7.42 (m, 3H, H-2ʹʹ, H-4ʹʹ, H-6ʹʹ); 6.35 (d, 1H, J3ʹ,5ʹ=2.0 Hz, H-3ʹ); 6.28 (d, 1H, H-
5ʹ); 5.36 (s, 2H, H-1ʹʹʹʹ); 5.26 (s, 2H, H-1ʹʹʹ); 3.82-3.72 (m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 1.28-1.24 (m, 
6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.9 (C-1); 167.4 (C-2ʹ); 163.7 (C-4ʹ); 
160.0 (C-6ʹ); 142.4 (C-3); 135.5 (C-1ʹʹ); 130.2 (C-4ʹʹ); 128.9 (C-2ʹʹ, C-6ʹʹ); 128.3 (C-3ʹʹ, C-
5ʹʹ); 127.5 (C-2); 107.4 (C-1ʹ); 97.4 (C-3ʹ); 94.8 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 65.3 (C-




en-1-one (21d): Yield 91.6%; orange solid; m.p.=55.9-56.7 ºC; Rf (6:1 
Hexane/EtOAc)=0.41; 1H NMR (CDCl3), δ  (ppm) 13.93 (s, 1H, OH-2ʹ); 7.89 (d, 1H, 
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J2,3=15.81 Hz, H-2); 7.77 (d, 1H, H-3); 7.50 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=7.94 Hz, H-2ʹʹ, H-6ʹʹ); 
7.21 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.32 (d, 1H, J3ʹ,5ʹ=1.70 Hz, H-3ʹ); 6.25 (d, 1H, H-5ʹ); 5.33 (s, 2H, 
H-1ʹʹʹʹ); 5.24 (s, 2H, H-1ʹʹʹ); 3.80-3.70 (m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 2.39 (s, 3H, CH3-4ʹʹ); 1.26-
1.22 (m, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.9 (C-1); 167.4 (C-2ʹ); 163.6 
(C-4ʹ); 159.9 (C-6ʹ); 142.6 (C-3); 140.7 (C-4ʹʹ); 132.7 (C-1ʹʹ); 129.7 (C-3ʹʹ, C-5ʹʹ); 128.4 
(C-2ʹʹ, C-6ʹʹ); 126.4 (C-2); 107.4 (C-1ʹ); 97.4 (C-3ʹ); 94.7 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 
65.3 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ, C-3ʹʹʹʹ); 21.5 (CH3-4ʹʹ); HRMS calcd for 
C22H26NaO6 409.16216 (MNa+) found 409.16287 
 
(E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(4-methoxyphenyl)prop-2-
en-1-one  (21e): Yield 87%; orange solid; m.p.=62.7-62.9 ºC;                                              
Rf (10:1 Hexane/EtOAc)= 0.28; 1H NMR (CDCl3), δ  (ppm) 14. 02 (s, 1H, OH-2ʹ); 7.86 (d, 
1H, J2,3=15.30 Hz, H-2); 7.79 (d, 1H, H-3); 7.57 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=8.52 Hz, H-2ʹʹ, H-6ʹʹ); 
6.94 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.34 (d, 1H, J3ʹ,5ʹ=1.37 Hz, H-3ʹ); 6.27 (d, 1H, H-5ʹ); 5.35 (s, 2H, 
H-1ʹʹʹʹ); 5.25 (s, 2H, H-1ʹʹʹ); 3,87 (s, 3H, -OCH3-4ʹʹ); 3.80-3.74 (m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 1.28-
1.24 (m, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.2 (C-1); 167.3 (C-2ʹ); 163.5 
(C-4ʹ); 161.4 (C-4ʹʹ); 159.9 (C-6ʹ); 142.5 (C-3); 130.2 (C-2ʹʹ, C-6ʹʹ); 128.2 (C-1ʹʹ); 124.9 
(C-2); 114.4 (C-3ʹʹ, C-5ʹʹ); 107.4 (C-1ʹ); 97.4 (C-3ʹ); 94.8 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-
1ʹʹʹ); 65.3 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 55.4 (-OCH3-4ʹʹ); 15.1 (C-3ʹʹʹ, C-3ʹʹʹʹ); HRMS calcd for 
C22H26NaO6 425.15707 (MNa+) found 425.15769 
 
(E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(4-ethoxyphenyl)prop-2-en-
1-one  (21f): Yield 86.3%; orange solid; m.p.=72.9-73.3 ºC; Rf (10:1 Hexane/EtOAc)= 
0.29; 1H NMR (CDCl3), δ  (ppm) 14.01 (s, 1H, OH-2ʹ); 7.86 (d, 1H, J2,3=15.68 Hz, H-2); 
7.80 (d, 1H, H-3); 7.57 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=8.33 Hz, H-2ʹʹ, H-6ʹʹ); 6.93 (d, 2H, H-3ʹʹ, H-
5ʹʹ); 6.34 (d, 1H, J3ʹ,5ʹ=2.26 Hz, H-3ʹ); 6.27 (d, 1H, H-5ʹ); 5.35 (s, 2H, H-1ʹʹʹʹ); 5.26 (s, 2H, 
H-1ʹʹʹ); 4.13-4.07 (m, 2H, -OCH2CH3-4ʹʹ); 3.82-3.72 (m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 1.46 (t, 3H, 
J=6.71 Hz, -OCH2CH3-4ʹʹ); 1.28-1.24 (m, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 
192.9 (C-1); 167.3 (C-2ʹ); 163.5 (C-4ʹ); 160.8 (C-4ʹʹ); 142.7 (C-3); 130.1 (C-6ʹ, C-2ʹʹ, C-
6ʹʹ); 129.9 (C-1ʹʹ); 124.9 (C-2); 114.9 (C-3ʹʹ, C-5ʹʹ); 107.5 (C-1ʹ); 97.4 (C-3ʹ); 94.8 (C-5ʹ); 
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93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 65.7 (C-2ʹʹʹʹ); 65.3 (-OCH2CH3-4ʹʹ); 64.8 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ, 




en-1-one  (21g): Yield 98.7%; dark orange solid; m.p.=79.4-79.9 ºC; Rf (10:1 Hexane/ 
EtOAc)= 0.39; 1H NMR (CDCl3), δ  (ppm) 14.01 (s, 1H, OH-2ʹ); 7.86 (d, 1H, J2,3=15.06 
Hz, H-2); 7.79 (d, 1H, H-3); 7.57 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=8.51 Hz, H-2ʹʹ, H-6ʹʹ); 6.96 (d, 2H, H-
3ʹʹ, H-5ʹʹ); 6.34 (d, 1H, J3ʹ,5ʹ =1.34 Hz, H-3ʹ); 6.27 (d, 1H, H-5ʹ); 6.13-6.03 (m, 1H, -O-
CH2CHCH2-4ʹʹ); 5.45, 5.34 (each d, 2H, J=17.41 Hz, J=9.96 Hz, -O-CH2CHCH2-4ʹʹ); 5.35 
(s, 2H, H-1ʹʹʹʹ); 5.26 (s, 2H, H-1ʹʹʹ); 4.61 (d, 2H, J=4.23 Hz, -O-CH2CHCH2-4ʹʹ); 3.78-3.74 
(m, 4H, H-2ʹʹʹ, H-2ʹʹʹʹ); 1.28-1.23 (m, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.8 
(C-1); 167.3 (C-2ʹ); 163.5 (C-4ʹ); 160.4 (C-4ʹʹ); 142.5 (C-3); 133.8 (-OCH2CHCH2-4ʹʹ); 
130.1 (C-6ʹ); 130.1 (C-6ʹ, C-2ʹʹ, C-6ʹʹ); 128.3 (C-1ʹʹ); 125.1 (C-2); 118.1 (-OCH2CHCH2-
4ʹʹ); 115.1 (C-3ʹʹ, C-5ʹʹ); 107.4 (C-1ʹ); 97.4 (C-3ʹ); 94.8 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 
68.8 (-OCH2CHCH2-4ʹʹ); 65.3 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ, C-3ʹʹʹʹ); HRMS calcd for 
C24H28NaO6 451.17272 (MNa+) found 451.17347 
 
(E)-3-(4-(benzyloxy)phenyl)-1-(2,4-bis(ethoxymethoxy)-6-hydroxyphenyl)prop-2-en-
1-one (21h): Yield 87.7%; reddish solid; m.p.=97.7-98.3 ºC; Rf (6:1 Hexane/ 
EtOAc)=0.64; 1H NMR (CDCl3), δ  (ppm) 13.99 (s, 1H, OH-2ʹ); 7.87 (d, 1H, J2,3=15.87 Hz, 
H-2); 7.80 (d, 1H, H-3); 7.58 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ=6.51 Hz, H-2ʹʹ, H-6ʹʹ); 7.47-7.37 (m, 5H, 
CH, Ph); 7.03 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.35 (d, 1H, J3ʹ,5ʹ =2.10 Hz, H-3ʹ); 6.28 (d, 1H, H-5ʹ); 
5.35 (s, 2H, H-1ʹʹʹʹ); 5.26 (s, 2H, H-1ʹʹʹ); 5.14 (s, 2H, CH2Ph); 3.80 (q, 2H, J2ʹʹʹʹ,3aʹʹʹʹ=7.08 
Hz, J2ʹʹʹʹ,3bʹʹʹʹ= 14.32 Hz, H-2ʹʹʹʹ); 3.75 (q, 2H, J2ʹʹʹ,3aʹʹʹ =7.24 Hz,  J2ʹʹʹ,3bʹʹʹ =14.16 Hz, H-2ʹʹʹ); 
1.26 (t, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 13C NMR (CDCl3), δ  (ppm) 192.9 (C-1); 167.3 (C-2ʹ); 163.5 (C-
4ʹ); 160.6 (C-4ʹʹ); 159.9 (C-6ʹ); 142.5 (C-3); 136.5 (Cq, Ph); 130.1 (C-2ʹʹ, C-6ʹʹ); 128.7, 
128.2, 127.5 (CH, Ph); 128.5 (C-1ʹʹ); 115.3 (C-3ʹʹ, C-5ʹʹ); 125.2 (C-2); 107.4 (C-1ʹ); 97.5 
(C-3ʹ); 94.8 (C-5ʹ); 93.9 (C-1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 70.1 (CH2Ph); 65.3 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 
15.1 (C-3ʹʹʹ, C-3ʹʹʹʹ); HRMS calcd for C28H30NaO7 501.18837 (MNa+) found 501.18976 
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(E)-1-[(2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(5-methylfuran-2-yl)prop-2-en-1-
one (21i): Yield 67.1%; reddish solid; m.p.=88.6-89.2 ºC; Rf (10:1 Hexane/ EtOAc)= 0.29; 
1H NMR (CDCl3), δ  (ppm) 14.03 (s, 1H, OH-2ʹ); 7.75 (d, 1H, J2,3=16.16 Hz, H-2); 7.54 (d, 
1H, H-3); 6.59 (d, 1H, J2ʹʹ,3ʹʹ =2.91 Hz, H-2ʹʹ); 6.30 (d, 1H, J3ʹ,5ʹ =2.58 Hz , H-5ʹ); 6.24 (d, 
1H, H-3ʹ); 6.12 (d, 1H, H-3ʹʹ); 5.34 (s, 2H, H-1ʹʹʹʹ); 5.23 (s, 2H, H-1ʹʹʹ); 3.84 (q, 2H, J2ʹʹʹʹ,3aʹʹʹʹ 
=7.25 Hz, J2ʹʹʹʹ,3bʹʹʹʹ=14.23 Hz H-2ʹʹʹʹ); 3.72 (q, 2H, J2ʹʹʹ,3aʹʹʹ =7.11 Hz, J2ʹʹʹ,3bʹʹʹ =14.10 Hz H-
2ʹʹʹ); 1.30-1.22 (m, 6H, H-3ʹʹʹ, H-3ʹʹʹʹ); 2.37 (s, 3H, CH3-4ʹʹ); 13C NMR (CDCl3), δ  (ppm) 
192.2 (C-1); 167.3 (C-2ʹ); 163.4 (C-4ʹ); 159.8 (C-6ʹ); 155.5 (C-4ʹʹ); 150.9 (C-1ʹʹ); 129.3 (C-
2); 123.1 (C-3); 117.7 (C-2ʹʹ); 109.3 (C-3ʹʹ); 107.4 (C-1ʹ); 97.3 (C-3ʹ); 94.5 (C-5ʹ); 93.5 (C-
1ʹʹʹʹ); 92.8 (C-1ʹʹʹ); 65.2 (C-2ʹʹʹʹ); 64.8 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ, C-3ʹʹʹʹ), 14.0 (CH3-4ʹʹ); HRMS 
calcd for C20H24NaO7 399.14142 (MNa+) found 399.14203 
 
7.2.3 General conventional procedure for the synthesis of 2-ethoxymethoxy-6-
hydroxy-chalcones 
To solution of 1-(2-ethoxymethoxy-6-hydroxyphenyl)ethan-1-one (24) (200 mg, 
0.951 mmol) and an aryl aldehyde (16a-16i, 2.0 equiv.) in ethanol (7.4 mL) was added at 
room temperature sodium hydroxide aqueous solution 50% (w/v) (7.4 mL). The reaction 
stirred for 24h at room temperature. The solution was neutralized using 10% aq. HCl and 
extracted with DCM. The organic layers were combined, washed with brine, dried over 
MgSO4 and concentrated in vacuum. The chalcones derivatives were purified by column 
chromatography (30:1 hexane/ EtOAc). 
 
7.2.4 General microwave procedure for the synthesis of 2-ethoxymethoxy-6-
hydroxy-chalcones 
To solution of 1-2-ethoxymethoxy-4,6-dihydroxyphenyl)ethan-1-one (2ʹ,4ʹ-
dihydroxyacetophenone) (24) (200 mg, 0.951 mmol) and an aryl aldehyde (16a-16i, 2.0 
equiv.) in ethanol (7.4 mL) was added at room temperature sodium hydroxide aqueous 
solution 50% (w/v) (7.4 mL). The reaction proceeded in a microwave oven at 150 W and 
40 ºC for 1 h. The solution was neutralized using 10% HCl aqueous solution and 
extracted with DCM. The organic layers were combined, washed with brine, dried over 
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MgSO4 and concentrated in vacuum. The chalcones derivatives were purified by column 
chromatography (30:1 hexane/ EtOAc). 
 
(E)-1-(4-ethoxymethoxy-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one 
(24a): Yield 91.2%; orange solid; m.p.=96.3-96.8 ºC; Rf (8:1 Hexane/ EtOAc)= 0.44; 1H 
NMR (CDCl3) δ  (ppm) 13.27 (s, 1H, OH-2ʹ); 7.88 (d, 1H, J2,3=15.43 Hz, H-3); 7.86 (d, 1H, 
J5ʹ,6ʹ =8.82 Hz, H-6ʹ); 7.67 (dd, 2H, J2ʹʹ,F =J6ʹʹ,F=5.40 Hz, J2ʹʹ,3ʹʹ =J6ʹʹ,5ʹʹ=8.72 Hz, H-2ʹʹ, H-6ʹʹ); 
7.53 (d, 1H, H-2); 7.15 (t, 2H, H-3’’, H-5ʹʹ); 6.68 (d, 1H, J3ʹ,5ʹ =2.32 Hz, H-3ʹ); 6.62 (dd, 1H, 
H-5ʹ); 5.30 (s, 2H, H-1ʹʹʹ); 3.76 (q, 2H, J2ʹʹʹ,3aʹʹʹ =7.13 Hz, J2ʹʹʹ,3bʹʹʹ =14.11 Hz, H-2ʹʹʹ); 1.28 (t, 
3H, H-3ʹʹʹ); 13C NMR (CDCl3) δ  (ppm) 191.8 (C-1); 166.3 (C-2ʹ); 163.9 (C-4ʹ); 163.9 (d, J 
= 252.5 Hz C-4ʹʹ); 143.2 (C-3); 131.0 (d, J = 3.4 Hz, C-1ʹʹ); 131.3 (C-6ʹ); 130.5 (d, J = 8.4 
Hz , C-2ʹʹ, C-6ʹʹ); 120.0 (C-2); 116.2 (d, J =21.7 Hz , C-3ʹʹ, C-5ʹʹ); 114.8 (C-1ʹ); 108.3 (C-
5ʹ); 103.9 (C-3ʹ); 92.8 (C-1ʹʹʹ); 64.9 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ); HRMS calcd for C18H17FNaO4 
339.10031 (MNa+) found 339.10069 
 
(E)-3-(4-bromophenyl)-1-(4-ethoxymethoxy-2-hydroxyphenyl)prop-2-en-1-one 
(24b): Yield 85.0%; orange solid; m.p=78.7-79.2 ºC; Rf (8:1 Hexane/ EtOAc)=0.36; 1H 
NMR (acetone-d6) δ  (ppm) 13.35 (s, 1H, OH-2ʹ); 8.23 (d, 1H, J5ʹ,6ʹ =8.57 HZ, H-6ʹ); 8.03 
(d, 1H, J2,3=15.21 Hz, H-2); 7.86 (d, 2H, H-3); 7.84 (dd, 2H, J2ʹʹ,3ʹʹ =J6ʹʹ,5ʹʹ =8.97 Hz, H-2ʹʹ, 
H-6ʹʹ); 7.66 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.64 (dd, 1H, J3ʹ,5ʹ=2.39 Hz, H-5ʹ); 6.61 (d, 1H, H-3ʹ); 5.36 
(s, 2H, H-1ʹʹʹ); 3.74 (q, 2H, J2ʹʹʹ,3aʹʹʹ =7.07 Hz, J2ʹʹʹ,3bʹʹʹ =14.08 Hz, H-2ʹʹʹ); 1.20 (t, 3H, H-3ʹʹʹ); 
13C NMR (acetone-d6) δ  (ppm) 192.1 (C-1); 166.3 (C-2ʹ); 164.2 (C-4ʹ); 142.9 (C-3); 
134.2 (C-1ʹʹ); 132.2 (C-6ʹ); 132.1 (C-2ʹʹ, C-6ʹʹ); 130.6 (C-3ʹʹ, C-5ʹʹ); 124.3 (C-4ʹʹ); 121.6 
(C-2); 114.6 (C-1’); 108.3 (C-5’); 103.3 (C-3’); 92.8 (C-1’’’); 64.4 (C-2’’’); 14.6 (C-3’’’); 
HRMS calcd for C18H17BrNaO4 399.02024 (MNa+) found 399.02084 
 
(E)-1-(4-ethoxymethoxy-2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one 
(24d): Yield 89.2%; orange solid; m.p.= 91.7-92.1 ºC; Rf (8:1 Hexane/ EtOAc)= 0.24; 1H 
NMR (CDCl3) δ  (ppm)13.34 (s, 1H, OH-2ʹ); 7.88 (d, 1H, J2,3=15.04 Hz, H-3); 7.84 (d, 1H, 
J5ʹ,6ʹ =8.11, H-6ʹ); 7.55 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =7.73 Hz, H-2ʹʹ, H-6ʹʹ); 7.54 (d, 1H, H-2); 7.23 
(d, 2H, H-3ʹʹ, H-5ʹʹ); 6.65 (d, 1H, J3ʹ,5ʹ =1.52 Hz, H-3ʹ); 6.59 (dd, 1H, H-5ʹ); 5.27 (s, 2H, H-
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1ʹʹʹ); 3.73 (q, 2H, J2ʹʹʹ,3aʹʹʹ=7.03  Hz, J2ʹʹʹ,3bʹʹʹ =14.05 Hz, H-2ʹʹʹ); 2.40 (s, 3H, CH3-4ʹʹ); 1.23 (t, 
3H, H-3ʹʹʹ); 13C NMR (CDCl3) δ  (ppm) 192.1 (C-1); 166.2 (C-2ʹ); 163.8 (C-4ʹ); 144.7 (C-3); 
141.3 (C-4ʹʹ); 132.0 (C-1ʹʹ); 131.3 (C-6ʹ); 129.8 (C-3ʹʹ, C-5ʹʹ); 128.6 (C-2ʹʹ, C-6ʹʹ); 119.3 
(C-2); 114.9 (C-1ʹ); 108.2 (C-5ʹ); 103.9 (C-3ʹ); 92.8 (C-1ʹʹʹ); 64.8 (C-2ʹʹʹ); 21.6 (CH3-4ʹʹ); 
15.1 (C-3ʹʹʹ); HRMS calcd for C19H20NaO4 335.12538 (MNa+) found 335.12582 
 
(E)-3-(4-(benzyloxy)phenyl)-1-(4-ethoxymethoxy-2-hydroxyphenyl)prop-2-en-1-
one (24h): Yield 92.3%; orange solid; m.p.=101.5-102.0 ºC; Rf (8:1 Hexane/ EtOAc)= 
0.56; 1H NMR (CDCl3) δ  (ppm) 13.40 (s, 1H, OH-2ʹ); 7.86 (d, 1H, J2,3=14.14 Hz, H-3); 
7.83 (d, 1H, J6ʹ,5ʹ =8.45 Hz, H-6ʹ); 7.61 (d, 2H, J2ʹʹ,3ʹʹ = J2ʹʹ,3ʹʹ =8.45 Hz, H-2ʹʹ, H-6ʹʹ); 7.48-
7.32 (m, 6H, H-2, ArH); 7.02 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.65 (d, 1H, J3ʹ,5ʹ =2.26 Hz, H-3ʹ); 6.58 
(dd, 1H, H-5ʹ); 5.27 (s, 2H, H-1ʹʹʹ); 5.12 (s, 2H, -OCH2-); 3.73 (q, 2H, J2ʹʹʹ,3aʹʹʹ=7.20 Hz, 
J2ʹʹʹ,3bʹʹʹ=14.36Hz, H-2ʹʹʹ); 1.23 (t, 3H, H-3ʹʹʹ); 13C NMR (CDCl3) δ  (ppm) 192.0 (C-1); 166.1 
(C-2ʹ); 163.7 (C-4ʹ); 160.9 (C-4ʹʹ); 144.3 (C-3); 136.4 (Cq, Ph); 131.2 (C-6ʹ); 130.4 (C-2ʹʹ, 
C-6ʹʹ); 128.7, 128.2, 127.5 (CH, Ph); 127.7 (C-1ʹʹ); 117.9 (C-2); 115.3 (C-3ʹʹ, C-5ʹʹ); 114.9 
(C-1ʹ); 108.2 (C-5ʹ); 103.9 (C-3ʹ); 92.8 (C-1ʹʹʹ); 70.1 (-OCH2-); 64.8 (C-2ʹʹʹ); 15.1 (C-3ʹʹʹ); 
HRMS calcd for C25H24NaO5 427.15159 (MNa+) found 427.15250 
 
(E)-1-(4-ethoxymethoxy-2-hydroxyphenyl)-3-(5-methylfuran-2-yl)prop-2-en-1-
one (24i): Yield 68.9%; reddish solid; m.p.=127.4-127.7 ºC; Rf (8:1 Hexane/ EtOAc)= 
0.52; 1H NMR (acetone-d6) δ  (ppm) 13.52 (s, 1H, OH-2ʹ); 8.06 (d, 1H, J5ʹ,6ʹ=8.95, H-6ʹ); 
7.66 (d, 1H, J2,3=15.14 Hz, H-2); 7.53 (d, 1H, H-3); 6.94 (d, 1H, J2ʹʹ,3ʹʹ =3.60 Hz, H-2ʹʹ); 
6.65 (d, 1H, J3ʹ,5ʹ =2.20 Hz, H-5ʹ); 6.59 (dd, 1H, H-3ʹ); 6.31 (d, 1H, H-3ʹʹ); 5.36 (s, 2H, H-
1ʹʹʹ); 3.75 (q, 2H, J2ʹʹʹ,3ʹʹʹ = 7.10 Hz, J2ʹʹʹ,3bʹʹʹ =14.20 Hz, H-2ʹʹʹ); 2.42 (s, 3H, CH3-4ʹʹ); 1.20 (t, 
3H, H-3ʹʹʹ); 13C NMR (acetone-d6) δ  (ppm) 191.7 (C-1); 166.1 (C-2ʹ); 163.9 (C-4ʹ); 156.7 
(C-4ʹʹ); 150.4 (C-1ʹʹ); 131.7 (C-6ʹ); 130.6 (C-2); 119.0 (C-2ʹʹ); 115.8 (C-3); 114.6 (C-1ʹ); 
109.7 (C-3ʹʹ); 108.3 (C-5ʹ); 103.3 (C-3ʹ); 92.7 (C-1ʹʹʹ); 64.4 (C-2ʹʹʹ); 14.5 (C-3ʹʹʹ); 13.0 
(CH3-4ʹʹ); HRMS calcd for C17H18NaO5 325.10464 (MNa+) found 325.10494 
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7.2.5 General conventional procedure for the synthesis of 4ʹ-fluoro-2- hydroxy-
chalcones 
To solution of 1-(4-fluoro-2-hydroxyphenyl)ethan-1-one (27) (200 mg, 1.30 mmol) 
and an aryl aldehyde (16a-16i, 2.0 equiv.) in ethanol (2.5 mL) was added at room 
temperature sodium hydroxide aqueous solution 50% (w/v) (2.5 mL). The reaction stirred 
for 24h at room temperature. The solution was neutralized using 10% HCl aqueous 
solution and extracted with DCM. The organic layers were combined, washed with brine, 
dried over MgSO4 and concentrated in vacuum. The chalcones derivatives were purified 
by column chromatography (40:1 hexane/ EtOAc). 
 
7.2.6 General microwave assisted procedure for the synthesis of 4ʹ-fluoro-2- 
hydroxy-chalcones 
To solution of 1-(4-fluoro-2-hydroxyphenyl)ethan-1-one   (27)  (200 mg, 1.300 mmol) 
and an aryl aldehyde (16a-16i, 2.0 equiv.) in ethanol (2.5 mL) was added at room 
temperature sodium hydroxide aqueous solution 50% (w/v) (2.5 mL). The reaction 
proceeded in a microwave oven at 150 W and 40 ºC for 1.5 h. The solution was 
neutralized using 10% HCl aqueous solution and extracted with DCM. The organic layers 
were combined, washed with brine, dried over MgSO4 and concentrated in vacuum. The 
chalcones derivatives were purified by column chromatography (30:1 hexane/ EtOAc). 
 
(E)-1-(4-fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (28a): 
Yield 72.6%; orange solid; m.p.=90.9-91.4 ºC; Rf (10:1 Hexane/ EtOAc)= 0.63; 1H NMR 
(acetone-d6) δ  (ppm) 13.33 (s, 1H, OH-2ʹ); 8.42 (dd, 1H, J6ʹ,F =6.82, J5ʹ,6ʹ =8.93, H-6ʹ); 
8.04-7.93 (m, 4H, H-2, H-3, H-2ʹʹ, H-6ʹʹ); 7.27 (t, 2H, J2ʹʹ,3ʹʹ=J5ʹʹ,6ʹʹ=8.66 Hz, H-3ʹʹ, H-5ʹʹ); 
6.80-6.74 (m, 2H, H-3ʹ, H-5ʹ); 13C NMR (acetone-d6) δ  (ppm) 192.9 (C-1); 166.2 (C-4ʹ); 
166.2 (d, J = 7.8 Hz, C-2ʹ); 167.2 (d, J = 254.1 Hz, C-4ʹʹ); 144.3 (C-3); 133.4 (d, J = 12.4 
Hz, C-6ʹ); 131.4 (d, J = 8.4 Hz, C-1ʹʹ, C-2ʹʹ, C-6ʹʹ); 120.4 (C-2); 117.2 (C-1ʹ); 115.9 (d, J =  
21.8 Hz, C-3ʹʹ, C-5ʹ); 106.9 (d, J = 21.8 Hz, C-5ʹ); 104.3 (d, J = 24.4 Hz, C-3ʹ); HRMS 
calcd for C15H11F2O2 261.07216 (MNa+) found 261.07361 
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(E)-3-(4-bromophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one (28b): 
Yield 87.3%; yellow solid; m.p.=89.4-89.9 ºC; Rf (10:1 Hexane/ EtOAc)= 0.59;                    
1H NMR (acetone-d6) δ  (ppm) 13.29 (s, 1H, OH-2ʹ); 8.43 (dd, 1H, J6ʹ,F =7.04, J5ʹ,6ʹ =8.71, 
H-6ʹ); 8.11 (d, 1H, J2,3=15.68 Hz, H-2); 7.93 (d, 1H, H-3); 7.88 (d, 2H, J2ʹʹ,3ʹʹ =J5’’,6’’=8.28 
Hz, H-2ʹʹ, H-6ʹʹ); 7.69 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.83-6.75 (m, 2H, H-3ʹ, H-5ʹ); 13C NMR 
(acetone-d6) δ  (ppm) 193.9 (C-1); 169.6 (C-4ʹ); 167.1 (d, J = 13.9 Hz, C-2ʹ); 144.9 (C-3); 
125.6 (C-4ʹʹ); 134.4 (d, J =  11.9Hz, C-6ʹ); 134.8 (C-1ʹʹ); 133.0 (C-3ʹʹ, C-5ʹʹ); 131.7 (C-2ʹʹ, 
C-6ʹʹ); 122.2 (C-2); 118.1 (C-1ʹ); 107.8 (d, J = 23.6 Hz, C-5ʹ); 105.2 (d, J = 23.5 Hz, C-3ʹ); 
HRMS calcd for C15H11BrFO2 320.99210 (MNa+) found 320.99422 
 
(E)-1-(4-fluoro-2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one (28d): 
Yield 83.0%; red solid; m.p.=87.9-88.3 ºC; Rf (10:1 Hexane/ EtOAc)= 0.54;                        
1H NMR (acetone-d6) δ  (ppm) 13.43 (s, 1H, OH-2ʹ); 8.42 (dd, 1H, J6ʹ,F =6.50, J5ʹ,6ʹ =8.83, 
H-6ʹ); 8.02 (d, 1H, J2,3=15.38 Hz, H-2); 7.95 (d, 1H, H-3); 7.81 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.73 
Hz, H-2ʹʹ, H-6ʹʹ); 7.32 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.82-6.74 (m, 2H, H-3ʹ, H-5ʹ); 2.40 (s, 1H, CH3-
4ʹʹ); 13C NMR (acetone-d6) δ  (ppm) 193.0 (C-1); 169.5 (C-4ʹ); 167.1 (C-2ʹ); 146.6 (C-3); 
142.6 (C-4ʹʹ); 134.2 (d, J = 11.7 Hz, C-6ʹ); 132.9 (C-1ʹʹ); 130.6 (C-3ʹʹ, C-5ʹʹ); 130.1 (C-2ʹʹ, 
C-6ʹʹ); 120.2 (C-2); 118.2 (C-1ʹ); 107.7 (d, J = 23.7 Hz, C-5ʹ); 105.2 (d, J = 23.9 Hz, C-3ʹ); 
21.5 (CH3-4ʹʹ); HRMS calcd for C16H14FO2 257.09723 (MNa+) found 257.09759 
 
(E)-3-(4-(benzyloxy)phenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one 
(28h): Yield 89.9%; reddish solid; m.p.=95.4-95.7.0 ºC; Rf (10:1 Hexane/ EtOAc)= 0.60; 
1H NMR (acetone-d6) δ  (ppm) 13.50 (s, 1H, OH-2ʹ); 8.40 (dd, 1H, J6ʹ,F =6.60, J5ʹ,6ʹ =8.97, 
H-6ʹ); 7.96 (d, 1H, J2,3=15.32 Hz, H-2); 7.90 (d, 1H, H-3); 7.88 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.66 
Hz, H-2ʹʹ, H-6ʹʹ); 7.53-7.35 (m, 5H, CH, Ph); 7.15 (t, 2H, H-3ʹʹ, H-5ʹʹ); 6.81-6.72 (m, 2H, H-
3ʹ, H-5ʹ); 5.24 (s, 2H, CH2Ph); 13C NMR (acetone-d6) δ  (ppm) 192.9 (C-1); 168.5 (C-4ʹ); 
165.6 (C-2ʹ); 161.5 (C-4ʹʹ); 145.6 (C-3); 136.9 (Cq, Ph); 133.2 (d, J =  11.6 Hz, C-6ʹ); 
131.1 (C-2ʹʹ, C-6ʹʹ); 128.5 (CH, Ph); 127.9 (CH, Ph); 127.6 (CH, Ph); 127.5 (C-1ʹʹ); 117.9 
(C-2); 117.3 (C-1ʹ); 115.4 (C-3ʹʹ, C-5ʹʹ); 106.7 (d, J = 22.4 Hz, C-5ʹ); 104.2 (d, J =  23.8 




 (E)-1-(4-fluoro-2-hydroxyphenyl)-3-(5-methylfuran-2-yl)prop-2-en-1-one (28i): 
Yield 84.6%; reddish oil; Rf (10:1 Hexane/ EtOAc)=0.63; 1H NMR (acetone-d6) δ  (ppm)  
13.33 (s, 1H, OH-2ʹ); 8.10 (dd, 1H, J6ʹ,F =7.12, J5ʹ,6ʹ =8.57, H-6ʹ); 7.56 (d, 1H, J2,3=14.84 
Hz, H-2); 7.42 (d, 1H, H-3); 6.87 (d, 1H, J2ʹʹ,3ʹʹ=2.70 Hz, H-2ʹʹ); 6.59 (dd, J3ʹ,5ʹ=1.89 Hz, 
J3ʹ,F =10.75 Hz, H-3ʹ); 6.68-6.63 (m, 1H, H-5ʹ); 6.19 (d, 1H, J3ʹ,5ʹ=2.52 Hz, J3ʹ,F =10.68 Hz, 
H-3ʹʹ); 2.28 (s, 3H, CH3-4ʹʹ); 13C NMR (acetone-d6) δ  (ppm) 192.4 (C-1); 167.5 (C-4ʹ); 
166.0 (C-2ʹ); 157.2 (C-4ʹʹ); 150.3 (C-1ʹʹ); 132.9 (d, J =  11.9 Hz, C-6ʹ); 131.5 (C-2); 119.9 
(C-2ʹʹ); 117.2 (C-1ʹ); 115.3 (C-3); 109.9 (C-3ʹʹ); 106.8 (d, J =  22.9 Hz, C-5ʹ); 104.3 (d, J = 
23.4 Hz, C-3ʹ); 13.1 (CH3-4ʹ); HRMS calcd for C14H12FO3 247.07650 (MH+) found 
247.07688 
 
7.3 Chalcones Deprotection 
7.3.1 General conventional procedure for the synthesis of 2ʹ ,4ʹ ,6ʹ-
trihydroxychalcones and 2ʹ ,4ʹ-dihydroxychalcones 
The protected chalcones (21a-21i and 28a-28i) (0.5 mmol) were dissolved in 
methanol (6.4 mL) and FeCl3·6H2O (2.5 equiv.) was added and the deprotection 
proceeded for 2h-3h at reflux. The residues were concentrated and purified by column 
chromatography (3:1 hexane/ EtOAc) affording the desired products.   
 
7.3.2 General microwave assisted procedure for the synthesis of 2ʹ ,4ʹ ,6ʹ-
trihydroxy-chalcones and 2ʹ ,4ʹ-dihydroxychalcones  
The protected chalcones (21a-21i and 28a-28i)  (0.5 mmol) were dissolved in 
methanol (6.4 mL) and FeCl3·6H2O (2.5 equiv.) was added and the deprotection 
proceeded in a microwave oven at 150 W at 80 ºC for 10 minutes. The residues were 
concentrated and purified by column chromatography (3:1 hexane/ EtOAc) yielding the 
desired chalcones. 
 
(E)-3-(4-fluorophenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22a): Yield 
87.7%; yellow solid; m.p.=178.2-179.3 ºC; Rf (2:1 Hexane/ EtOAc)=0.36; 1H NMR 
(acetone-d6), δ  (ppm) 12.01 (s, 2H, OH-2ʹ, OH-6ʹ); 9.39 (s, 1H, OH-4ʹ); 8.21 (d, 1H, J2,3 
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=14.54 Hz, H-2); 7.80-7.76 (m, 3H, H-3, H-2ʹʹ, H-6ʹʹ); 7.23 (t, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.73 Hz, 
H-3ʹʹ, H-5ʹʹ); 6.0 (s, 2H, H-3ʹ, H-5ʹ); 13C NMR (acetone-d6), δ  (ppm) 192.2 (C-1); 164.9 
(C-4ʹ); 164.8 (C-2ʹ, C-6ʹ); 162.4 (C-4ʹʹ); 140.5 (C-3); 132.2 (d, J = 3.2 Hz, C-1ʹʹ); 130.4 (d, 
J = 7.9 Hz, C-2ʹʹ, C-6ʹʹ); 127.5 (C-2); 115.9 (d, J = 21.6 Hz, C-3ʹʹ, C-5ʹʹ); 104.8 (C-1ʹ); 
95.2 (C-3ʹ, C-5ʹ); HRMS calcd for C15H12FO4 275.07141 (MH+) found 275.07163 
 
(E)-3-(4-bromophenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one  (22b): Yield 
96.0%; yellow solid; m.p.=187.4-188.3 ºC; Rf (4:1 Hexane/EtOAc)=0.52; 1H NMR 
(acetone-d6), δ  (ppm) 11.99 (s, 2H, OH-2ʹ, OH-6ʹ); 9.39 (s, 1H, OH-4ʹ); 8.27 (d, 1H, 
J2,3=15.66 Hz, H-2); 7.73 (d, 1H, H-3); 7.66 (d, 2H, J2ʹʹ,3ʹʹ=J5ʹʹ,6ʹʹ=8.73 Hz, H-3ʹʹ, H-5ʹʹ); 7.63 
(d, 2H, H-2ʹʹ, H-6ʹʹ); 6.0 (s, 2H, H-3ʹ, H-5ʹ); 13C NMR (acetone-d6), δ  (ppm) 192.1 (C-1); 
164.9 (C-4ʹ); 164.8 (C-4ʹ, C-6ʹ); 140.2 (C-3); 134.9 (C-1ʹʹ); 132.1 (C-3ʹʹ, C-5ʹʹ); 129.9 (C-
2ʹʹ, C-6ʹʹ); 128.5 (C-2); 123.6 (C-4ʹʹ); 104.8 (C-1ʹ); 95.2 (C-3ʹ, C-5ʹ); HRMS calcd for 
C15H12BrO4 334.99135 (MH+) found 334.99157 
 
(E)-3-(phenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22c): Yield 79.9%; 
yellow solid; m.p.=172.7-172.9 ºC; Rf (4:1 Hexane/EtOAc)= 0.26; 1H NMR (acetone-d6), 
δ  (ppm) 8.27 (d, 1H, J2,3 =15.72 Hz, H-2); 7.79 (d, 1H, H-3); 7.70 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ 
=6.90 Hz, H-2ʹʹ, H-6ʹʹ); 7.48-7.42 (m, 3H, H-3ʹʹ, H-4ʹʹ, H-5ʹʹ); 6.00 (s, 2H, H-3ʹ, H-5ʹ); 13C 
NMR (acetone-d6), δ  (ppm) 192.3 (C-1); 164.7 (C-2ʹ, C-4ʹ, C-6ʹ); 142.0 (C-3); 135.7 (C-
1ʹʹ); 130.0 (C-4ʹʹ); 128.9 (C-3ʹʹ, C-5ʹʹ); 128.3 (C-2ʹʹ, C-6ʹʹ); 127.7(C-2); 104.7 (C-1ʹ); 95.1 
(C-3ʹ, C-5ʹ); HRMS calcd for C15H13O4 257.08084 (MH+) found 257.08106 
 
(E)-3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22d): Yield 
80.7%; yellow solid; m.p.=157.0-157.9 ºC; Rf (4:1 Hexane/EtOAc)=0.30; 1H NMR 
(acetone-d6), δ  (ppm) 12.07 (s, 2H, OH-2ʹ, OH-6ʹ); 9.42 (s, 1H, OH-4ʹ); 8.23 (d, 1H, 
J2,3=16.20 Hz, H-2); 7.78 (d, 1H, H-3); 7.60 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ=7.90 Hz, H-2ʹʹ, H-6ʹʹ); 
7.28 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.99 (s, 2H, H-3ʹ, H-5ʹ); 2.38 (s, 3H, CH3-4ʹʹ); 13C NMR 
(acetone-d6), δ  (ppm) 192.3 (C-1); 164.8 (C-2ʹ, C-4ʹ, C-6ʹ); 141.9 (C-3); 140.4 (C-4ʹʹ); 
132.9 (C-1ʹʹ); 129.6 (C-3ʹʹ, C-5ʹʹ); 128.3 (C-2ʹʹ, C-6ʹʹ); 126.6(C-2); 104.8 (C-1ʹ); 95.2 (C-3ʹ, 




Yield 79.6%; yellow solid; m.p.=186.8-186.9 ºC; Rf (2:1 Toluene/EtOAc)= 0.20; 1H NMR 
(acetone-d6), δ  (ppm) 8.17 (d, 1H, J2,3 =15.83 Hz, H-2); 7.74 (d, 1H, H-3); 7.66 (d, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.68 Hz, H-2ʹʹ, H-6ʹʹ); 7.02 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.98 (s, 2H, H-3ʹ, H-5ʹ); 3.87 
(s, 3H, -OCH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 192.3 (C-1); 164.6 (C-4ʹ); 164.5 (C-
2ʹ, C-6ʹ); 161.6 (C-4ʹʹ); 141.9 (C-3); 130.3 (C-2ʹʹ, C-6ʹʹ); 128.1 (C-1ʹʹ); 125.2 (C-2); 114.4 
(C-3ʹʹ, C-5ʹʹ); 104.7 (C-1ʹ); 95.0 (C-3ʹ, C-5ʹ); 54.9 (-OCH3-4ʹʹ); HRMS calcd for 
C16H14NaO5 309.07334 (MNa+) found 309.07333 
 
(E)-3-(4-ethyloxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22f): 
Yield 88.5%; yellow solid; m.p.=182.3-182.6 ºC; Rf (2:1 Toluene/ EtOAc)= 0.32; 1H NMR 
(acetone-d6), δ  (ppm) 12.09 (s, 2H, OH-2ʹ, OH-6ʹ); 9.43 (s, 1H, OH-4ʹ); 8.16 (d, 1H, 
J2,3=15.69 Hz, H-2); 7.78 (d, 1H, H-3); 7.75 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ=8.73 Hz, H-2ʹʹ, H-6ʹʹ); 
7.00 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.98 (s, 2H, H-3ʹ, H-5ʹ); 4.12 (q, 2H, J=7.13 Hz, J=13.97 Hz, -
OCH2CH3-4ʹʹ); 1.98-1.96 (m, 3H, -OCH2CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 192.3 
(C-1); 164.8 (C-2ʹ, C-6ʹ); 164.5 (C-4ʹ); 160.9 (C-4ʹʹ); 142.1 (C-3); 130.1 (C-2ʹʹ, C-6ʹʹ); 
128.1 (C-1ʹʹ); 124.9 (C-2); 114.8 (C-3ʹʹ, C-5ʹʹ); 104.8 (C-1ʹ); 95.1 (C-3ʹ, C-5ʹ); 63.4 (-




Yield 82.4%; yellow solid; m.p.=175.1-175.4 ºC; Rf (2:1 Toluene/ EtOAc)= 0.55; 1H NMR 
(acetone-d6), δ  (ppm) 12.06 (s, 2H, OH-2ʹ, OH-6ʹ); 9.30 (s, 1H, OH-4ʹ); 8.16 (d, 1H, 
J2,3=14.82 Hz, H-2); 7.79 (d, 1H, H-3); 7.66 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ=8.40 Hz, H-2ʹʹ, H-6ʹʹ); 
7.04 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.15-6.05 (m, 1H, -OCH2CHCH2-4ʹʹ);  5.99 (s, 2H, H-3ʹ, H-5ʹ); 
5.45, 5.28 (each d, 2H, J=17.51 Hz, J=10.74 Hz, OCH2CHCH2-4ʹʹ); 4.66 (d, 2H, J=5.27 
Hz, -OCH2CHCH2-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 192.3 (C-1); 164.8 (C-2ʹ, C-6ʹ); 
164.5 (C-4ʹ); 160.5 (C-4ʹʹ); 141.9 (C-3); 133.4 (-OCH2CHCH2-4ʹʹ);  130.0 (C-2ʹʹ, C-6ʹʹ); 
128.3 (C-1ʹʹ); 125.2 (C-2); 118.8 (-OCH2CHCH2-4ʹʹ); 115.1 (C-3ʹʹ, C-5ʹʹ); 104.8 (C-1ʹ); 
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95.1 (C-3ʹ, C-5ʹ); 68.5 (-OCH2CHCH2-4ʹʹ); HRMS calcd for C18H16NaO5 335.08899 
(MNa+) found 335.08908 
 
(E)-3-(4-(benzyloxy)phenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22h): 
Yield 86.8%; yellow solid; m.p.=163.0-164.7 ºC; Rf (6:1 Hexane/ EtOAc)=0.30; 1H NMR 
(acetone-d6), δ  (ppm) 8.16 (d, 1H, J2,3=15.25 Hz, H-2); 7.78 (d, 1H, H-3); 7.66 (d, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.46 Hz, H-2ʹʹ, H-6ʹʹ); 7.50 (d, 2H, J=8.03 Hz, ArH); 7.41 (t, 2H, J=7.88 Hz, 
ArH); 7.35 (d, 1H, ArH); 7.10(d, 2H, H-5ʹʹ, H-6ʹʹ); 5.98 (s, 2H, H-3’, H-5ʹ); 5.20 (s, 2H, 
CH2Ph); 13C NMR (acetone-d6), δ  (ppm) 192.3 (C-1); 164.8 (C-4ʹ); 168.6 (C-2ʹ, C-6ʹ); 
160.7 (C-4ʹʹ); 141.9 (C-3); 137.1 (C-1ʹʹ, Cq, Ph); 130.1 (C-2ʹʹ, C-6ʹʹ); 128.5, 127.9, 127.6 
(CH-Ph); 125.2 (C-2); 115.3 (C-3ʹʹ, C-5ʹʹ); 104.8 (C-1ʹ); 95.2 (C-3ʹ, C-5ʹ); 69.7 (-OCH2Ph); 
HRMS calcd for C22H18NaO5 385.10464 (MNa+) found 385.10470 
 
(E)-3-(5-methylfuran-2-yl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (22i): 
Yield 93.5%; dark orange solid; m.p.=118.2-118.9 ºC; Rf (6:1 Hexane/ EtOAc)=0.50; 1H 
NMR (acetone-d6), δ  (ppm) 12.06 (s, 2H, OH-2ʹ, OH-6ʹ); 9.30 (s, 1H, OH-4ʹ); 8.04 (d, 
1H, J2,3=15.99 Hz, H-3); 7.56 (d, 1H, H-2); 6.78 (d, 1H, J2ʹʹ,3ʹʹ =2.96 Hz, H-2ʹʹ); 6.25 (d, 1H, 
H-3ʹʹ); 5.97 (s, 2H, H-3ʹ, H-5ʹ); 2.30 (s, 3H, CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 
191.8 (C-1); 164.8 (C-2ʹ, C-6ʹ); 164.5 (C-4ʹ); 155.7 (C-4ʹʹ); 150.9 (C-1ʹʹ); 128.8 (C-2); 
123.0 (C-3); 117.7 (C-2ʹʹ); 109.3 (C-3ʹʹ); 104.7 (C-1ʹ); 95.1 (C-3ʹ, C-5ʹ); 12.9 (CH3-4ʹʹ); 
HRMS calcd for C14H12NaO5 283.05769 (MNa+) found 283.05777 
 
(E)-1-(2,4-dihydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (26a): Yield 
84.6%; yellow solid; m.p.=129.1-129.8 ºC; Rf (3:1 Hexane/EtOAc)= 0.30; 1H NMR 
(acetone-d6) δ  (ppm) 13.49 (s, 1H, OH-2ʹ); 9.52 (s, 1H, OH-4ʹ); 8.17 (d, 1H, J5ʹ,6ʹ=8.93, 
H-6ʹ); 7.98-7.93 (m, 3H, H-2, H-2ʹʹ, H-6ʹʹ); 7.87 (d, 1H, J2,3=15.53 Hz, H-3); 7.26 (t, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =J=5ʹʹ,F =J6ʹʹ,F =8.84 Hz, H-3ʹʹ, H-5ʹʹ); 6.50 (dd, 1H, J3ʹ,5ʹ =1.44 Hz, H-5ʹ); 6.40 
(dd, 1H, H-3ʹ); 13C NMR (acetone-d6) δ  (ppm) 191.8 (C-1); 166.8 (C-2ʹ); 165.0 (C-4ʹ); 
164.0 (d, J = 248.7 Hz, C-4ʹʹ); 142.6 (C-3); 132.7 (C-6ʹ); 131.6 (d, J = 2.9 Hz, C-1ʹʹ); 
131.1 (d, J = 8.8 Hz, C-2ʹʹ, C-6ʹʹ); 120.7 (C-2); 115.9 (d, J = 22.1 Hz, C-3ʹʹ, C-5ʹʹ); 113.6 
122  
(C-1ʹ); 108.0 (C-5ʹ); 102.9 (C-3ʹ); HRMS calcd for C15H12FO3 259.07650 (MH+) found 
259.07678 
 
(E)-3-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (26b): Yield 
93.7%; yellow solid; m.p.=134.6-135.0 ºC; Rf (3:1 Hexane/ EtOAc)= 0.45; 1H NMR 
(acetone-d6) δ  (ppm) 13.42 (s, 1H, OH-2ʹ); 9.64 (s, 1H, OH-4ʹ); 8.17 (d, 1H, J5ʹ,6ʹ =8.86, 
H-6ʹ); 8.02 (d, 1H, J2,3=15.28 Hz, H-2); 7.86-7.83 (m, 3H, H-3, H-2ʹʹ, H-6ʹʹ); 7.67 (d, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.39 Hz, H-3ʹʹ, H-5ʹʹ); 6.50 (dd, 1H, J3ʹ,5ʹ =1.92 Hz, H-5ʹ); 6.40 (d, 1H, H-3ʹ); 
13C NMR (acetone-d6) δ  (ppm) 191.7 (C-1); 166.8 (C-2ʹ); 165.1 (C-4ʹ); 142.4 (C-3); 
134.3 (C-1ʹʹ); 132.7 (C-6ʹ); 132.1 (C-3ʹʹ, C-5ʹʹ); 130.5 (C-2ʹʹ, C-6ʹʹ); 124.2 (C-4ʹʹ); 121.7 
(C-2); 113.6 (C-1ʹ); 108.1 (C-5ʹ); 102.9 (C-3ʹ); HRMS calcd for C15H12BrO3 318.99643 
(MH+) found 318.99680 
 
(E)-1-(2,4-dihydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one (26c): Yield 
96.8%; yellow solid; m.p.=132.1-133.4 ºC; Rf (3:1 Hexane/ EtOAc)= 0.12; 1H NMR 
(acetone-d6) δ  (ppm) 13.55 (s, 1H, OH-2ʹ); 9.56 (s, 1H, OH-4ʹ); 8.18 (d, 1H, J5ʹ,6ʹ =7.19, 
H-6ʹ); 7.93 (d, 1H, J2,3=15.53 Hz, H-2); 7.86 (d, 1H, H-3); 7.77 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =7.86 
Hz, H-2ʹʹ, H-6ʹʹ); 7.31 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.50 (dd, 1H, J3ʹ,5ʹ =1.97 Hz, H-5ʹ); 6.39 (dd, 
1H, H-3ʹ); 2.40 (s, 1H, CH3-4ʹʹ); 13C NMR (acetone-d6) δ  (ppm) 191.9 (C-1); 166.8 (C-2ʹ); 
164.9 (C-4ʹ); 144.0 (C-3); 141.1 (C-4ʹʹ); 132.6 (C-6ʹ); 132.3 (C-1ʹʹ); 119.7 (C-2); 129.6 (C-
3ʹʹ, C-5ʹʹ);128.9 (C-2ʹʹ, C-6ʹʹ); 113.6 (C-1ʹ); 107.9 (C-5ʹ); 102.8 (C-3ʹ); 20.6 (CH3-4ʹʹ); 




Yield 96.7%; yellow solid; m.p.=127.5-128.1 ºC; Rf (3:1 Hexane/ EtOAc)= 0.21; 1H NMR 
(acetone-d6) δ  (ppm)  13.62 (s, 1H, OH-2ʹ); 9.68 (s, 1H, OH-4ʹ); 8.15 (d, 1H, J5ʹ,6ʹ =8.88, 
H-6ʹ); 7.89-7.80 (m, 4H, H-2, H-3, H-2ʹʹ, H-6ʹʹ); 7.52-7.36 (m, 5H, ArH, Ph); 7.12 (d, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.71 Hz, H-3ʹʹ, H-5ʹʹ); 6.49 (dd, 1H, J3ʹ,5ʹ=2.19 Hz, H-5ʹ); 6.40 (d, 1H, H-3ʹ); 
5.22 (s, 2H, -OCH2Ph); 13C NMR (acetone-d6) δ  (ppm)  191.9 (C-1); 166.7 (C-2ʹ); 164.8 
(C-4ʹ); 161.1 (C-4ʹʹ); 143.9 (C-3); 137.0 (Cq, Ph); 132.5 (C-6ʹ); 130.7 (C-2ʹʹ, C-6ʹʹ); 128.8 
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(CH, Ph); 128.2 (CH, Ph); 127.9 (CH, Ph); 127.8 (C-1ʹʹ); 118.4 (C-2); 115.3 (C-3ʹʹ, C-5ʹʹ); 
113.6 (C-1ʹ); 107.8 (C-5ʹ); 102.9 (C-3ʹ); 69.7 (-OCH2Ph); HRMS calcd for C22H18NaO4 
369.10973 (MNa+) found 369.10992 
 
(E)-1-(2,4-dihydroxyphenyl)-3-(5-methylfuran-2-yl)prop-2-en-1-one (26i): Yield 
90.9%; yellow solid; m.p.=125.6-125.9 ºC; Rf (3:1 Hexane/ EtOAc)= 0.35; 1H NMR 
(acetone-d6) δ  (ppm)  13.43 (s, 1H, OH-2ʹ); 9.41 (s, 1H, OH-4ʹ); 7.85 (d, 1H, J5ʹ,6ʹ =8.65, 
H-6ʹ); 7.48 (d, 1H, J2,3=14.92 Hz, H-2); 7.37 (d, 1H, H-3); 6.78 (d, J2ʹʹ,3ʹʹ =2.84 Hz, H-2ʹʹ); 
6.36 (dd, 1H, J3ʹ,5ʹ =1.98 Hz, H-5ʹ); 6.23 (d, 1H, H-3ʹ); 6.16 (d, 1H, H-3ʹʹ); 2.27 (s, 3H, 
CH3-4ʹʹ); 13C NMR (acetone-d6) δ  (ppm)  191.3 (C-1); 166.6 (C-2ʹ); 164.8 (C-4ʹ); 156.4 
(C-4ʹ); 150.4 (C-1ʹʹ); 132.2 (C-6ʹ); 130.2 (C-2); 118.7 (C-2ʹʹ); 115.9 (C-3); 113.5 (C-1ʹ); 
109.6 (C-3ʹʹ); 108.0 (C-5ʹ); 102.9 (C-3ʹ); 13.0 (CH3-4ʹʹ); HRMS calcd for C14H13O4 
245.08084 (MH+) found 245.08115 
 
7.4 Synthesis of dihydrochalcones 
7.4.1 General procedure for the synthesis of dihydrochalcones 
To a solution of chalcone (22a-22i, 26a-26i and 28a-28i, 2.0 mmol) in EtOAc (5 mL) 
and MeOH was added (2-3 mL) Pd/C (10% mmol) in N2 atmosphere. Et3SiH (10 equiv.) 
was added dropwise while effervescence was observed (meaning that hydrogen was 
being formed in situ). After all the Et3SiH was added the reaction was kept at room 
temperature for another 10 minutes until change in the color (orange/yellow to 
colourless). TLC was used to confirm the completion of the reaction. Catalyst was filtered 
off through celite, 2/3 of volume of solvent was removed under vacuum and extraction 
with ACN/Hex was used to remove most of the Et3SiH from the mixture. The final product 
was purified by column chromatography (10:1 or 7:1 hexane/ EtOAc). 
 
3-(4-fluorophenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18a): Yield 97.9 %; 
white solid; m.p.=199.9-200.5 ºC; Rf (3:1 Hexane/ EtOAc)= 0.35; 1H NMR (acetone-d6), δ  
(ppm) 11.76 (s, 2H, OH-2ʹ, OH-6ʹ); 9.31 (s, 1H, OH-4ʹ); 7.31 (dd, 2H, J2ʹʹ,F =J6ʹʹ,F =6.60 
Hz, J2ʹʹ,3ʹʹ=J5ʹʹ,6ʹʹ =8.39 Hz, H-2ʹ, H-6ʹ); 7.03 (t, 2H, H-3ʹ, H-5ʹ); 5.94 (s, 2H, H-3ʹ, H-5ʹ); 3.38 
(t, 2H, J2,3=7.54 Hz, H-2); 2.97 (t, 2H, H-3); 13C NMR (acetone-d6), δ  (ppm) 204.1 (C-1); 
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164.5 (C-4ʹ); 164.4 (C-2ʹ, C-6ʹ); 165.9 (d, J =  261.8 Hz, C-4ʹʹ); 138.0 (C-1ʹʹ); 130.1 (d, J = 
7.8 Hz, C-2ʹʹ, C-6ʹʹ); 114.8 (d, J = 20.8 Hz, C-3ʹʹ, C-5ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 
45.5 (C-2); 30.3 (C-3); HRMS calcd for C15H13FNaO4 299.06901 (MNa+) found 299.06902 
 
3-(phenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18c): Yield 94.4%; white 
solid; m.p.=133.0-133.4 ºC; Rf (2:1 Hexane/ EtOAc)= 0.28; 1H NMR (acetone-d6), δ  
(ppm) 11.82 (s, 2H, OH-2ʹ, OH-6ʹ); 9.37 (s, 1H, OH-4ʹ); 7.31-7.17 (m, 5H, H-2ʹʹ, H-3ʹʹ, H-
4ʹʹ, H-5ʹʹ, H-6ʹʹ); 5.95 (s, 2H, H-3ʹ, H-5ʹ); 3.40 (t, 2H, J2,3=7.86 Hz, H-2); 2.99 (t, 2H, H-3); 
13C NMR (acetone-d6), δ  (ppm) 204.3 (C-1); 164.5 (C-4ʹ); 164.4 (C-2ʹ, C-6ʹ); 142.0 (C-
1ʹʹ); 128.4 (C-3ʹʹ, C-5ʹʹ); 128.3 (C-2ʹʹ, C-6ʹʹ); 125.7 (C-4ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 
45.5 (C-2); 30.5 (C-3); HRMS calcd for C15H14NaO4 281.07843 (MNa+) found 281.07847 
 
3-(4-methylphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18d): Yield 98.8%; 
white solid; m.p.=198.7-199.4 ºC; Rf (3:1 Hexane/ EtOAc)= 0.17; 1H NMR (acetone-d6), δ  
(ppm) 11.83 (s, 2H, OH-2ʹ, OH-6ʹ); 9.38 (s, 1H, OH-4ʹ); 7.17 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =7.40 
Hz, H-2ʹʹ, H-6ʹʹ); 7.09 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.94 (s, 2H, H-3ʹ, H-5ʹ); 3.37 (t, 2H, J2,3=7.29 
Hz, H-2); 2.94 (t, 2H, H-3); 2.28 (s, 3H, CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 204.4 
(C-1); 164.6 (C-4ʹ); 164.5 (C-2ʹ, C-6ʹ); 138.9 (C-1ʹʹ); 134.9 (C-4ʹʹ); 128.9 (C-3ʹʹ, C-5ʹʹ); 
128.3 (C-2ʹʹ, C-6ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 45.7 (C-2); 30.1 (C-3); 20.1 (CH3-4ʹʹ); 
HRMS calcd for C16H16NaO4 295.09408 (MNa+) found 295.09410 
 
3-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18e): Yield 
96.9%; white solid; m.p.=200.8-201.4 ºC; Rf (2:1 Toluene/ EtOAc)= 0.29; 1H NMR 
(acetone-d6), δ  (ppm) 11.74 (s, 2H, OH-2ʹ, OH-6ʹ); 9.27 (s, 1H, OH-4ʹ); 7.20 (d, 2H, J2ʹʹ,3ʹʹ 
= J5ʹʹ,6ʹʹ =7.81 Hz, H-2ʹʹ, H-6ʹʹ); 6.86 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.95 (s, 2H, H-3ʹ, H-5ʹ); 3.77 (s, 
3H, -OCH3-4ʹʹ); 3.37 (t, 2H, J2,3=8.07 Hz, H-2); 2.93 (t, 2H, H-3); 13C NMR (acetone-d6), δ  
(ppm) 204.5 (C-1); 164.5 (C-4ʹ); 164.3 (C-2ʹ, C-6ʹ); 158.0 (C-4ʹʹ); 133.8 (C-1ʹʹ); 129.3 (C-
2ʹʹ, C-6ʹʹ); 113.7 (C-3ʹʹ, C-5ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 54.5 (-OCH3-4ʹʹ); 45.8 (C-2); 
29.6 (C-3); HRMS calcd for C16H16NaO5 311.08899 (MNa+) found 311.08905 
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3-(4-ethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18f): Yield 96.1%; 
white solid; m.p.=187.9-188.2 ºC; Rf (2:1 Toluene/ EtOAc)= 0.25; 1H NMR (acetone-d6), 
δ  (ppm) 11.96 (s, 2H, OH-2ʹ, OH-6ʹ); 9.65 (s, 1H, OH-4ʹ); 7.18 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.39 
Hz, H-2ʹʹ, H-6ʹʹ); 6.83 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.93 (s, 2H, H-3ʹ, H-5ʹ); 4.00 (q, 2H, J=6.74 Hz, 
J=14.96 Hz, -OCH2CH3-4ʹʹ); 3.34 (t, 2H, J2,3=8.07 Hz, H-2); 2.91 (t, 2H, H-3); 1.35 (t, 3H, 
-OCH2CH3-4ʹʹ);  13C NMR (acetone-d6), δ  (ppm) 204.5 (C-1); 164.6 (C-4ʹ); 164.5 (C-2ʹ, 
C-6ʹ); 157.3 (C-4ʹʹ); 133.7 (C-1ʹʹ); 129.3 (C-2ʹʹ, C-6ʹʹ); 114.2 (C-3ʹʹ, C-5ʹʹ); 104.2 (C-1ʹ); 
94.9 (C-3ʹ, C-5ʹ); 62.9 (-OCH2CH3-4ʹʹ); 45.9 (C-2); 29.7 (C-3); 14.3 (-OCH2CH3-4ʹʹ); 
HRMS calcd for C17H18NaO5 325.10464 (MNa+) found 325.10470 
 
3-(4-propyloxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18g): Yield 
93.8%; white solid; m.p.=187.9-188.2 ºC; Rf (2:1 Toluene/ EtOAc)= 0.24; 1H NMR 
(acetone-d6), δ  (ppm) 11.77 (s, 2H, OH-2ʹ, OH-6ʹ); 9.27 (s, 1H, OH-4ʹ); 7.19 (d, 2H, J2ʹʹ,3ʹʹ 
= J5ʹʹ,6ʹʹ =8.39 Hz, H-2ʹʹ, H-6ʹʹ); 6.84 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.95 (s, 2H, H-3ʹ, H-5ʹ); 3.90 (t, 
2H, J=8.60 Hz, -OCH2CH2CH3-4ʹʹ); 3.36 (t, 2H, J2,3=8.07 Hz, H-2); 2.92 (t, 2H, H-3); 1.76 
(sextet, 2H, J=13.35 Hz, J=6.34 Hz, -OCH2CH2CH3-4ʹʹ); 1.07 (t, 3H, OCH2CH2CH3-4ʹʹ); 
13C NMR (acetone-d6), δ  (ppm) 205.5 (C-1); 164.5 (C-4ʹ); 164.4 (C-2ʹ, C-6ʹ); 157.5 (C-
4ʹʹ); 133.7 (C-1ʹʹ); 129.3 (C-2ʹʹ, C-6ʹʹ); 114.2 (C-3ʹʹ, C-5ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 
69.0 (-OCH2CH2CH3-4ʹʹ); 45.9 (C-2); 29.6 (C-3); 22.4 (-OCH2CH2CH3-4ʹʹ); 9.9 (-
OCH2CH2CH3-4ʹʹ); HRMS calcd for C18H20NaO5 339.12029 (MNa+) found 339.12041 
 
3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18h): Yield 
97.4%; white solid; m.p.=200.9-201.2 ºC; Rf (3:1 Hexane/ EtOAc)= 0.45; 1H NMR 
(acetone-d6), δ  (ppm) 11.76 (s, 2H, OH-2ʹ, OH-6ʹ); 9.26 (s, 1H, OH-4ʹ); 8.10 (s, 1H, OH-
4ʹʹ); 7.11 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ=7.63 Hz, H-2ʹ, H-6ʹ); 6.76 (d, 2H, H-3ʹ, H-5ʹ); 5.95 (s, 2H, H-
3ʹ, H-5ʹ); 3.35 (t, 2H, J2,3=8.05 Hz, H-2); 2.89 (t, 2H, H-3); 13C NMR (acetone-d6), δ  
(ppm) 204.6 (C-1); 164.5 (C-4ʹ); 164.4 (C-2ʹ, C-6ʹ); 155.5 (C-4ʹʹ); 132.6 (C-1ʹʹ); 129.3 (C-
2ʹʹ, C-6ʹʹ); 115.1 (C-3ʹʹ, C-5ʹʹ); 104.2 (C-1ʹ); 94.9 (C-3ʹ, C-5ʹ); 45.9 (C-2); 29.7 (C-3); 
HRMS calcd for C15H14NaO5 297.07334 (MNa+) found 297.07341 
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3-(5-methylfuran-2-yl)-1-(2,4,6-trihydroxyphenyl)propan-1-one (18i): Yield 
98.4%; white solid; m.p.=182.7-183.3 ºC; Rf (3:1 Hexane/ EtOAc)=0.40; 1H NMR 
(acetone-d6), δ  (ppm) 11.73 (s, 2H, OH-2ʹ, OH-6ʹ); 9.28 (s, 1H, OH-4ʹ); 5.96 (s, 2H, H-3ʹ, 
H-5ʹ), 5.91 (d, 1H, J2ʹʹ,3ʹʹ =2.41Hz, H-2ʹʹ), 5.87 (d, 1H, H-3ʹʹ); 3.42 (t, 2H, J2,3=7.94 Hz, H-
2); 2.94 (t, 2H, H-3); 2.21 (s, 3H, CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 203.7 (C-1); 
164.5 (C-4ʹ); 164.4 (C-2ʹ, C-6ʹ); 153.6 (C-1ʹʹ); 149.9 (C-4ʹʹ); 105.9 (C-2ʹ); 105.5 (C-3ʹʹ); 
94.9 (C-3ʹ, C-5ʹ); 42.0 (C-2); 31.9 (C-3); 12.6 (CH3-4ʹʹ); HRMS calcd for C14H14NaO5 
285.07334 (MNa+) found 285.07345 
 
1-(2,4-dihydroxyphenyl)-3-(4-fluorophenyl)propan-1-one (29a): Yield 99.7%; 
white solid; m.p.=187.6-187.9 ºC; Rf (3:1 Hexane/ EtOAc)= 0.29; 1H NMR (acetone-d6), δ  
(ppm) 12.61 (s, 2H, OH-2ʹ); 9.52 (s, 1H, OH-4ʹ); 7.68 (d, 1H, J5ʹ,6ʹ =8.78 Hz, H-6ʹ); 7.20 
(d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ=7.99 Hz, H-2ʹʹ, H-6ʹʹ); 6.90 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.28 (dd, 1H, 
J3ʹ,5ʹ=2.48 Hz, H-5ʹ); 6.19 (d, 1H, H-3ʹ); 3.18 (t, 2H, J2,3=7.37 Hz, H-2); 2.88 (t, 2H, H-3); 
13C NMR (acetone-d6), δ  (ppm) 203.7 (C-1); 165.3 (C-2ʹ); 164.7 (C-4ʹ); 161.4 (d, J = 
24.4 Hz, C-4ʹʹ); 137.3 (d, J =  3.3 Hz, C-1ʹʹ); 132.7 (C-6ʹ); 130.2 (d, J = 8.1 Hz, C-2ʹʹ, C-
6ʹʹ); 114.8 (d, J = 21.0 Hz, C-3ʹʹ, C-5ʹʹ); 112.9 (C-1ʹ); 107.9 (C-5ʹ); 102.7 (C-3ʹ); 39.0 (C-
2); 29.1 (C-3); HRMS calcd for C15H14FO3 261.09215 (MH+) found 261.09245 
 
1-(2,4-dihydroxyphenyl)propan-1-one)-3-phenyl-propan-1-one (29c): Yield 
98.7%; white solid; m.p.=190.9-191.4 ºC; Rf (3:1 Hexane/ EtOAc)=0.50; 1H NMR 
(acetone-d6), δ  (ppm) 12.80 (s, 2H, OH-2ʹ); 9.47 (s, 1H, OH-4ʹ); 7.87 (d, 1H, J5ʹ,6ʹ=9.90 
Hz, H-6ʹ); 7.33-7.28 (m, 4H, H-2ʹʹ, H-3ʹʹ, H-5ʹʹ, H-6ʹʹ); 7.20 (t, 1H, J4ʹʹ,5ʹʹ =J5ʹʹ,6ʹʹ =7.56 Hz, H-
4ʹʹ);  6.44 (dd, 1H, J3ʹ,5ʹ =2.42 Hz, H-5ʹ); 6.34 (d, 1H, H-3ʹ); 3.34 (t, 2H, J2,3=7.23 Hz, H-2); 
3.03 (t, 2H, H-3); 13C NMR (acetone-d6), δ  (ppm) 203.9 (C-1); 165.4 (C-2ʹ); 164.6 (C-4ʹ); 
141.3 (C-1ʹʹ); 132.7 (C-6ʹ); 128.4 (C-2ʹʹ, C-6ʹʹ); 128.3 (C-3ʹʹ, C-5ʹʹ); 125.0 (C-4ʹʹ); 112.9 
(C-1ʹ); 107.9 (C-5ʹ); 102.7 (C-3ʹ); 39.0 (C-2); 30.0 (C-3); HRMS calcd for C15H14NaO3 
265.08532 (MNa+) found 265.08366 
 
1-(2,4-dihydroxyphenyl)-3-(4-methylphenyl)propan-1-one (29d): Yield 99.1%; 
white solid; m.p.=190.0-190.7 ºC; Rf (3:1 Hexane/ EtOAc)= 0.25; 1H NMR (acetone-d6), δ  
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(ppm) 12.80 (s, 2H, OH-2ʹ); 9.62 (s, 1H, OH-4ʹ); 7.84 (d, 1H, J5’,6’=8.78 Hz, H-6ʹ); 7.19 (d, 
2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =7.90 Hz, H-2ʹʹ, H-6ʹʹ); 7.10 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.43 (dd, 1H, J3ʹ,5ʹ =2.34 
Hz, H-5ʹ); 6.33 (d, 1H, H-3ʹ); 3.30 (t, 2H, J2,3=7.41 Hz, H-2); 2.99 (t, 2H, H-3); 2.89 (s, 3H, 
-CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 204.8 (C-1); 165.3 (C-2ʹ, C-4ʹ); 138.2 (C-4ʹʹ); 
135.7 (C-1ʹʹ); 128.9 (C-2ʹʹ, C-6ʹʹ); 128.3 (C-3ʹʹ, C-5ʹʹ); 132.7 (C-6ʹ); 112.9 (C-1ʹ); 107.9 (C-
5ʹ); 102.7 (C-3ʹ); 39.2 (C-2); 29.5 (C-3); 20.1 (-CH3-4ʹʹ); HRMS calcd for C16H16NaO3 
279.09917 (MNa+) found 279.09922 
 
1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)propan-1-one (29h): Yield 99.0%; 
white solid; m.p.=205.9-206.4 ºC; Rf (3:1 Hexane/ EtOAc)= 0.25; 1H NMR (acetone-d6), δ  
(ppm)12.84 (s, 1H, OH-2ʹ); 8.64 (brs, 1H, OH-4ʹ); 7.81 (d, 1H, J5ʹ,6ʹ =9.13, H-6ʹ); 7.12 (d, 
2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.91 Hz, H-2ʹʹ, H-6ʹʹ); 6.78 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.44 (dd, 1H, J3ʹ,5ʹ =2.40 
Hz H-5ʹ); 6.35 (d, 1H, H-3ʹ); 3.24 (t, 2H, J2,3=7.86 Hz, H-2); 2.93 (t, 2H, H-3); 13C NMR 
(acetone-d6), δ  (ppm) 204.2 (C-1); 165.4 (C-2ʹ); 164.6 (C-4ʹ); 155.6 (C-4ʹʹ); 132.7 (C-6ʹ); 
131.9 (C-1ʹʹ); 129.4 (C-2ʹʹ, C-6ʹʹ); 115.2 (C-3ʹʹ, C-5ʹʹ); 113.0 (C-1ʹ); 107.9 (C-5ʹ); 102.7 (C-
3ʹ); 39.5 (C-2); 29.4 (C-3); HRMS calcd for C15H14NaO4 281.07843 (MNa+) found 
281.07850 
 
1-(2,4-dihydroxyphenyl)-3-(5-methylfuran-2-yl)propan-1-one (29i): Yield 98.2%; 
white solid; m.p.=198.3-198.5 ºC; Rf (3:1 Hexane/ EtOAc)= 0.40; 1H NMR (acetone-d6), δ  
(ppm) 12.73 (s, 1H, OH-2ʹ); 9.57 (s, 1H, OH-4ʹ); 7.84 (d, 1H, J5ʹ,6ʹ =8.84, H-6ʹ); 5.97 (d, 
1H, J2ʹʹ,3ʹʹ =2.25 Hz, H-2ʹʹ); 5.86 (d, 1H, H-3ʹʹ); 6.46 (dd, 1H, J3ʹ,5ʹ =1.86 Hz H-5ʹ); 6.35 (d, 
1H, H-3ʹ); 3.31 (t, 2H, J2,3=7.56 Hz, H-2); 2.98 (t, 2H, H-3); 2.21 (s, 3H, CH3-4ʹʹ); 13C NMR 
(acetone-d6), δ  (ppm) 203.9 (C-1); 165.3 (C-2ʹ); 164.7 (C-4ʹ); 152.8 (C-1ʹʹ); 150.2 (C-4ʹʹ); 
132.7 (C-6ʹ); 112.9 (C-1ʹ); 107.9 (C-2ʹʹ); 106.0 (C-3ʹʹ); 105.9 (C-5ʹ); 102.7 (C-3ʹ); 35.7 (C-
2); 22.4 (C-3); 12.6 (CH3-4ʹʹ); HRMS calcd for C14H14NaO4 269.07843 (MNa+) found 
269.07860 
 
1-(4-fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)propan-1-one (30a): Yield 
99.3%; white solid; m.p.=212.7-213.3 ºC; Rf (3:1 Hexane/ EtOAc)=0.62; 1H NMR 
(acetone-d6), δ  (ppm) 12.51 (s, 1H, OH-2); 7.95 (dd, 1H, J6ʹ,F =6.87, J5ʹ,6ʹ =8.70, H-6ʹ); 
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7.21 (dd, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =8.20 Hz, J2ʹʹ,F =J6ʹʹ,F =5.93 Hz, H-2ʹʹ, H-6ʹʹ); 6.91 (t, 2H, J3ʹʹ,F 
=J5ʹʹ,F =8.68 Hz, H-3ʹʹ, H-5ʹʹ); 6.61-6.53 (m, 2H, H-3ʹ, H-5ʹ); 3.31 (t, 2H, J2,3=7.83 Hz, H-2); 
2.91 (t, 2H, H-3); 13C NMR (acetone-d6), δ  (ppm) 205.1 (C-1); 167.1 (d, J = 251.4 Hz, C-
4ʹ); 164.8 (d, J = 14.4 Hz, C-2ʹ); 137.0 (d, J = 3.2 Hz, C-1ʹʹ); 161.4 (d, J = 246.4 Hz, C-
4ʹʹ); 133.5 (d, J = 11.5 Hz, C-6ʹ); 114.9 (d, J = 2.3 Hz, C-3ʹʹ, C-5ʹʹ); 130.2 (d, J = 7.9 Hz, 
C-2ʹʹ, C-6ʹʹ); 116.7 (d, J = 2.3 Hz, C-1ʹ); 106.8 (d, J = 22.4 Hz, C-5ʹ); 104.2 (d, J = 22.5 
Hz, C-3ʹ); 39.7 (C-2); 28.6 (C-3); HRMS calcd for C15H13F2O2 263.08781 (MH+) found 
263.08951 
 
1-(4-fluoro-2-hydroxyphenyl)-3-(phenyl)propan-1-one (30c): Yield 99.4% ; liquid 
solid; Rf (3:1 Hexane/ EtOAc)= 0.62; 1H NMR (acetone-d6), δ  (ppm) 12.71 (s, 1H, OH-
2ʹ); 8.11 (dd, 1H, J6ʹ,F =6.78, J5ʹ,6ʹ =9.31, H-6ʹ); 7.34-7.28 (m 4H, H-2ʹʹ, H-3ʹʹ, H-5ʹʹ, H-6ʹʹ); 
7.21 (t, 1H, J3ʹʹ,4ʹʹ =J4ʹʹ,5ʹʹ =7.02, H-4ʹʹ); 6.77-6.69 (m, 2H, H-3ʹ, H-5ʹ); 3.46 (t, 2H, J2,3=7.94 
Hz, H-2); 3.06 (t, 2H, H-3); 13C NMR (acetone-d6), δ  (ppm) 205.1 (C-1); 167.1 (d, J = 
259.2 Hz, C-4ʹ); 164.8 (d, J = 12.6 Hz, C-2ʹ); 141.0 (C-1ʹʹ); 133.3 (J = 13.3 Hz, C-6ʹ); 
128.5 (C-3ʹʹ, C-5ʹʹ); 128.4 (C-2ʹʹ, C-6ʹʹ); 126.1 (C-4ʹʹ); 116.7 (C-1ʹ); 106.9 (d, J = 23.6 Hz, 
C-5ʹ); 104.3 (d, J = 24.6 Hz, C-3ʹ); 39.8 (C-2); 29.2 (C-3); 20.2 (CH3-4ʹʹ); HRMS calcd for 
C15H14FO2 245.09723 (MH+) found 245.0986 
 
1-(4-fluoro-2-hydroxyphenyl)-3-(4-methylphenyl)propan-1-one (30d): Yield 
99.0%; white solid; m.p.=210.9-211.4 ºC; Rf (3:1 Hexane/ EtOAc)=0.53; 1H NMR 
(acetone-d6), δ  (ppm) 12.72 (s, 1H, OH-2ʹ); 8.04 (dd, 1H, J6’,F =6.85, J5’,6’ =8.62, H-6ʹ); 
7.19 (d, 2H, J2ʹʹ,3ʹʹ=J5ʹʹ,6ʹʹ =7.75 Hz, H-2ʹʹ, H-6ʹʹ); 7.10 (d, 2H, H-3ʹʹ, H-5ʹʹ); 6.74-6.67 (m, 
2H, H-3ʹ, H-5ʹ); 3.37 (t, 2H, J2,3=7.55 Hz, H-2); 3.00 (t, 2H, H-3); 2.29 (s, 3H, CH3-4ʹʹ); 13C 
NMR (acetone-d6), δ  (ppm) 205.2 (C-1); 167.1 (d, J = 256.3 Hz, C-4ʹ); 164.8 (d, J = 17.5 
Hz, C-2ʹ); 137.9 (C-1ʹʹ); 135.3 (C-4ʹʹ); 133.6 (d, J = 11.5 Hz, C-6’); 129.0 (C-3ʹʹ, C-5ʹʹ); 
128.3 (C-2ʹʹ, C-6ʹʹ); 116.7 (C-1ʹ); 106.9 (d, J = 22.6 Hz, C-5ʹ); 104.2 (d, J = 23.7 Hz, C-3ʹ); 
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1-(4-fluoro-2-hydroxyphenyl)-3-(4-hydroxyphenyl)propan-1-one (30h): Yield 
98.2%; white solid; m.p.=209.6-209.9 ºC; Rf (3:1 Hexane/ EtOAc)= 0.65; 1H NMR 
(acetone-d6), δ  (ppm) 12.73 (s, 1H, OH-2ʹ); 8.16 (s, 1H, OH-4ʹʹ); 8.10 (dd, 1H, J6ʹ,F 
=6.64, J5ʹ,6ʹ =8.74, H-6ʹ); 7.13 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =7.93 Hz, H-2ʹʹ, H-6ʹʹ); 6.77 (d, 2H, H-
3ʹʹ, H-5ʹʹ); 6.76-6.68 (m, 2H, H-3’, H-5’); 3.38 (t, 2H, J2,3=7.49 Hz, H-2); 2.96 (t, 2H, H-3); 
13C NMR (acetone-d6), δ  (ppm) 205.5 (C-1); 167.1 (d, J = 253.8 Hz, C-4ʹ); 164.8 (d, J = 
13.9 Hz, C-2ʹ); 155.7 (C-4ʹʹ); 133.5 (d, J = 11.9 Hz, C-6ʹ); 131.5 (C-1ʹʹ); 115.2 (C-3ʹʹ, C-
5ʹʹ); 129.3 (C-2ʹʹ, C-6ʹʹ); 116.7 (C-1ʹ); 106.8 (d, J = 22.3 Hz, C-5ʹ); 104.1 (d, J = 23.6 Hz, 
C-3ʹ); 40.1 (C-2); 26.6 (C-3); HRMS calcd for C15H13FNaO3 283.07409 (MNa+) found 
283.07579 
 
1-(4-fluoro-2-hydroxyphenyl)-3-(5-methylfuran-2-yl)propan-1-one (30i): Yield 
58.4%; liquid; Rf (3:1 Hexane/ EtOAc)=0.80; 1H NMR (acetone-d6), δ  (ppm) 12.63 (s, 
1H, OH-2ʹ); 8.10 (dd, 1H, J6ʹ,F =6.31, J5ʹ,6ʹ =8.32, H-6ʹ); 6.78-6.69 (m, 2H, H-3ʹ, H-5ʹ); 5.99 
(s, 1H, H-2ʹʹ); 5.89 (s, 1H, H-3ʹʹ); 3.44 (t, 2H, J2,3=7.24 Hz, H-2); 3.01 (t, 2H, H-3); 2.22 (s, 
3H, CH3-4ʹʹ); 13C NMR (acetone-d6), δ  (ppm) 204.7 (C-1); 167.1 (d, J = 252.2 Hz, C-4ʹ); 
164.8 (d, J = 13.6 Hz, C-2ʹ); 152.6 (C-4ʹʹ); 150.2 (C-1ʹʹ); 133.4 (d, J = 11.4 Hz, C-6ʹ); 
116.7 (C-1ʹ); 106.9 (d, J = 22.6 Hz, C-5ʹ); 106.0 (C-3ʹʹ); 105.9 (C-2ʹʹ); 104.2 (d, J = 23.8 
Hz, C-3ʹ); 36.4 (C-2); 22.1 (C-3); 12.5 (CH3-4ʹʹ); HRMS calcd for C14H14FO3 249.09215 
(MH+) found 249.09372 
 
1-(4-fluoro-2-hydroxyphenyl)-3-(5-methyltetrahydrofuran-2-yl)propan-1-one 
(30j): Yield 40.8%; liquid; Rf (3:1 Hexane/ EtOAc)=0.69; 1H NMR (acetone-d6), δ  (ppm) 
12.74 (s, 1H, OH-2ʹ); 8.10 (dd, 1H, J6ʹ,F =6.69, J5ʹ,6ʹ =8.94, H-6ʹ); 6.78-6.68 (m, 2H, H-3ʹ, 
H-5ʹ); 3.93-3.85 (m, 2H, H-1ʹʹ, H-4ʹʹ); 3.21-3.16 (m, 2H, H-2); 2.08-1.83 (m, 4H, H-3,H-
2aʹʹ, H-3aʹʹ); 1.63-1.56 (m, 1H, H-2bʹʹ); 1.48-1.42 (m, 1H, H-3bʹʹ); 1.17 (d, 3H, J4ʹʹ,5ʹʹ=5.86 
Hz, CH3-ʹ4ʹ); 13C NMR (acetone-d6), δ  (ppm) 206.2 (C-1); 167.0 (d, 253.6 Hz, C-4ʹ); 
164.8 (d, J = 14.7 Hz, C-2ʹ); 133.4 (d, J = 11.6 Hz, C-6ʹ); 116.7 (C-1ʹ); 106.8 (d, J = 22.2 
Hz, C-5ʹ); 104.1 (d, J = 23.5 Hz, C-3ʹ); 77.9 (C-1ʹʹ); 75.0 (C-4ʹʹ); 34.8 (C-2); 32.7 (C-3ʹʹ); 
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7.5.1 General Procedure for the synthesis of protected C-glucosyl 
dihydrochalcones 
A solution of dihydrochalcone (18a-18i, 2 equiv.) in ACN (2 mL) was added to a 
solution of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (3, 1.23 mmol) in DCM (10 mL) at 
room temperature. Drierite (200mg) was added and the reaction vessel was maintained 
under N2. The mixture was cooled to -30 ºC and TMSOTf (0.5 equiv.) was added 
dropwise. After 20-30 minutes the reaction was allowed to reach room temperature. The 
total consumption of the glycosyl donor was confirmed by TLC (1:1 Hexane/Acetone) and 
after 2h-5h (depending on substrate) the reaction was quenched with NaCl sat. solution. 
Drierite was filtered off under celite and the residue was extracted with DCM, washed 
with brine and dried over anhydrous MgSO4. The benzylated C-glucosyldihydrochalcones 
were purified as oil by column chromatography (7:1 Hexane/Acetone).  
 
3-(4-fluorophenyl)-1-[3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2,4,6-tri-
hydroxyphenyl]propan-1-one (37a): Yield 42.9%; Rf (3:1 Hexane/ EtOAc)=0.58; 1H 
NMR (CDCl3) δ  (ppm) 14.30 (s, 2H, OH-2ʹ, OH-6ʹ); 9.72 (s, 1H, OH-4ʹ); 7.37-6.95 (m, 
24H, ArH, H-2ʹʹ, H-3ʹʹ, H-5ʹʹ, H-6ʹʹ); 6.01 (s, 1H, H-5ʹ); 4.98 (s, 2H, -OCH2Ph); 4.88-4.86 
(m, 3H, -OCH2Ph, H-1ʹʹʹ); 4.73, 4.29 (each d, 2H, J =10.65 Hz, -OCH2Ph); 4.57, 4.48 
(each d, 2H, J =9.18 Hz, -OCH2Ph); 4.57, 4.48 (each d, 2H, J =9.18 Hz, -OCH2Ph); 3.90-
3.60 (m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, H-6bʹʹʹ); 3.28-4.24 (m, 2H, H-2); 2.95 (t, 
2H, J2,3=7.21 Hz,  H-3); 13C NMR (CDCl3) δ  (ppm) 135.9 (C-1ʹʹ); 138.2, 137.7, 137.4, 
137.3 (Cq-Ph); 129.9 (C-2ʹʹ, C-6ʹʹ); 128.7, 128.6, 128.5, 128.3, 128.0, 127.8, 127.6 (CH-
Ph); 115.2 (C-3ʹʹ, C-5ʹʹ); 105.6 (C-3ʹ); 103.4 (C-1ʹ); 99.9 (C-5ʹ); 86.2 (C-2ʹʹʹ); 78.7 (C-3ʹʹʹ); 
77.2 (C-4ʹʹʹ); 76.3 (C-5ʹʹʹ); 75.7 (-OCH2Ph); 75.3 (C-1ʹʹʹ); 75.0, 74.6, 73.4 (-OCH2Ph); 67.5 
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3-phenyl-1-[3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2,4,6-trihydroxy-
phenyl]-propan-1-one (37c): Yield 41.8%; Rf (3:1 Hexane/Acetone)=0.19; 1H NMR 
(CDCl3) δ  (ppm) 7.35-6.98 (m, 25H, ArH, H-2ʹʹ, H-3ʹʹ, H-3ʹʹ, H-4ʹʹ, H-5ʹʹ, H-6ʹʹ); 5.96 (s, 
1H, H-5ʹ); 4.95 (s, 2H, -OCH2Ph); 4.85 (d, 1H, J1ʹʹʹ,2ʹʹʹ =8.67 Hz, H-1ʹʹʹ); 4.83, 4.51 (each d, 
2H, J=11.03 Hz, -OCH2Ph); 4.69, 4.27 (each d, 2H, J=9.97 Hz, -OCH2Ph); 4.55, 4.46 
(each d, 2H, J=11.27 Hz, -OCH2Ph); 3.86-3.58 (m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, 
H-6bʹʹʹ); 3.30-3.26 (m, 2H, H-2); 2.97 (t, 2H, J2,3=8.94 Hz, H-3); 13C NMR (CDCl3) δ  
(ppm) 205.0 (C-1);141.8 (C-1ʹʹ); 138.2, 137.7, 137.3, 136.2 (Cq-Ph); 128.7, 128.5, 128.4, 
128.3, 128.0, 127.9, 127.8, 127.6 (CH-Ph, C-2ʹʹ, C-3ʹʹ, C-5ʹʹ, C-6ʹʹ); 125.9 (C-4ʹʹ); 106.0 
(C-3ʹ); 102.8 (C-1ʹ); 99.9 (C-5ʹ); 86.2 (C-2ʹʹʹ); 78.7 (C-3ʹʹʹ); 77.2 (C-4ʹʹʹ); 76.3 (C-5ʹʹʹ); 75.7 
(-OCH2Ph); 75.3 (C-1ʹʹʹ); 75.2, 75.0, 73.4 (-OCH2Ph); 67.5 (C-6ʹʹʹ); 45.9 (C-2); 30.5 (C-3); 
HRMS calcd for C49H48NaO9 803.31905 (MNa+) found 803.32129 
 
3-(4-methylphenyl)-1-[3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2,4,6-tri-
hydroxy-phenyl]propan-1-one (37d): Yield 52.1%; Rf (3:1 Hexane/ EtOAc)=0.60; 1H 
NMR (CDCl3) δ  (ppm) 14.03 (s, 2H, OH-2ʹ, OH-6ʹ); 9.87 (s, 1H, OH-4ʹ); 7.34-6.97 (m, 
24H, ArH, H-2ʹʹ, H-3ʹʹ, H-5ʹʹ, H-6ʹʹ); 5.89 (s, 1H, H-5ʹ); 4.95 (dd, 2H, J=9.99 Hz, J=17.18 
Hz, -OCH2Ph); 4.87 (d, 1H, J1ʹʹʹ,2ʹʹʹ =9.98 Hz, H-1ʹʹʹ); 4.83 (d, 1H, J=8.53 Hz, part A system 
AB of -OCH2Ph); 4.62, 4.21 (each d, 2H, J=10.55 Hz, -OCH2Ph); 4.57-4.47 (m, 3H, part 
B system AB of -OCH2Ph, -OCH2Ph); 3.80-3.59 (m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-
6aʹʹʹ, H-6bʹʹʹ); 3.27 (t, 2H, J2,3=7.36 Hz, H-2); 2.97 (t, 2H, H-3); 2.92 (s, 3H, -OCH3-4ʹʹ); 
13C NMR (CDCl3) δ  (ppm) 205.2 (C-1); 138.8 (C-1ʹʹ); 138.3, 137.8, 137.1, 136.4 (Cq-Ph); 
135.4 (C-4ʹʹ); 129.1, 128.7, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 127.8, 127.7 (CH-
Ph, C-2ʹʹ, C-3ʹʹ, C-5ʹʹ, C-6ʹʹ); 105.7 (C-3ʹ); 102.5 (C-1ʹ); 97.5 (C-5ʹ); 86.2 (C-2ʹʹʹ); 81.7 (C-
3ʹʹʹ); 78.3 (C-4ʹʹʹ); 77.3 (C-5ʹʹʹ); 76.1 (C-1ʹʹʹ); 75.7, 75.3, 74.9, 73.5 (-OCH2Ph); 67.9 (C-




tri-hydroxyphenyl]propan-1-one (37e): Yield 39.3%; Rf (1:1 Hexane/Acetone)=0.19; 1H 
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NMR (CDCl3) δ  (ppm) 14.43 (s, 2H, OH-2ʹ, OH-6ʹ); 7.33-7.12 (m, 20H, ArH); 6.98 (d, 2H, 
J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =7.83 Hz,  H-2ʹʹ, H-6ʹʹ); 6.82 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.89 (s, 1H, H-5ʹ); 4.96-4.81 
(m, 2H, -OCH2Ph, H-1ʹʹʹ); 4.59, 4.20 (each d, 2H, J =8.89 Hz, -OCH2Ph); 4.55-4.46 (m, 
3H, -OCH2Ph); 3.80-3.59 (m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, H-6bʹʹʹ); 3.27 (t, 2H, 
J2,3 =7.32 Hz,  H-2); 2.93 (t, 2H, H-3); 13C NMR (CDCl3) δ  (ppm) 205.2 (C-1); 138.4, 
137.7, 137.1, 136.6 (Cq-Ph); 133.9 (C-1ʹʹ); 129.5 (C-2ʹʹ, C-6ʹʹ); 128.7, 128.6, 128.5, 128.1, 
128.0, 127.7 (CH-Ph); 113.8 (C-3ʹʹ, C-5ʹʹ); 105.6 (C-3ʹ); 102.5 (C-1ʹ); 97.3 (C-5ʹ); 86.2 (C-
2ʹʹʹ); 81.1 (C-3ʹʹʹ); 78.8 (C-4ʹʹʹ); 77.4 (C-5ʹʹʹ); 76.0 (C-1ʹʹʹ); 75.8, 75.3, 74.8, 73.5 (-
OCH2Ph); 68.0 (C-6ʹʹʹ); 55.3 (-OCH3-4ʹʹ); 46.2 (C-2); 31.9 (C-3); HRMS calcd for 
C50H50NaO10 833.32962 (MNa+) found 833.33521 
 
3-(4-ethyloxyphenyl)-1-[3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2,4,6-
trihydroxy-phenyl]propan-1-one (37f): Yield 46.7%; Rf (1:1 Hexane/Acetone)=0.16; 1H 
NMR (CDCl3) δ  (ppm) 7.32-7.11 (m, 20H, ArH); 6.98 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =7.58 Hz, H-2ʹʹ, 
H-6ʹʹ); 6.81 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.92 (s, 1H, H-5ʹ); 4.97-4.82 (m, 4H, -OCH2Ph, part A-
OCH2Ph, H-1ʹʹʹ); 4.63, 4.22 (each d, 2H, J =10.33 Hz, -OCH2Ph); 4.56-4.55 (m, 3H, -
OCH2Ph, part B-OCH2Ph); 4.00 (q, 2H, J=7.37 Hz, J=13.13 Hz, -OCH2CH3-4ʹʹ); 3.81-3.59 
(m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, H-6bʹʹʹ); 3.28-3.24 (m, 2H, H-2); 2.91 (t, 2H, 
J2,3 =7.63 Hz,  H-3); 1.40 (t, 3H, -OCH2CH3-4ʹʹ); 13C NMR (CDCl3) δ  (ppm) 205.2 (C-1); 
157.1 (C-4ʹʹ); 138.3, 137.7, 137.2, 136.4 (Cq-Ph); 133.8 (C-1ʹʹ); 129.4 (C-2ʹʹ, C-6ʹʹ); 128.7, 
128.5, 128.4, 128.1, 128.0, 127.8, 127.6 (CH-Ph); 114.4 (C-3ʹʹ, C-5ʹʹ); 105.7 (C-3ʹ); 102.6 
(C-1ʹ); 97.5 (C-5ʹ); 86.2 (C-2ʹʹʹ); 81.9 (C-3ʹʹʹ); 78.7 (C-4ʹʹʹ); 77.2 (C-5ʹʹʹ); 76.1 (C-1ʹʹʹ); 67.8 
(C-6ʹʹʹ); 75.7, 75.3, 74.9, 73.4 (-OCH2Ph);  63.4 (-OCH2CH3-4ʹʹ); 46.2 (C-2); 29.7 (C-3); 
14.9 (-OCH2CH3-4ʹʹ); HRMS calcd for C51H52NaO10 847.34527 (MNa+) found 847.34662 
 
3-(4-propyloxyphenyl)-1-[3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-2,4,6-
tri-hydroxyphenyl]propan-1-one (37g): Yield 45.9%; Rf (1:1 Hexane/Acetone)=0.18; 1H 
NMR (CDCl3) δ  (ppm) 7.34-7.12 (m, 20H, ArH); 6.98 (d, 2H, J2ʹʹ,3ʹʹ =J5ʹʹ,6ʹʹ =6.80 Hz, H-2ʹʹ, 
H-6ʹʹ); 6.82 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.93 (s, 1H, H-5ʹ); 4.97-4.91 (m, 1H, -OCH2Ph); 4.88 (d, 
1H, J1ʹʹʹ,2ʹʹʹ =9.57 Hz, H-1ʹʹʹ); 4.83 (d, 1H, J=10.52 Hz, part A -OCH2Ph); 4.65, 4.24 (each 
d, 2H, J =10.33 Hz, -OCH2Ph); 4.56-4.45 (m, 3H, -OCH2Ph, part B-OCH2Ph); 3.89 (t, 2H, 
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J=6.88 Hz, -OCH2CH2CH3-4ʹʹ); 3.82-3.60 (m, 6H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, H-
6bʹʹʹ); 3.30-3.18 (m, 2H, H-2); 2.91 (t, 2H, J2,3 =7.12 Hz, H-3); 1.79 (q, 2H, J=14.06 Hz, 
J=20.43 Hz, -OCH2CH2CH3-4ʹʹ); 1.03 (t, 3H, -OCH2CH2CH3-4ʹʹ);  13C NMR (CDCl3) δ  
(ppm) 205.2 (C-1); 157.3 (C-4ʹʹ); 138.3, 137.7, 137.3, 136.7 (Cq-Ph); 133.7 (C-1ʹʹ); 129.4 
(C-2ʹʹ, C-6ʹʹ); 128.7, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.6 (CH-Ph); 
114.4 (C-3ʹʹ, C-5ʹʹ); 105.8 (C-3ʹ); 102.7 (C-1ʹ); 97.7 (C-5ʹ); 86.2 (C-2ʹʹʹ); 81.7 (C-3ʹʹʹ); 78.7 
(C-4ʹʹʹ); 77.2 (C-5ʹʹʹ); 76.2 (C-1ʹʹʹ); 69.5 (C-6ʹʹʹ); 75.7, 75.3, 74.9, 73.4 (-OCH2Ph); 67.7 (-
OCH2CH2CH3-4ʹʹ); 46.2 (C-2); 29.7 (C-3); 22.7 (-OCH2CH2CH3-4ʹʹ); 10.6 (-OCH2CH2CH3-
4ʹʹ); HRMS calcd for C52H54NaO10 861.36092 (MNa+) found 861.36124 
 
7.5.2 Synthesis of compound 37h 
7.5.2.1 C-glucosylation 
Method A: A solution of 2ʹ,4ʹ,6ʹ-trihydroxyacetophenone (13, 2 equiv.) in ACN (5 
mL) was added to a solution of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (3, 1.49 mmol) in 
DCM/CAN (1:1) (13.5 mL) at room temperature. Drierite (300mg) was added and the 
reaction vessel was maintained under N2. The mixture was cooled to -30 ºC and TMSOTf 
(0.5 equiv.) was added dropwise. After 20-30 minutes the reaction was allowed to reach 
room temperature. The total consumption of the glycosyl donor was confirmed by TLC 
(1:1 Hexane/Acetone) and after 5h the reaction was quenched with NaCl sat. solution. 
Drierite was filtered off under celite and the residue was extracted with DCM, washed 
with brine and dried over anhydrous MgSO4. Compound 39 was purified by column 
chromatography (7:1 Hexane/Acetone) and obtained as colourless oil in 56.4% yield. Rf = 
0.23 (3:1 Hexane/ EtOAc); 1H NMR (CDCl3) δ  (ppm) 7.34-6.98 (m, 20H; ArH), 5.89 (s, 
1H; H-3ʹ), 4.88 (d, 1H, J1ʹʹ,2ʹʹ =9.71 Hz, H-1ʹʹ); 4.97-4.48 (m, 8H; -CH2Ph), 3.81-3.60 (m, 
6H; H-2ʹʹ, H-3ʹʹ, H-4ʹʹ, H-5ʹʹ, H-6aʹʹ, H-6bʹʹ), 2.56 (s, 3H; H-2); 13C NMR (CDCl3) δ  (ppm) 
203.9 (C-1); 164.0 (C-4ʹ); 161.9 (C-2ʹ); 161.4 (C-6ʹ); 138.3, 137.7, 137.0, 136.6 (Cq-Ph); 
128.6, 128.5, 128.3, 128.1, 127.7, 127.6 (CH, Ph); 105.7 (C-3ʹ); 102.4(C-1ʹ); 97.1 (C-5ʹ); 
86.2 (C-2ʹʹ); 81.7 (C-3ʹʹ); 78.7 (C-4ʹʹ); 77.4 (C-5ʹʹ); 75.7 (C-1ʹʹ); 75.9, 75.2, 74.8, 74.5 (-
OCH2Ph); 68.1 (C-6ʹ’); 32.9 (C-2); HRMS calcd for C42H42NaO19 713.27210 (MNa+) found 
713.27335. 
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Compound 39 (1.67 mmol) was dissolved in DMF (23 mL) and K2CO3 (2.2 equiv.) 
was added at 0 ºC. After 10 minutes BnBr (2.2. equiv.) was added to the reaction and 10 
minutes later the ice bath was removed and the reaction was allowed to reach room 
temperature. The reaction proceeded for 1 hour at room temperature and then was 
neutralized with 2M HCl. The residue was extracted with DCM, washed with brine and 
dried over anhydrous MgSO4. Compound 31 was purified by column chromatography 
(7:1 Hexane/ EtOAc) and obtained as oil in 73.8% yield. Rf = 0.30 (5:1 Hexane/ EtOAc). 
Method B: Compounds 4 (2.20 mmol) and 14 (2.0 equiv.) were dissolved in DCE 
(10 mL) in the presence of drierite (ca. 100 mg). The solution was stirred at -30 ºC and 
Sc(OTf)3 (0.25 equiv.) was added. The stirring continued for 30 min at -30 ºC and then at 
room temperature for 5 h. The reaction was quenched with water and filtered through 
celite, extracted with DCM and concentrated. Compound 31 was purified by CC (10:1 P. 
Ether/EtOAc) and obtained in 49 % yield. Rf =0.33 (4:1 Et.P./EtOAc); 1H NMR (CDCl3) δ  
(ppm) 14.11 (s, 1H; OH-2ʹ), 7.43-6.89 (m, 30H; ArH), 6.36 (s, 1H, H-3ʹ), 4.96-4.45 (m, 
13H; -OCH2Ph, H-1ʹʹ), 3.74-3.37 (m, 6H; H-2ʹʹ, H-3ʹʹ, H-4ʹʹ, H-5ʹʹ, H-6aʹʹ, H-6bʹʹ); 2.52 (s, 
3H; H-2); 13C NMR (CDCl3) δ  (ppm)  203.1 (C-1); 164.7 (C-2ʹ); 163.5 (C-4ʹ); 160.7 (C-6ʹ); 
138.7, 138.6, 138.2, 138.1, 137.9, 137.4, 137.5, 136.4, 135.8; (Cq-Ph); 128.5, 128.5, 
128.4, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.6, 127.3, 
126.2 (CH. Ph); 111.5 (C-5); 105.9 (C-1ʹ); 90.0 (C-5ʹ); 82.1 (C-3ʹʹ); 78.8 (C-5ʹʹ); 77.6 (C-
4ʹʹ); 77.4, 77.1, 76.7, 75.7, 75.7, 75.7, 75.3, 75.3, 75.0, 73.5, 73.4, 73.2 (-OCH2Ph); 72.8 
(C-2ʹʹ); 70.0 (C-1ʹʹ); 68.4 (C-6ʹʹ); 33.5 (C-2); HRMS calcd for C56H54NaO9 893.36600 
(MNa+) found 893.36942. NOTE: All signals are duplicated due to the presence of 
rotamers 
 
7.5.2.2 Synthesis of the C-glucosyl chalcone  
Compound 31 (1.14 mmol) and 4-benzyloxybenzaldehyde (16h, 2.0 equiv.) were 
dissolved in 1,4-Dioxane (11.3 mL) and 50% (w/v) aq. NaOH. The mixture was kept 
under reflux for 24 h and then neutralized with 2M HCl. The orange residue was extracted 
with DCM, washed with brine and dried over MgSO4. The pure compound 41 was 
obtained as orange oil in 62.5% yield after purification by column chromatography (7:1 
Hexane/ EtOAc). Rf=0.24 (3:1 Hexane/ EtOAc); 1H NMR (CDCl3) δ  (ppm) 15.02 (s, 1H, 
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OH-2ʹ); 7.75-6.75 (m, 41H, ArH, H-2ʹʹ, H-3ʹʹ, H-4ʹʹ, H-6ʹʹ, H-2, H-3); 6.06 (s, 1H, H-5ʹ); 
5.12-4.24 (m, 16H, -OCH2Ph, H-1ʹʹʹ, H-2ʹʹʹ, H-3ʹʹʹ); 3.84-3.60 (m, 5H, H-4ʹʹʹ, H-5ʹʹʹ, H-6aʹʹʹ, 
H-6bʹʹʹ); 13C NMR (CDCl3) δ  (ppm) 192.9 (C-1); 166.9, 166.1 (C-2ʹ)*; 164.2, 163.4 (C-4ʹ); 
162.1, 161.9 (C-6ʹ); 142.9, 142.6 (C-2); 139.1, 138.9, 138.6, 138.5, 138.4, 138.3, 136.6, 
136.4, 136.3, 135.5, 135.3 (Cq-Ph, C-1ʹʹ); 130.2, 130.1 (C-2ʹʹ, C-6ʹʹ); 115.0, 114.9 (C-3ʹʹ, 
C-5ʹʹ); 129.0-126.9 (CH-Ph); 125.6, 125.4 (C-2); 107.5, 107.1 (C-3ʹ); 106.7, 106.1 (C-1ʹ); 
89.2, 89.0 (C-5ʹ); 87.9 (C-5ʹʹʹ); 79.4 (C-3ʹʹʹ); 78.4 (C-4ʹʹʹ); 75.6, 75.5, 75.2, 74.4, 74.3, 
73.5, 73.3, 72.9, 72.5, 71.4, 71.3, 70.7, 70.2, 70.1 (-OCH2Ph, C-1ʹʹʹ, C-2ʹʹʹ); 69.4 (C-6ʹʹʹ); 
HRMS calcd for C70H64NaO10 1087.43917 (MHNa+) found 1088.44461. NOTE: All signals 
are duplicated due to the presence of rotamers.  
 
7.5.3 General procedure for the synthesis of C-glucosyl dihydrochalcones  
Compounds 37a-37h and 41 (0.5 mmol) were dissolved in EtOAc (1 mL) methanol 
(2 mL). The catalyst Pd/C or Pd(OH)2 (5% mol) was added was the reaction vessel was 
kept under N2. Et3SiH (10 equiv.) was added drop wise while effervescence was 
observed (meaning that hydrogen was being formed in situ). After all the Et3SiH was 
added the reaction was kept at room temperature for another 10 minutes until change in 
the colour (orange/yellow to colourless). TLC was used to confirm the completion of the 
reaction. Catalyst was filtered off through celite, 2/3 of volume of solvent was removed 
under vacuum and extraction with ACN/Hex was used to remove most of the Et3SiH from 
the mixture. The final product was purified by column chromatography (EtOAc only). 
 
3-(4-fluorophenyl)-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]propan- 
1-one (33a): Yield 84.0%; m.p= 80.2-80.7 ºC; Rf (7:1 DCM/MeOH)=0.36; 1H NMR 
(acetone-d6) δ  (ppm) 7.33 (dd, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.37 Hz, J2ʹʹ,F= J6ʹʹ,Fʹ=5.16 HZ, H-2ʹʹ, H-
6ʹʹ); 7.05 (t, 2H, J5ʹʹ,F =J3ʹʹ,F =8.73 Hz, H-3ʹʹ, H-5ʹʹ); 5.95 (s, 1H, H-5ʹ); 4.94 (d, 1H, J1ʹʹʹ,2ʹʹʹ 
=9.59 Hz, H-1ʹʹʹ); 3.91-3.83 (m, 2H, H-6aʹʹʹ, H-6bʹʹʹ); 3.67 (t, 2H, J2ʹʹʹ,3ʹʹʹ=9.02 Hz, H-2ʹʹʹ, H-
3ʹʹʹ); 3.58 (t, 1H, J3ʹʹʹ,4ʹʹʹ=9.17 Hz, H-4ʹʹʹ); 3.50 (ddd, 1H, J4ʹʹʹ,5ʹʹʹ=9.55 Hz, J5ʹʹʹ,6aʹʹʹ=6.05 Hz, 
J5ʹʹʹ,6bʹʹʹ=2.98 Hz, H-5ʹʹʹ); 3.39 (t, 2H, J2,3=7.27 Hz, H-2); 2.98 (t, 2H, H-3); 13C NMR 
(acetone-d6) δ  (ppm) 204.5 (C-1ʹ); 163.0 (C-4ʹ); 162.4 (C-2ʹ, C-6ʹ); 160.0  (C-4ʹʹ); 137.8 
(d, J = 39.6 Hz, C-1ʹʹ); 130.2 (d, J = 7.2 Hz, C-2ʹʹ, C-6ʹʹ); 114.8 (d, J = 21.1 Hz, C-3ʹʹ, C-
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5ʹʹ); 104.5 (C-3ʹ); 103.4 (C-1ʹ); 95.6 (C-5ʹ); 81.1 (C-5ʹʹʹ); 78.3 (C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.3 
(C-3ʹʹʹ); 69.6 (C-2ʹʹʹ); 60.9 (C-6ʹʹʹ); 45.9 (C-2); 29.7 (C-3); HRMS calcd for C21H23FNaO9 
461.12183 (MNa+) found 461.12238 
 
3-phenyl-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]propan-1-one 
(33c): Yield 82.0%; m.p= 80.0-80.1 ºC; Rf (7:1 DCM/MeOH)=0.40; 1H NMR (acetone-d6) 
δ  (ppm) 12.20 (s, 1H, OH-6ʹ); 11.50 (s, 1H, OH-2ʹ); 9.10 (s, 1H, OH-4ʹ); 7.30-7.26 (m, 
4H, H-2ʹʹ, H-3ʹʹ, H-5ʹʹ, H-6ʹʹ); 7.21-7.17 (m, 1H, H-4ʹʹ); 5.95 (s, 1H, H-5ʹ); 4.94 (d, 1H, 
J1ʹʹʹ,2ʹʹʹ =9.72 Hz, H-1ʹʹʹ); 3.91-3.81 (m, 2H, H-6aʹʹʹ, H-6bʹʹʹ); 3.70-3.62 (m, 2H, H-2ʹʹʹ, H-
3ʹʹʹ); 3.58-3.46 (m, 2H, H-4ʹʹʹ, H-5ʹʹʹ); 3.40 (t, 2H, J2,3=7.71 Hz, H-2); 2.99 (t, 2H, H-3); 13C 
NMR (acetone-d6) δ  (ppm)  205.5 (C-1); 163.0 (C-2ʹ, C-4ʹ, C-6ʹ); 141.9 (C-1ʹʹ); 128.5 (C-
2ʹʹ, C-6ʹʹ); 128.3 (C-3ʹʹ, C-5ʹʹ); 125.8 (C-4ʹʹ); 104.5 (C-3ʹ); 103.8 (C-1ʹ); 95.6 (C-5ʹ); 81.1 
(C-5ʹʹʹ); 78.7 (C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.3 (C-3ʹʹʹ); 69.9 (C-2ʹʹʹ); 60.7 (C-6ʹʹʹ); 45.8 (C-2);  
30.4 (C-3); HRMS calcd for C21H24NaO9 443.13125 (MNa+) found 443.13169 
 
3-(4-methylphenyl)-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]propan-1-
one (33d): Yield 82.0%; m.p= 117.0-117.5 ºC; Rf (7:1 DCM/MeOH)=0.38; 1H NMR 
(acetone-d6) δ  (ppm) 7.19 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=7.16 Hz, H-2ʹʹ, H-6ʹʹ); 7.11 (d, 2H, H-3ʹʹ, 
H-5ʹʹ); 5.96 (s, 1H, H-5ʹ); 4.95 (d, 1H, J1ʹʹʹ,2ʹʹʹ =9.13 Hz, H-1ʹʹʹ); 3.91-3.84 (m, 6H, H-6aʹʹʹ, 
H-6bʹʹʹ); 3.67 (t, 2H, J2ʹʹʹ,3ʹʹʹ= 9.08 Hz, H-2ʹʹʹ, H-3ʹʹʹ); 3.58 (t, 1H, J3ʹʹʹ,4ʹʹ= 9.00 Hz, H-4ʹʹʹ); 
3.50 (ddd, 1H, J4ʹʹʹ,5ʹʹ=9.46 Hz, J5ʹʹʹ,6aʹʹ= 6.57 Hz, J5ʹʹʹ,6aʹʹ=2.94 Hz H-5ʹʹʹ); 3.38 (t, 2H, 
J2,3=6.95 Hz, H-2); 2.95 (t, 2H, H-3); 2.30 (s, 3H, -CH3-4ʹʹ); 13C NMR (acetone-d6) δ  
(ppm) 204.8 (C-1); 163.2 (C-2ʹ, C-6ʹ); 163.0 (C-4ʹ); 138.9 (C-1ʹʹ); 134.9 (C-4ʹʹ); 128.9 (C-
2ʹʹ, C-6ʹʹ); 128.2 (C-3ʹʹ, C-5ʹʹ); 104.5 (C-3ʹ); 103.4 (C-1ʹ); 95.6 (C-5ʹ); 81.1 (C-5ʹʹʹ); 78.4 
(C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.4 (C-3ʹʹʹ); 69.6 (C-2ʹʹʹ); 60.7 (C-6ʹʹʹ); 45.9 (C-2); 30.0 (C-3); 20.5 
(-CH3-4ʹʹ); HRMS calcd for C22H26NaO9 457.14690 (MNa+) found 457.14758 
 
3-(4-methoxyphenyl)-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]-
propan-1-one (12e): Yield 84.0%; m.p= 90.4-90.7 ºC;  Rf (7:1 DCM/MeOH)=0.31; 1H 
NMR (acetone-d6) δ  (ppm) 12.29 (s, 2H, OH-2ʹ, OH-6ʹ); 11.57 (s, 1H, OH-4ʹ); 9.17 (s, 
1H, OH-4ʹʹ); 7.21 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ=7.68 Hz, H-2ʹʹ, H-6ʹʹ); 6.85 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.94 
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(s, 1H, H-5ʹ); 4.94 (d, 1H, J1ʹʹʹ,2ʹʹʹ =9.71 Hz, H-1ʹʹʹ); 3.91-3.87 (m, 6H, H-6aʹʹʹ, H-6bʹʹʹ); 3.77 
(s, 3H, -OCH3-4ʹʹ); 3.66 (t, 2H, J2ʹʹʹ,3ʹʹʹ= 8.99 Hz, H-2ʹʹʹ, H-3ʹʹʹ); 3.56 (t, 1H, J3ʹʹʹ,4ʹʹʹ=8.72 Hz, 
H-4ʹʹʹ); 3.50 (ddd, 1H, J4ʹʹʹ,5ʹʹʹ=9.85 Hz, J5ʹʹʹ,6aʹʹʹ=6.74 Hz, J5ʹʹʹ,6bʹʹʹ=3.28 Hz, H-5ʹʹʹ); 3.36 (t, 
2H, J2,3=7.60 Hz, H-2); 2.92 (t, 2H, H-3); 13C NMR (acetone-d6) δ  (ppm) 205.3 (C-1); 
162.9 (C-2ʹ, C-4ʹ, C-6ʹ); 158.0 (C-4ʹʹ); 133.8 (C-1ʹʹ); 129.4 (C-2ʹʹ, C-6ʹʹ); 113.7 (C-3ʹʹ, C-
5ʹʹ); 104.5 (C-3ʹ); 104.5 (C-1ʹ); 95.6 (C-5ʹ); 81.1 (C-5ʹʹʹ); 78.4 (C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.4 
(C-3ʹʹʹ); 69.6 (C-2ʹʹʹ); 60.6 (C-6ʹʹʹ); 54.5 (-OCH3-4ʹʹ); 46.2 (C-2); 29.5 (C-3); HRMS calcd 
for C22H26NaO10 473.14182 (MNa+) found 473.14245 
 
3-(4-ethoxyphenyl)-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]propan-1-
one (33f): Yield 89.0%; m.p= 91.4-92.0 ºC;  Rf (EtOAc)=0.10; 1H NMR (acetone-d6) δ  
(ppm) 12.36 (s, 1H, OH-6ʹ); 11.45 (s, 1H, OH-2ʹ); 9.11 (s, 1H, OH-4ʹ); 7.17 (d, 2H, J2ʹʹ,3ʹʹ= 
J5ʹʹ,6ʹʹ =8.21 Hz, H-2ʹʹ, H-6ʹʹ); 6.82 (d, 2H, H-3ʹʹ, H-5ʹʹ); 5.94 (s, 1H, H-5ʹ); 4.93 (d, 1H, 
J1ʹʹʹ,2ʹʹʹ =9.67 Hz, H-1ʹʹʹ); 3.99 (q, 2H, J=7.22 Hz, J=13.32 Hz, -OCH2CH3-4ʹʹ); 3.89-3.86 
(m, 6H, H-6aʹʹʹ, H-6bʹʹʹ); 3.72-3.47 (m, 4H, H-2ʹʹʹ, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ); 3.33 (t, 2H, 
J2,3=9.44 Hz, H-2); 2.89 (t, 2H, H-3); 1.34 (t, 3H, -OCH2CH3-4ʹʹ); 13C NMR (acetone-d6) δ  
(ppm)  204.9 (C-1); 163.1 (C-2ʹ, C-6ʹ); 163.0 (C-4ʹʹ); 157.3 (C-4ʹʹ); 133.7 (C-1ʹʹ); 129.4 
(C-2ʹʹ, C-6ʹʹ); 114.3 (C-3ʹʹ, C-5ʹʹ); 104.5 (C-3ʹ); 103.1 (C-1ʹ); 95.6 (C-5ʹ); 81.1 (C-5ʹʹʹ); 78.4 
(C-4ʹʹʹ); 75.3 (C-1ʹʹʹ); 73.3 (C-3ʹʹʹ); 69.7 (C-2ʹʹʹ); 62.9 (-OCH2CH3-4ʹʹ); 60.8 (C-6ʹʹʹ); 46.1 




propan-1-one (33g): Yield 90.6%; m.p= 80.0-80.2 ºC;  Rf (EtOAc)=0.10; 1H NMR 
(acetone-d6) δ (ppm) 7.11 (d, 2H, J2ʹʹ,3ʹʹ= J5ʹʹ,6ʹʹ =7.55 Hz, H-2ʹʹ, H-6ʹʹ); 6.85 (d, 2H, H-3ʹʹ, 
H-5ʹʹ); 5.95 (s, 1H, H-5ʹ); 4.94 (d, 1H, J1ʹʹʹ,2ʹʹʹ =8.78 Hz, H-1ʹʹʹ); 3.94-3.90 (m, 2H, -
OCH2CH2CH3-4ʹʹ); 3.89-3.83 (m, 6H, H-6aʹʹʹ, H-6bʹʹʹ); 3.66 (t, 2H, J2ʹʹʹ,3ʹʹʹ =J3ʹʹʹ,4ʹʹʹ=9.34 Hz, 
H-2ʹʹʹ, H-3ʹʹʹ); 3.58-3.49 (m, 2H, H-4ʹʹʹ, H-5ʹʹʹ); 3.36 (t, 2H, J2,3=7.56 Hz, H-2); 2.92 (t, 2H, 
H-3); 1.81-1.73 (m, 2H, -OCH2CH2CH3-4ʹʹ); 1.02 (t, 3H, -OCH2CH2CH3-4ʹʹ); 13C NMR 
(acetone-d6) δ  (ppm) 204.8 (C-1); 162.9 (C-2ʹ, C-4ʹ, C-6ʹ); 157.5 (C-4ʹʹ); 133.7 (C-1ʹʹ); 
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129.3 (C-2ʹʹ, C-6ʹʹ); 114.3 (C-3ʹʹ, C-5ʹʹ); 104.5 (C-3ʹ); 103.4 (C-1ʹ); 95.6 (C-5ʹ); 81.1 (C-
5ʹʹʹ); 78.5 (C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.3 (C-3ʹʹʹ); 69.6 (C-2ʹʹʹ); 69.1 (-CH2CH2CH3-4ʹʹ);  60.6 
(C-6ʹʹʹ); 40.2 (C-2); 29.7 (C-3); 22.4 (-CH2CH2CH3-4ʹʹ); 9.9 (-CH2CH2CH3-4ʹʹ);  HRMS 
calcd for C24H30NaO10 501.17312 (MNa+) found 501.17373 
 
3-(4-hydroxyphenyl)-1-[3-β-D-glucopyranosyl)-2,4,6-trihydroxyphenyl]-propan-
1-one (33h): Yield 78.8%; m.p= 133.3-133.4 ºC; Rf (7:1 DCM/MeOH)=0.26; 1H NMR 
(acetone-d6) δ  (ppm) 7.11 (d, 2H, J2ʹʹ,3ʹʹ = J5ʹʹ,6ʹʹ =8.04 Hz, H-2ʹʹ, H-6ʹʹ); 6.75 (d, 2H, H-3ʹʹ, 
H-5ʹʹ); 5.96 (s, 1H, H-5ʹ); 4.94 (d, 1H, J1ʹʹʹ,2ʹʹʹ =9.58 Hz, H-1ʹʹʹ); 3.90-3.83 (m, 2H, H-6aʹʹʹ, 
H-6bʹʹʹ); 3.30-3.64 (m, 2H, H-2ʹʹʹ, H-3ʹʹʹ); 3.56 (t, 1H, J3ʹʹʹ,4ʹʹʹ= 8.86 Hz, H-4ʹʹʹ); 3.50 (ddd, 
1H, J4ʹʹʹ,5ʹʹʹ= 9.63Hz, J5ʹʹʹ,6aʹʹʹ= 6.59 Hz, J5ʹʹʹ,6bʹʹʹ= 3.12 Hz, H-5ʹʹʹ); 3.34 (t, 2H, J2,3=7.27 Hz, 
H-2); 2.88 (t, 2H, H-3); 13C NMR (acetone-d6) δ  (ppm) 204.9 (C-1ʹ); 163.1 (C-2ʹ, C-4ʹ); 
162.9 (C-6ʹ); 155.5 (C-4ʹʹ); 132.5 (C-1ʹʹ); 129.4 (C-2ʹʹ, C-6ʹʹ); 115.1 (C-3ʹʹ, C-5ʹʹ); 104.5 
(C-3ʹ); 103.4 (C-1ʹ);  81.1 (C-5ʹʹʹ); 78.5 (C-4ʹʹʹ); 75.4 (C-1ʹʹʹ); 73.3 (C-3ʹʹʹ); 69.6 (C-2ʹʹʹ); 
60.6 (C-6ʹʹʹ); 46.3 (C-2); 29.7 (C-3); HRMS calcd for C21H24NaO10 459.12617 (MNa+) 
found 459.12664 
 
Materials and Methods – ENZYMATIC SYNTHESIS 
 
p-Nitrophenol glucuronic acid, UDP-GlcA, Luria Broth, and other generic chemicals 
(Trizma, MgCl2, NaCl, imidazole, etc)  were purchased from Sigma. Polyamine-based 
HPLC column was used to purify the saccharides. UDP-GlcNAc and UDP-GlcNTFA were 
prepared and gently supplied by the co-workers from the lab.  
 
7.6 Synthesis of disaccharides 
Disaccharide α-D-GlCNAc-(1→4)-β-D-GlcApnp (45) 
The monomer p-nitrophenol glucuronic acid (GlcApnp, 44) (10 mg, 31.7 µmol) was 
incubated with UDP-GlcNAc (48, 1.2 equiv.) and KfiA (0.2 µg/µL) in buffer (12.7 mL) 
containing 25 mM Tris-HCl (pH 7.2) and 10 mM MgCl2. The reaction was incubated at 
room temperature overnight. An aliquot of the reaction mixture was analyzed by a 
polyamine-based (PAMN-HPLC) column to ensure that >95% of UDP-GlcNHAc was 
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converted to UDP. After purification, compound 45 was dried and obtained in 70.7% 
yield.  
 
Disaccharide α-D-GlCNTFA-(1→4)-β-D-GlcApnp (50) 
The monomer p-nitrophenol glucuronic acid (GlcApnp, 44) (10 mg, 31.7 µmol) was 
incubated with UDP-GlcNTFA (48, 1.2 equiv.) and KfiA (0.2 µg/µL) in buffer (12.6 mL) 
containing 25 mM Tris-HCl (pH 7.2) and 10 mM MgCl2. The reaction was incubated at 
room temperature overnight. An aliquot of the reaction mixture was analysed by a 
polyamine-based (PAMN-HPLC) column to ensure that >95% of UDP-GlcNAc was 
converted to UDP. The desired saccharide 50 was obtained in 89.7% yield. 
 
7.7 Synthesis of trisaccharides 
Trisaccharide β-D-GlcA-(1→4)-α-D-GlCNAc-(1→4)-β-D-GlcApnp (46) 
The disaccharide (45) (11.6 mg, 22.4 µmol) was incubated with UDP-GlcA (47, 1.2 
equiv.) and pmHS2 (0.2 µg/µL) in buffer (8.9 mL) containing 25 mM Tris-HCl (pH 7.2) and 10 
mM MgCl2. The reaction was incubated at room temperature overnight. An aliquot of the 
reaction mixture was analysed by a polyamine-based (PAMN-HPLC) column to ensure that 
>95% of UDP-GlcNHAc was converted to UDP. After purification the product was dried and 
obtained in 89.9% yield. 
 
Trisaccharide (β-D-GlcA-(1→4)-α-D-GlCNTFA-(1→4)-β-D-GlcApnp) (51) 
The disaccharide 50 (13.6 mg, 22.4 µmol) was incubated with UDP-GlcA (47, 1.2 
equiv.) and pmHS2 (0.2 µg/µL) in buffer (11.4 mL) containing 25 mM Tris-HCl (pH 7.2) and 
10 mM MgCl2. The reaction was incubated at room temperature overnight. An aliquot of the 
reaction mixture was analysed by a polyamine-based (PAMN-HPLC) column to ensure that 
>95% of UDP-GlcNHAc was converted to UDP. After purification the product (88.2 % yield) 
was confirmed by electrospray ionization (ESI) mass spectrometry. 
 
7.7.1 General methodology for the purification of oligosaccharides 
Upon the complete consumption of UDP-GlcA (47), UDP-GlcNHAc (48) or          
UDP-NTFA (49) 30% trifluoroacetic acid (TFA) solution was added until pH 2.0. The 
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mixture was centrifuged for 15-20 minutes and then purified by a C18 column under 
reverse phase HPLC (RP-HPLC) conditions. The column was eluted with a linear 
gradient from 90% solution A (0.1% TFA in water) to 50% solution A for 40 min at a flow 
rate of 0.5 mL/min, then followed by an additional wash for 20 min with 100% solution B 
(0.1% TFA in acetonitrile) at a flow rate of 0.5 mL/min. 
 
7.8 pmHS2 expression and purification 
BL21 cells (carrying pmHS2) were grown in Luria Broth (LB) containing 50μg/mL 
carbenicillin overnight at 37 ºC. A small portion (1 mL) of the overnight culture was diluted 
into 1 L of the same growth media and the incubated at 37 ºC for 4-5 hours at 300 rpm 
until optimal density at 600 nm (OD600) reached 0.6-0.8. The temperature was decreased 
to 22 ºC and the culture was maintained at that temperature for at least 30 minutes. 
Isopropyl β-D-1-thiogalactopyranoside was added to the media to the final concentration 
of 0.2 mM and the shaking was maintained at 22 ºC overnight (ca. 18 hours).  
Bacteria were harvested by spinning the bacterial culture at 6000 g for 15 minutes. 
The bacteria pellet were resuspended in 25 mL of buffer containing 25 mM Tris (pH 7.5), 
500 mM NaCl, and 10 mM imidazole (Buffer A). The suspension was sonicated for 3×30 
seconds with 8-9 output power and 50% cycle and kept in ice during the process. The 
lyase was spinned 10,000g for 30 minutes. The supernatant was kept and filtered 
through a 0.45 µm filter. The lysate was loaded into a 10 mL NTA-agarose column, which 
was equilibrated with Buffer A and eluted with a linear gradient of Buffer B (containing 25 
mM Tris pH 7.5, 500 mM NaCl, and 250 mM imidazole).  
 
7.8.1 Testing the activity of pmHS2 
The activity of the expressed enzyme was tested in a 100 µL reaction. The primer 
GlcApnp (0.25 µg) was incubated with UDP-GlcNHAc (1.2 equiv.) and pmHS2 (0.1 
µg/µL) in 100 µL buffer containing 25 mM Tris (pH 7.2), 10 mM MgCl2. The reaction was 
incubated at room temperature overnight. An aliquot of the reaction mixture was analysed 
by a polyamine-based (PAMN-HPLC) column to ensure that >95% of UDP-GlcNHAc was 
converted to UDP. 
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7.8.2 Testing the purity of pmHS2 by SDS-PAGE  
The sample of the expressed enzyme (10 µL) was mixed with loading buffer (10 µL, 
containing 50 µL of 2-mercaptoethanol and 950 µL of Laemmli sample buffer) and then 
heated at 100 ºC for 1 minute in a waterbath. The solution was spinned down at 13,000 
rpm for 2 minutes and placed in ice to decrease the internal temperature. The samples 
(including the protein marker) were applied in the gel and ran at 106 V. After this the gel 
was washed with deionized water. The gel was immersed on SDS dye and kept in the 
dancer for 40 minutes. The gel was washed with 10% acetic acid and placed in the 
dancer for several minutes and replacing the acetic acid until the excess blue color 
disappear.    
 
Materials and Methods – Cell Biology 
2-deoxy-D-glucose, 2-deoxy-D-glucose 6-phosphate sodium salt, hexokinase (from 
Saccharomyces cerevisae), glucose-6-phosphate dehydrogenase (G6PDH, from 
Leuconostoc mesenteroides), resazurin sodium salt, triethanolamine (TEA) buffer, 
HEPES, β-nicotinamide adenine dinucleotide phosphate (β-NADP+), adenosine 5ʹ-
triphosphate disodium salt (ATP), phlorizin, cytochalasin B, diaphorase (from Clostridium 
kluyveri type II-L), bovine serum albumin (BSA), potassium chloride, sodium 
deoxycholate, choline chloride, fetal bovine serum (FBS), Dulbeco’s modified Eagle’s 
medium (DMEM), geneticin (G418®) and phosphate buffered saline were purchased 
from Sigma. 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG), 
6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (6-NBDG) and 
Dapagliflozin were purchased from Cayman Chemical.  
 
7.9 Cell Culture  
Human Embryonic kidney cells (HEK293) were obtained from the American Type 
Culture Collection (ATCC). COS-7 cells were obtained from another group from NYUAD 
and HEK293T cells were obtained from Georgia University (USA). All cell lines were 




7.10 Cell Viability Assay 
HEK293 cells were plated in a 96-well plate at a density of 2.0×104 cells/well 24 
hours prior the assay. Each compound (18a-18h, 22a-22h, 26a-26h, 28a-28h, 29a-29h, 
30a-30h, 33a-33h) was added at a concentration of 100 µM to three wells and incubated 
for 20-24 h at 37 ºC in a 5% CO2 atmosphere.  
Cell titter Blue® (20 µL) was added to each well and incubated at 37 ºC for 4 h. 
Fluorescence was measure in a microplate reader (λexc=560 nm, λem=590 nm). Cell 
viability (%) was calculated in comparison with non-treated cells. Cells treated with 
DMSO were used as a positive control. 
 
7.11 Preparation of pCMV6-Neo containing hSGLT1 and hSGLT2 
DH5α cells were transformed with vectors containing human SGLT1 and SGLT2 
complementary DNAs (cDNAs) (pCMV6-Neo, Origene) and plated on Luria-Bertani (LB) 
agar plates overnight at 37 ºC. After 24 h of incubation two colonies were picked and 
grown further in LB broth at 37 ºC overnight. pCMV6-Neo vectors containing SGLT1 and 
SGLT2 cDNA, respectively, were purified using A PureLink HiPure Plasmid Filter 
Maxiprep kit (Sigma). Purity and concentration of each plasmid was confirmed by 
NanoDrop spectrometer before use. 
 
7.12 Determination of geneticin concentration – Killing Curve 
HEK293 cells were plated in a 96-well plate at a density of 2.0×104 cells/well 24 
hours prior the addition of geneticin (G418). Geneticin was added to each well (in 
duplicate) at concentrations ranging from 0-1000 µg/mL. The media was replaced every 
two days and fresh antibiotic was added and the treatment was carried out for 7 days. 
The working concentration of G418 was determined as the lowest concentration that 
killed all the cells in the period of the treatment. 
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7.13 Transient transfection 
Both hSGLT1 and hSGLT2 constructs were subjected to restriction enzyme 
digestion analysis prior transfection. Moreover, both SGLT1 and SGLT2 insert clones 
were fully sequenced (Bioneer, South Korea) and their nucleotide sequences confirmed.  
Cells were plated on an appropriate plate at a proper density according to each 
experiment. Each construct was transfected into the cells using TrueFect. In addition, 
cells treated with transfection reagent alone were used as vehicle control.  
 
7.14 Stable cell lines 
HEK293 cells were seeded on 35 mm dish at a density of 4.0×105 cells/dish and 
incubated at 37 ºC overnight. Each dish was transfected with hSGLT1, hSGLT2 plasmids 
using Truefect. A third dish using only Truefect was used as control. Cells were 
trypsinized 24 h post-transfection and plated on 24-well plate at a density of 0.8×105 
cells/well. G418 was added to each well (700 µg/mL) 48 h post-transfection. The medium 
was replaced every 2 days and adding fresh antibiotic for 7 days. After this period, the 
concentration of G418 was reduced to 300 µg/mL and the clones were allowed to grow 
for several weeks until confluent enough for cryopreservation.  
 
7.15 RNA isolation and reverse transcription PCR 
Stable clones were plated on 35 mm dishes at 4.0×105 cells/dish and incubated at 
37 ºC overnight. Total RNA of each clone was isolated using the High Pure RNA isolation 
kit (Roche 11828665001). Reverse transcriptase reactions were performed using 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen) for first-strand cDNA synthesis. 
Polymerase chain reaction (PCR) was performed using Taq DNA polymerase 
(Invitrogen). The primers used were designed using Primer-3 Software.  
The primers for SGLT1 were 5ʹ-TCCACTCATTTTGGCATTCA-3ʹ (forward) and 5ʹ-
AAACCAACCCTGCTGACATC-3ʹ (reverse). The primers for SGLT2 were 5ʹ-
AGAGCCTGACCCACATCAAG-3ʹ (forward) and 5ʹ-GCGTGTAGATGTCCATGGTG-3ʹ 
(reverse). The RT-PCR was carried out in a thermal cycler using the following conditions: 
94 ºC for 2 min, 30 cycles of 94 ºC for 30 seconds, 60 ºC for 30 seconds, 72 ºC for 1 
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minute, then 72 ºC for 5 minutes, hold at 4 ºC. Agarose gel electrophoreseis was used to 
separate PCR-amplified products whose were visualized under UV light.  
 
7.16 Western Blot 
Cells were plated on 60 mm dishes at 6.0×105 cells/dish and incubated at 37 ºC 
overnight. Cells were lysed and 50 µg of each lysate was separated by sodium dodecyl 
sulphate polyacrylamide gel (SDS-PAGE). After electrophoresis, protein was transferred 
to nitrocellulose membranes (Z613630 Whatman from Sigma) and then blocked with 10% 
milk in TBST (20 mM Tris [pH 7.6], 140 mM NaCl and 0.1% Tween 20) for 75 minutes. 
The membranes were washed with TBST and subsequently incubated with primary 
antibody SGLT1 (1:200, H-85 Santa Cruz Biotechnology) and SGLT2 (1:500, H-45 Santa 
Cruz Biotechnology) in 5% BSA for 75 minutes at room temperature. Beta-actin was used 
as a loading control and the membrane was incubated with the corresponding primary 
antibody (1:1000, #4967, Cell Signaling). After washing the membranes with TBST, all 
the membranes were incubated with anti-rabbit horseradish peroxidase-conjugated 
secondary antibody (1:2000 for SGLT1/β-Actin and 1:4000 for SGLT2) for 1 r at room 
temperature. Signal was detected by chemiluminescence using ECL detection system 
(Milipore WBLUR0100). 
 
7.17 Fluorescence microscopic analysis – 2-NBDG uptake assay 
HEK293, HEK293-SGLT1 and HEK293-SGLT2 cells were grown until 80% 
confluent. Medium was removed and cells washed with Krebs-Ringer-Phosphate-HEPES 
(KRPH) buffer (140 mM NaCl, 20 mM HEPES [pH 7.4], 1mM MgSO4, 1 mM CaCl2, 4.7 
mM KCl, 5 mM KH2PO4). KRPH buffer (500 µL) was added to each well and incubated at 
37 ºC for 1 h. 2-NBDG (600 µM) was added to each well and the cells were incubated at 
37 ºC for 30 minutes. Cells were washed with choline buffer (140 mM choline chloride, 20 
mM HEPES [pH 7.4], 1mM MgSO4, 1 mM CaCl2, 4.7 mM KCl, 5 mM KH2PO4) three times 
and cells were examined with Olympus inverted confocal microscope, with a 30X 
objective. As a control, the above experiment was repeated in the absence of 2-NBDG 
and cells were treated with DMSO as vehicle.  
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7.18 2-Deoxyglucose uptake assay 
HEK293 and SGLT1/SGLT2-transfected cells were plated at 2.0×104 cells/well in a 
96-well plate. After 24 h of incubation the culture media was removed and cells were 
rinsed once with KRPH buffer and incubated in the same buffer for 1 h at 37 ºC. 2-
Deoxyglucose (1 mM) was added to each well and the cells were incubated at 37 ºC for 1 
hour after which, cells were lysed with 50 µL of 0.1 M NaOH and then incubated at 80-85 
ºC for 40 minutes. After this period, lysate was neutralized with 50 µL of 0.1 M HCl and 
50 µL of TEA buffer was added. In a 96-well plate, 100 µL of lysate was dispensed into 
each well and incubated at 37 ºC for 15-20 h after the addition of an enzymatic cocktail 
solution consisting of 50 mM TEA (pH 8.2), 50 mM KCl, 0.02 % BSA, 1 mM NADP, 0.5 
U/mL G6PDH, 0.1 U/mL diaphorase, 10 µM resazurin. Fluorescence was measured at 
590 nm using a Multiplate reader (Biotek) after excitation at 560 nm. The fluorescence of 
resofurin, the reduced form of resazurin, is a measure of the amount of 2DG inside the 
cells.  
 
7.19 Determination of IC50 
To determine the IC50 values of compounds 18a-18h, 22a-22h and 33a-33h 
HEK293 and SGLT1/SGLT2-transfected cells were plated at 2.0×104 cells/well in a 96-
well plate. After 24 h of incubation the culture media was removed and cells were rinsed 
once with KRPH buffer and incubated in the same buffer for 1 h at 37 ºC. Each 
compound (0.1 nM to 200 µM was added to the buffer and incubated for 10 minutes. 2-
Deoxyglucose (1 mM) was added to each well and the cells were incubated at 37 ºC for 1 
hour. Cells were lysed with 50  µL of 0.1 M NaOH and then incubated at 80-85 ºC for 40 
minutes. After this period, lysate was neutralized with 50 µL of 0.1 M HCl and 50 µL of 
TEA buffer was added. The enzymatic assay to determine the ammout of 2DG was 
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1. NMR & MS Data 
1.1 Glucosyl donors 
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1.2 Protected acetophenones 
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(E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(4-methylphenyl)prop-2-en-1-
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(E)-1-[2,4-bis(ethoxymethoxy)-6-hydroxyphenyl]-3-(4-ethoxyphenyl)prop-2-en-1-
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Disaccharide α-D-GlCNTFA-(1→4)-β-D-GlcApnp (50) 
 
 
2mer ntfa  #60 RT: 0.99 AV: 1 NL: 1.59E7
T: - c ESI ms [ 400.00-1500.00]





































1047.9590.2443.0 808.7 1159.5 1340.6699.1 1018.5541.2 660.6 1129.4 1384.51315.5513.0 886.6 930.3 1426.91266.8730.1
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1.10 Trisaccharides 
Trisaccharide β-D-GlcA-(1→4)-α-D-GlCNAc-(1→4)-β-D-GlcApnp (46) 
 
20121030  3mer #2-58 RT: 0.02-1.00 AV: 57 NL: 1.09E8
T: - c ESI ms [ 200.00-1400.00]






































807.7554.3371.1 663.1 1387.0744.1227.0 524.2 631.1396.2 1039.8822.0345.3 1154.9 1210.8958.8 1061.5931.1 1244.5 1358.1
